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ABSTRACT 
 
Prion diseases comprise a group of fatal neurodegenerative disorders caused by the 
conformational re-arrangement of a normal host-encoded prion protein, PrPC, to an 
abnormal infectious isoform, PrPSc.  Currently, the precise cellular mechanism(s) of prion-
mediated neurodegeneration remain unclear.  However, increasing evidence suggests a 
role for the ubiquitin proteasome system (UPS) in prion disease pathogenesis, with a direct 
functional impairment of the 26S proteasome leading to the accumulation of UPS 
substrates in the brains of prion-infected mice.  The UPS functions to regulate the targeted 
degradation of intracellular proteins and maintain cellular proteostasis. Alterations in 
proteasome proteolysis have been shown to contribute to the build up of proteins 
associated with aging and dysregulation of the UPS has been linked to several 
neurodegenerative diseases.  The principal aim of this thesis was to characterise the 
progression of UPS dysfunction in vivo in the brains of prion-infected mice using a 
ubiquitin-GFP reporter mouse model.  Using the UbG76V-GFP transgenic mouse model, UPS 
dysfunction was observed in the brain early in the prion disease incubation period, before 
key hallmarks of disease pathology were observed.  The accumulation of Ub-GFP reporter 
coincided with markers of prion disease neuropathology, such as PrPSc deposition and 
extensive astrogliosis.  The majority of cells in which the Ub-GFP reporter was observed in 
the thalamus appeared to be astrocytes, suggesting that altered proteolysis and reactive 
astrocyte pathology may be linked.  Ubiquitin levels were increased significantly in the 
brains of prion infected mice, while 26S proteasome peptidase activity was reduced.  
Behavioural abnormalities and motor skills deficits were also observed in prion-infected 
UbG76V-GFP mice, which may correlate to neuronal loss and/or synaptic dysfunction 
associated with impairment of the UPS machinery.  Collectively, the data presented in this 
thesis provide evidence of an early  and potentially important role for UPS dysfunction in 
prion disease pathogenesis. 
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1 INTRODUCTION 
 
Prion diseases, or transmissible spongiform encephalopathies (TSEs), comprise a group 
of fatal and untreatable neurodegenerative diseases that affect humans (e.g., Creutzfeldt-
Jacob disease) and various other mammals (e.g., bovine spongiform encephalopathy). Prion 
diseases can be transmitted naturally or experimentally by inoculation, dietary exposure or 
by contact with infectious tissue.  Although a number of prion diseases have been 
identified in various mammals, including humans, they are believed to be caused by a single 
protein (Prusiner et al., 1991).  Prion diseases are grouped together on the basis of their 
distinct neuropathological characteristics, as well as various clinical symptoms. Mammalian 
prions are characterized by their ability to cause fatal degeneration of the central nervous 
system (CNS).  Biologically, the normal prion protein, PrPC (C for cellular), undergoes a post-
translational conformational change to the abnormal prion protein PrPSc (Sc denotes 
scrapie). A major conformational difference exists between the isoforms: PrPC has a 
predominantly alpha–helical structure, whereas PrPSc is largely β-sheet in content. The 
altered structure of the protein is very stable and accumulates in infected tissue causing 
cell death and tissue damage.  Prion diseases have incubation periods (the latent period 
from point of infection to appearance of the first sign of clinical disease) of months to 
several years, depending on the type of prion disease. 
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1.1 Prion diseases in animals  
 
Scrapie, an endemic brain disease of sheep and goats, is known to have been first 
described in Europe in the 18th century, although it was not known to be infectious at the 
time.  Scrapie is often considered to be the prototypic prion disease. A number of other 
mammals, however, develop prion diseases, including chronic wasting disease (CWD) in 
mule deer and elk, and bovine spongiform encephalopathy (BSE) in cattle. The clinical 
manifestation of animal prion diseases is characterised by the loss of motor control, 
paralysis and muscle wasting, which together ultimately lead to death.  Other animal prion 
diseases such as transmissible mink encephalopathy (TME) have also been reported (Table 
1.1). 
1.1.1 Scrapie 
Scrapie is a fatal, sub-acute, progressive disease found in sheep and goats. Animals 
affected by scrapie have been recognised by shepherds for many centuries. The name 
scrapie corresponds to the unusual condition of the disease where the suffering animal 
scrapes itself up against walls or fences to alleviate itchiness caused by the disease 
However, for many years the disorder was regarded as an inherited, degenerative disease 
of the brain and spinal cord. The various symptoms of scrapie include hyperexcitability, 
itching, tremors, gait disorders, and loss of fur and skin damage due to scraping. The first 
report of scrapie being transmissible from one individual sheep to another was in the 
1930s, with an incubation period of one year (Cuillé and Chelle, 1936). The transmissibility 
of scrapie was comprehensively demonstrated in 1943, when Scottish sheep were 
accidently inoculated against a common virus using infected material from a scrapie sick 
animal (Gordon, 1946).  The natural mode of transmission of scrapie and the relative role of 
genetic susceptibility to the disease are long-standing areas of research, but are not yet 
fully understood (Parry, 1979). 
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1.1.2 Bovine spongiform encephalopathy (BSE) 
Bovine spongiform encephalopathy (BSE), also known as “mad cow disease”, is a 
disease in cattle that was first observed as an epidemic in the 1980s, mainly in the UK 
(Wilesmith et al., 1988; Anderson et al., 1996).  BSE was reported to be caused by 
processed animal feed, such as bone meal, containing rendered remains of scrapie affected 
sheep being fed to dairy cattle (Wilesmith et al., 1991; Wilesmith et al., 1988). The 
incidence of BSE assumed epidemic proportion within a very short period of time, with 
thousands of animals becoming affected (Wilesmith et al., 1988; Anderson et al., 1996).   
Since the outbreak in the UK, BSE cases have been reported in many other countries across 
the world, including the USA, Canada and Japan. The disease is characterised 
neuropathologically by spongiform change, neuronal loss and astrogliosis, which comprise 
the core characteristics of prion diseases (Wells et al., 1987).  Clinical symptoms include 
changes in temperament, sensitivity to light and sound, as well as various movement 
disorders. The incidence of BSE in Australia and New Zealand, which are free of scrapie, is 
similar to that in the UK where scrapie in sheep is endemic. As an alternative explanation, 
the origins of BSE may lie in some sporadic cases that arose by chance to trigger the 
epidemic (Weissmann and Aguzzi, 1997). 
1.1.3 Chronic wasting disease (CWD) 
Chronic wasting disease (CWD) is a scrapie-like disease of unknown origin, found in 
North American wild and captive cervids, including mule deer, Rocky Mountain elk and 
captive mule (Sigurdson and Aguzzi, 2006). The disease ranges in duration from a few days 
to a few weeks from the initial onset of symptoms, which can include weight loss and 
excessive drinking (Williams, 2005; Williams and Miller, 2002).  Experimentally, evidence 
confirms the presence of neuronal vacuolation (William and Young, 1980), aggregation of 
PrP in the CNS, as well as lymphoid tissues damage in affected animals (Browning et al., 
2004). It is thought to be transmitted in a manner similar to scrapie, via saliva and blood 
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(Miller and William 2003; Mathiason et al., 2006). However, the route of transmission is not 
clear and there is no evidence for CWD transmission to humans.   
1.1.4 Transmissible mink encephalopathy (TME) 
Transmissible mink encephalopathy (TME) is an animal prion disease seen in farmed 
mink. It has similar characteristics to the CWD found in elk and mule deer, and its 
occurrence is thought to have originated from being fed the meat of scrapie-infected sheep 
(Marsh et al., 1991; Marsh, 1992).  Symptoms of TME include loss of muscle coordination 
and aggression. Following onset, the animal dies within a few weeks. Recent studies have 
reported similarities between TME and BSE in a mouse model (Baron et al., 2007). 
1.1.5 Other animal prion diseases 
Other animal prion diseases such as feline spongiform encephalopathy (FSE) have 
been reported.  FSE has been reported in domestic and captive wild cats, predominantly in 
the UK (Leggett et al., 1990). Other TSEs have been reported in species such as kudu. 
Similarly to FSE, these diseases have been reported to exert similar characteristics to BSE 
and may have been caused by a BSE-like strain transmitted through feeding on 
contaminated material from cattle (Bruce et al., 1994; Collinge et al., 1996b). 
 
 
 
 
 
 
 
 
 
23 | P a g e  
 
 
 
Table 1.1 Prion diseases in animals 
 
 
 
1.2 Human prion diseases 
Humans are susceptible to several prion diseases, amongst which are Creutzfeldt-
Jakob disease (CJD), Gerstmann-Straussler-Scheinker disease (GSS), fatal familial insomnia 
(FFI) and kuru (Table 1.2).  Human prion diseases are rare neurodegenerative disorders, but 
are invariably fatal. They are characterised by the accumulation of aggregated and 
abnormally folded protease resistant PrPSc. Most manifestations of prion diseases in 
humans share a common non-inflammatory pathological process that is largely restricted 
to the CNS and includes deposits of PrPSc in the form of diffuse plaques (Figure 1.3).  
General neuropathological characteristics of human prion disease include spongiform 
degeneration, gliosis and severe neuronal loss (Collinge and Palmer, 1992), which 
ultimately lead the brain to degenerate resulting in a progressive decline in cognitive and 
motor function. Human prion diseases have been classified as occurring as inherited, 
sporadic and acquired forms, with a further sub-classification according to certain 
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molecular criteria (Wadsworth and Collinge, 2007).  Most cases of human prion disease 
occur sporadically, but hereditary, iatrogenic and dietary transmission can also occur. There 
has been a considerable interest in the disease following the identification of new variant 
(v)CJD, and the demonstration through transmission studies that vCJD is caused by the 
same prion strain as that causing BSE (Weissmann and Aguzzi, 1997; Mallucci and Collinge, 
2004). With recent reports of blood-borne transmission (Wroe and Pal, 2006), prion 
diseases remain in the spotlight due to public health concerns. Particular attention has 
focused on the development of therapeutic agents and a diagnostic test (Miller and 
Williams, 2003; Mathiason et al., 2006). 
1.2.1 Sporadic Creutzfeldt-Jakob disease (sCJD) 
Sporadic CJD (sCJD) is a rapidly progressive multifocal dementing disease with 
neurological features that include cerebellar ataxia, neuropsychiatric symptoms and 
myoclonus (Brown et al., 1984; Collins et al., 2006).  sCJD makes up 85% of all recognized 
human prion disease, with an incidence of about 1.2 per million per year and an apparently 
random distribution (Caramelli et al., 2006).  This is possibly an underestimate, since prion 
disease can sometimes be misdiagnosed and confused with other neurological disorders.  
Onset usually occurs from 45-75 years of age, with a peak age of onset between 60-65 
years. Rapid clinical progression usually leads to death within weeks or months. The 
median duration of illness in sCJD is four months with, 14 % of cases having illness duration 
of a year or more, and 5 % of cases surviving greater than twenty years.  Possible causes of 
sCJD are spontaneous production of PrPSc via rare stochastic events, somatic mutation of 
the PrP-encoding gene (PRNP), or some unidentified environmental exposure. Reports on a 
two-case control study suggested prior surgery as a risk factor for sCJD, therefore raising 
the possibility of some sCJD being classified as an acquired illness (Collins et al., 1999; Ward 
et al., 2002). 
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Much clinical heterogeneity exists within sCJD, especially at symptom onset where 
particular focal deficits may be present.  For instance, an isolated progressive cerebellar 
syndrome is observed in approximately 10% of cases, or an isolated progressive visual 
disturbance culminating with cortical blindness known as the Heidenhain’s variant is also 
sometimes reported (Collinge et al., 1996; Hill et al., 1999).  The various clinical phenotypes 
associated with sCJD make it prone to misdiagnosis.  The most difficult differential 
diagnosis of sCJD is the rapidly progressive feature, which can also be a characteristic of 
Alzheimer’s disease (AD), with cases misdiagnosed as sCJD in several series (Zerr et al., 
2000; Tschampa et al., 2001). Definitive diagnosis of sCJD is achieved through 
neuropathological examination of the brain at autopsy.  Cerebral imaging is important in 
excluding other diagnoses, but more recently imaging analysis of sCJD revealed a 
combination of cortical and basal ganglia signal change on magnetic resonance imaging 
(MRI) to have a diagnosis sensitivity of greater than 90% (Young et al., 2005).  MRI is able to 
reveal changes in the density of deep grey nuclei (Di Rocco, et al., 1993).  Pathologically, 
PrP amyloid plaques are not typically present in sCJD.  However, diffuse or synaptic PrPSc 
deposits are often present.  PrP deposits are usually confirmed by immunohistochemistry 
(IHC) (Budka, 2003). The differential diagnosis also includes dementia with Lewis bodies, 
lymphoma and multiple cerebral infarctions (Poser et al., 1999; Steinhoff et al., 2004). 
1.2.2 Acquired prion diseases 
Acquired prion diseases in humans include kuru, iatrogenic CJD and vCJD. Kuru 
arose in the mid-20th century as an epidemic disease in localised parts of Papua New 
Guinea and is associated with exposure to prions during cannibalistic mortuary feasts. 
Iatrogenic exposure occurs through accidental exposure to human prions through medical 
or surgical procedures, most frequently through implantation of dura mater or through 
administration of growth hormone derived from the pituitary glands of human cadavers 
(Brown et al., 1992).  Variant CJD has been shown through strain-typing studies and 
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transmission studies in transgenic mice to be caused by the same prion strain as that 
causing BSE (Parchi et al., 1999; Hill et al., 2003).  
 
Kuru 
Kuru was the first disorder in humans to be shown to be a transmissible prion 
disease. It was brought to prominence in the 1950s during pivotal descriptions of the 
disease in the Fore tribal people in the highlands of Papua New Guinea. It reached epidemic 
proportions among the Fore ethnic group in the remote mountainous areas in which they 
lived (Mead et al., 2003; Gajdusek et al., 1966; Gajdusek et al., 1957).  Kuru means 
shivering or trembling in the Fore language, but is also known as “laughing disease” due to 
the facial grimaces it causes. Kuru is a sub-acute, fatal disease associated with cerebellar 
degeneration. It is a progressive ataxic syndrome with late dementia and other neurologic 
impairments. It is neuropathologically characterised by non-inflammatory loss of neurons, 
gliosis, spongiform change and accumulation of abnormal protease-resistant PrPSc plaques 
(Collinge et al., 2006; Mead et al., 2003).  
A remarkable characteristic of kuru is its association with the practice of ritual 
mortuary cannibalism as a sign of respect for deceased loved ones. The rites involved 
grinding up the brain into a pale Grey soup, which was heated and eaten as a sign of 
respect and mourning for deceased relatives (Alpers, 1987). Studies of the Fore tribe 
showed that kuru transmission was more common amongst women and children, as they 
ate the highly infectious tissue of the CNS, while the men ate relatively safe tissue such as 
muscle. Kuru has gradually disappeared over the past 60 years since the practice of 
mortuary feasting ceased following a ban by the Australian government. Cases of Kuru 
since this ban in the 1950s represent not new infections, but rather long incubation periods 
of infections before the ban (Lindenbaum, 1979).  That kuru could be a human prion 
disease was noted on the basis of similarities in the epidemiology, clinical course and 
histopathological features of kuru and scrapie. This led to the suggestion that the 
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transmission of kuru should be attempted (Collinge et al., 2006), prompting the successful 
experimental transmission of kuru to non-human primates (Gajdusek et al., 1966) 
Iatrogenic CJD 
Iatrogenic CJD is usually referred to as CJD despite having a prominent cerebral 
syndrome more reminiscent of kuru (Wadsworth and Collinge, 2007).  Transmission may 
occur by one of a number of routes involving the use of inadequately sterilised 
neurosurgical instruments due to the high heat resistance of the infectious prion agent.  
The acquired sources of such infection are through medical procedures such as 
neurosurgery, growth hormone injections, and dura mater and corneal transplants, as well 
as the use of gonadotrophin derived from the pituitary gland from cadavers (Brown et al., 
1992; Brown et al., 2000).  Contaminated surgical instruments have been shown to remain 
infectious two years after their reported sterilization (Brown et al., 1992; Brown et al., 
2000).  Over a hundred people have acquired CJD from injections of human growth 
hormone or human gonadotropins, prepared from pooled pituitary glands that 
inadvertently included glands taken from humans with sCJD (Collinge, 1999; Wadsworth et 
al., 2001; Peden et al., 2005). 
Variant CJD (vCJD) 
 
In 1995, a new human prion disease in humans resembling CJD, but showing 
clinically distinct traits, was reported in teenage patients with manifest clinical signs (Will et 
al., 1996; Collinge and Rossor, 1996).  Concerns about cross-species transmission of BSE 
resulting from its epidemic in cattle lead to the establishment in the UK of a National 
Surveillance Unit for CJD, in 1990. Although no cases were noted during the first four years 
of monitoring the disease, twenty two cases of vCJD were reported between 1994 and 
1997. These patients were typically younger than those with more familiar forms CJD, with 
prominent early psychiatric and behavioural manifestations, and persistent paraesthesias 
and dysaesthesias.  Cerebellar ataxia uniformly develops and the course of the disease is 
28 | P a g e  
 
 
 
prolonged.  These new cases of a previously unrecognised prion disease were termed new 
variant CJD (vCJD) (Collinge et al., 1996b; Hill et al., 1997; Bruce et al., 1997; Asante et al., 
2002).  Although rare, further cases in young adults were discovered, with their post-
mortem brain histology showing a consistent and unique neuropathological appearance of 
prominent and diffuse PrPSc plaques reminiscent of kuru. Other symptoms of vCJD include 
anxiety, depression, persistent pain in the limb/face, withdrawal and behavioural changes 
with progression of the disease, with dementia developing thereafter (Peden et al., 2006).   
Direct experimental evidence from molecular analysis of prion strain types, 
transmission studies in transgenic and wild-type mice, and clinical and neuropathological 
correlates, collectively revealed that the disease was caused by the same prion strain as 
that causing BSE in cattle (Collinge et al., 1996b; Hill et al., 1997; Bruce et al., 1997; Asante 
et al., 2002). Intracerebral inoculation of BSE material into primates produced a disease 
pathologically similar to vCJD (Lasmezas et al., 1996). In addition, analysis of proteolysis 
and glycosylation patterns showed identical patterns for BSE and vCJD (Collinge et al., 
1996a). Therefore, vCJD poses a serious potential public health threat. Evidence that the 
causative agents of vCJD and BSE were the same, distinct from the patterns associated with 
sporadic and iatrogenic disease (Hill and Desbruslais, 1997), raised the possibility that an 
epidemic could occur in the UK and other countries as a result of dietary or other routes of 
exposure (Ghani et al., 1999; Collinge , 1999).  
1.2.3 Inherited human prion diseases 
Around 10-15 percent of prion diseases in humans are inherited, occurring due to 
pathogenic autosomal dominant mutations in the PRNP gene (Masters et al., 1981; Windl 
et al., 1999). The human PRNP gene is located on the short (p) arm of chromosome 20 
between the end (terminus) of the arm and position 12, from base pair 4,615,068 to base 
pair 4,630, 233 (Figure 1.2).  The first report of PRNP mutations described insertion and 
missense mutations found in families with a prominence of dominant inherited 
29 | P a g e  
 
 
 
neurodegenerative disease (Owen et al., 1989; Hsiao et al., 1989). Over thirty different 
pathogenic mutations have since been recognised, with point mutations leading to amino 
acid substitution, a premature stop codon, or insertion of additional octapeptide repeats.   
 
 
 
Figure 1.1 Mutations and polymorphisms in the PRNP cDNA. 
Diagram of the human prion protein gene showing the octapeptide (51-91). Pathogenic 
mutations associated with inherited prion disease are shown above the gene (red), while 
non-synonymous polymorphisms and synonymous polymorphisms are shown below the 
gene (green). A polymorphism at codon 129 methionine (M) versus valine (V) is a common 
mutation in European populations, while a polymorphism at codon 219 glutamic acid (E) 
versus lysine (K) is common in Japanese populations1. 
 
                                                        
1 Adapted from Llyod et al., 2011. 
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Analysis of the PRNP gene has allowed for a clear pre-symptomatic diagnosis of 
inherited prion diseases (Collinge, 2005).  There are many clinical symptoms manifested 
depending on the type of mutation involved, as well as a variety of neuropathological 
features (Chapman et al., 1993; Barbanti et al., 1996; Wadsworth et al., 2006).  It is 
important to note that a single PRNP mutation can elicit different phenotypes, highlighting 
the role of epigenetic factors in prion disease pathogenesis.  Although it is unclear how the 
PRNP mutations cause disease, many hypotheses have been postulated (Peden et al., 
2004).  The most common one is a tendency of the mutated PrPC to spontaneously form 
abnormal infectious PrPSc (Section 1.7).   Other studies report that the pathogenesis of 
inherited prion diseases may be due to a change in the thermodynamic stability of the 
mutated PrP (Riek et al., 1998; Swietnicki et al., 1998). 
Familial CJD (fCJD) 
Between 10 and 15 percent of persons with CJD have a family history consistent 
with an autosomal dominant inheritance of the disease.  Most of these point mutations, 
deletions or insertions are found in the coding sequence of the gene for PrP on the short 
arm of chromosome 20.  More than 20 mutations in this gene have been described that are 
associated with phenotypes mimicking typical CJD or induce distinctive progressive 
diseases with spongiform changes in the nervous system (Johnson and Gibbs, 1998).  In 
general, familial CJD has an early age of onset and a more protracted course than sporadic 
disease.  The typical electroencephalographic changes are often missing and the 14-3-3 
protein is not detected in cerebral fluid in about half of cases (Zerr et al., 1998).  The 
neuropathological changes may vary in topographic distribution and in the prevalence of 
amyloid plaques, but the essential changes of vacuolization of neural cells with gliosis and 
neuronal loss are generally present.  The most common mutation leading to the typical 
clinical and pathological findings of CJD is at codon 200.  Clusters of disease among Libyan 
Jew in Israel, in a region of Slovakia, and in Chile are all explained by this mutation 
(Goldfarb et al., 1991). 
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Gerstmann-Straussler Scheinker disease (GSS) 
GSS, first described in the early 20th century, is a distinct autosomal dominant prion 
disease.  Phenotypic variability is a major feature with a median range of onset of 50 years 
of age (range 25-70 years) and a median duration of 4 years (Barbanti et al., 1996).  The 
traditional GSS phenotype is a slowly progressive ataxia resulting later in dementia 
(Kretzschmar et al., 1992).  Although dementia is less common in GSS, the disease course 
lasts several years until death. The histological hallmark is the presence of the multicentric 
amyloid plaques.  GSS is most commonly associated with the P102L mutation in the PRNP 
gene, in which a proline is replaced by a leucine residue at position 102. It can also be 
associated with a valine instead of an alanine residue at position 117 (A117V).  
Fatal Familial Insomnia (FFI) 
FFI is a progressive and untreatable insomnia disorder, first described in 1986.  It is 
an autosomal dominant inherited sleep disorder, associated with particularly prominent 
cortical astrocytosis (Collinge and Palmer, 1997). Early thalamic generation of FFI and 
related disorders produces the distressing symptom complex of progressive insomnia with 
late dementia. People with this rare disorder have inherited a PRNP gene with an 
asparagine residue instead of aspartic acid encoded at position 178 (D178N).   
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Table 1.2 Neuropathological criteria for diagnosis of human prion diseases2. 
 
 
1.3 Prion disease genetics 
 
Most inherited human prion diseases, as described above, are associated with 
mutations in the PRNP gene. However, PRNP polymorphisms can also influence the 
conformational change of the protein to influence sporadic and acquired forms of the 
disease. In particular, homozygosity at amino acid position 129 of human PrP predisposes 
                                                        
2 From the world Health Organisation, http://www.WHO.int 
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an individual to acquired and sporadic CJD. Individuals can be either homozygous for 
methionine (M) or valine (M) at this codon, or heterozygous.  The influence of codon 129 is 
seen, for example, in patients with a D178N mutation and a methionine at position 129 
who will go on to develop FFI, whereas family members with a valine at 129 in addition to 
the D178N mutation will develop familial CJD (Gambetti et al., 1995; Goldfarb et al., 1992)  
(Figure 1.1).  
The codon 129 genotype also has a profound effect on the incubation period of and 
susceptibility to kuru, with the MM genotype having the shortest incubation period, 
followed by VV homozygotes (Lee et al., 2001).  MV heterozygotes are the most resistant 
genotype, having been reported to show incubation times greater than fifty years (Collinge  
et al., 2006).  Several families previously exposed to mortuary feasts have been studied and 
elderly women survivors who were monitored are predominantly PRNP codon 129 
heterozygotes (Lee et al., 2001; Mead et al., 2003). It is notable that PRNP codon 129 
homozygotes have been essentially eliminated in the Fore population, as kuru imposed a 
strong balancing selection.  The polymorphism at codon 129 appears to be the main 
genetic risk factor for vCJD (Mead et al., 2009), with every case genotyped being 
homozygous for methionine at codon 129 apart from a recent case report of vCJD in an 
individual heterozygous for PRNP codon 129 (Kaski et al., 2009). This particular case 
highlights the further potential of clinically silent cases of vCJD in the UK population.  There 
is a marked genetic susceptibility to sCJD, with most cases occurring in homozygotes of 
methionine (M) or valine (V) at codon 129 of the PRNP gene; MV heterozygotes appear to 
be relatively protected from developing sCJD (Palmer et al., 1991).  Moreover, genetic 
studies have revealed polymorphisms upstream of exon 1 of the PRNP gene (Mead et al., 
2001) and in the 5’ UTR (Vollmert et al., 2006), that are reported to be associated with 
sCJD. 
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One possibility of a genetic explanation for these mutations could be that they 
enhance the rate of spontaneous conversion of PrPC to PrPSc, permitting disease 
manifestation within the lifetime of an individual. This suggests that some sporadic 
incidents of prion disease can be accounted for by somatic mutations of the PRNP gene, 
which is an alternative explanation that these mutations confer susceptibility to infection. It 
has been known that some breeds of sheep in the UK have specific genotypes that confer 
resistance to sheep scrapie and these sheep are resistant to BSE as well (Weissmann and 
Aguzzi, 1997).   
 
 
Figure 1.2 The PRNP gene. 
The human PRNP gene is located on the short (p) arm of chromosome 20 between the end 
(terminus) of the arm and position 12, from base pair 4,615,068 to base pair 4,630, 233.   
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1.4 Prion disease neuropathology 
 
Prion diseases are diagnosed clinically at post-mortem by histopathological 
examination of brain tissue: neuropathological assessment of the structural changes in the 
CNS has been the mainstay in diagnosis of human prion diseases for many years.  
Histological analyses of both human and animal tissue shows that prion diseases cause a 
variety of neurological damage in the CNS resulting in neuronal cell death and brain 
atrophy (Kubler et al., 2003). The neuropathology of human prion diseases is characterised 
by four features: spongiform change, neuronal loss, astrogliosis and amyloid plaque 
formation, though the last feature is not always present. However, different prion diseases 
often have unique neuropathological features (Budka, 2003) (Figure 1.3, 1.4). For instance, 
vCJD is characterised by markedly increased accumulation of PrPSc in the brain and an 
accumulation of discrete plaques surrounded by prominent spongiosis (Will et al., 1996; 
Collinge and Rossor, 1996).  In most human prion disease cases, the histologically 
distinctive vacuoles can appear in any layer of the cerebral cortex and may become 
confluent resulting in substantial distortion of the cortical network cytoarchitecture.  Most 
cases of CJD are usually accompanied by spongiform change in the basal ganglia, thalamus, 
and cerebellar cortex.  However, it is also recognized that these changes are enormously 
variable both from case to case, and within different parts of the CNS in individual cases.   
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Figure 1.3. Characterisation of disease-related spongiosis and gliosis in human 
prion disease. 
(A) Spongiform changes in the cerebellum comprise multiple small vacuoles in the 
molecular layer which usually do not appear confluent. Spongiform change in most brain 
regions is accompanied by neuronal loss and gliosis involving both astrocytes and microglia. 
The tissue was stained for Glial Fibrillary Acidic Protein (GFAP). (B) Microglial hypertrophy 
and hyperplasia occur in a widespread distribution within the CNS in CJD, and microglia are 
also implicated in the pathogenesis of PrP plaques.  Immunocytochemistry studies in both 
human and animal prion diseases have demonstrated that microglial cells are intimately 
involved in PrP plaque formation, and may perhaps play a role in the processing of PrP into 
an amyloid structure. The tissue was stained with haematoxylin and eosin (H&E). 
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Figure 1.4 Characterisation of disease-related PrP in human prion disease. 
Brain sections from sporadic CJD (A) and variant CJD (B) showing abnormal PrP 
accumulation following immunohistochemistry using anti-PrP monoclonal antibody, 
ICSM35. Abnormal PrP deposition in sCJD most commonly present itself as diffuse, synaptic 
staining, whereas vCJD brain is distinguished by the presence of florid plaques consisting of 
a round amyloid core surrounded by a ring of spongiform vacuoles3.  Scale bars: 50 µm. 
1.5 Prion disease transmission 
 
Prion disease transmission occurs naturally through peripheral routes, either orally or 
trans-cutaneously. They can be transmitted through direct inoculation into the brain, or a 
closely related organ such as the eye (Johnson and Gibbs, 1998).  CJD cases occurring after 
growth hormone injection show transmission via the bloodstream (Brown et al., 1992). 
Scrapie prions injected into limbs are able travel along peripheral nerves to the CNS 
(Kimberlin and Walker, 1980).    
 
                                                        
3 Adapted from Wadsworth et al., 2010. 
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Several lines of evidence suggest an involvement of the lymphoid system in the early 
stages of acquired prion disease. In particular, the spleen and lymph nodes have been 
demonstrated to be the first sites of the PrPSc replication after infection by peripheral 
routes (Hilton et al., 2002). Indeed, splenectomy and other methods that reduce peripheral 
lymphoid structures delay clinical manifestations following infection (Hilton et al., 2002).  
Diagnostic tests for scrapie based on detecting PrP in tonsillar tissue of infected sheep and 
goats have been developed (Van Keulen et al., 1996; Schreuder et al., 1996). The presence 
of PrP in peripheral lymphoid tissue can be observed on the surface of follicular dendritic 
cells (Muramoto et al., 1992), suggesting that transport by immune cells, such as 
macrophages or lymphocytes, could be important. However, the role of the immune 
system in this group of diseases is not well understood (Aguzzi and Calella, 2009; Brandner 
et al., 1999). 
In BSE, infected animals showed that infectivity is virtually restricted to the nervous 
system, with only low infectivity in the lymph nodes and spleen (Brown et al., 1994). 
Muscle tissue seems to be relatively free of infectivity, even though PrPC is expressed in 
skeletal muscle (DeArmond, 2004; DeArmond et al., 1996). In lambs exposed to scrapie-
infected flocks, infectivity is first found at about one year of age in the lymphatic tissues 
and intestines, suggesting transmission by way of the alimentary tract.  Infectivity in the 
brain is found at about two years of age, and infectivity slowly increases in the brain, with 
resultant spongiform changes and clinical disease during the subsequent year. In studies 
with mice infected with prions by sub-cutaneous inoculation, infectivity was found first in 
the lymphatics and spleen, and later in the brain (Eklund et al., 1967). Other studies have 
shown infectivity has been found in the blood of experimentally infected rodents (Kuroda 
et al., 1983). In addition, the presence of differentiated B cells appears important for 
invasion of the nervous system of the mouse after intraperitoneal inoculation (Klein et al., 
1997). In all affected species, infectivity is greatest in brain tissue, but is also present in 
some peripheral tissues. The route of entry of the pathogen, infectivity of blood and tissue 
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at different stages of the infection, and variations between species and between the routes 
of inoculation of the nervous system, are central to many of the questions about the risk of 
prion infection.   
1.6 The protein-only hypothesis of prion propagation 
 
The prion protein-only hypothesis asserts that infectivity in prion diseases resides 
solely in a protein – a proteinaceous infectious particle, or prion. For many years, the 
nature of the infectious agent causing scrapie was subject to much debate. In particular, 
the scrapie infectious agent was known to be highly resistant to treatments that modify 
nucleic acids such as ultraviolet radiation and nucleases, but could be inactivated by 
exposure to compounds that destroy or denature proteins such as detergents (Alper et al., 
1967; Alper et al., 1978; Prusiner 1982). In the 1960s, a physicist called J.S Griffith first 
raised the possibility that the material responsible for the transmission of prion diseases 
could be a protein that is able to replicate itself (Griffith, 1967).  This hypothesis required 
that a protein with the ability to be infectious was purified and characterised. The work of 
Stanley Prusiner culminated in a partial purification protocol, involving ultracentrifugation 
and treatment with proteinase K, for a proteinaceous infectious agent (Prusiner et al., 
1981).  Further work by Prusiner and colleagues demonstrated the presence of a disease-
associated protein as a component of the infectious agent, rather than a product of the 
disease (Bolton et al., 1982; Prusiner et al., 1982; Hope et al., 1986; Safar et al., 1990). The 
lack of a nucleic acid genome distinguishes prions from other infectious pathogen such as 
bacteria, fungi, viruses and viroids (Prusiner, 1982).   
The initial purification protocols were adapted by the addition of a sucrose gradient 
step to isolate and identify the major constituent of infective fractions from hamster brain 
homogenates (Prusiner et al., 1982).  Subsequent experimental data showed that the major 
constituent of infectivity was a 27-30 kDa protease-resistant protein, designated prion 
protein (PrP)27-30 (Figure 1.5).  A protein of similar size was identified in uninfected brain 
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tissue, but unlike the disease-associated protein, it was completely digested by proteinase 
K treatment (Bolton et al., 1982). Experimental evidence confirming that the purified 
protein was infectious came from the transmission of scrapie into Syrian golden hamsters 
(Prusiner et al., 1980; Prusiner et al., 1982). 
The successful purification of PrP led to the identification of its amino acid sequence, 
allowing further analysis of the protein and the production of anti-PrP antibodies 
(Bendheim et al., 1984). The protease-resistant protein fragment, PrP27-30, was co-purified 
with scrapie infectivity in hamster brain, which allowed the molecular cloning and 
sequencing of PrP cDNA (Basler et al., 1986).  Following the purification of the prion 
protein, the gene encoding PrP was identified.  Amino acid sequencing of the N-terminus 
PrP27-30 was used to derive a cDNA clone encoding a host protein, which subsequently 
demonstrated that PrP27-30 was encoded by a chromosomal gene (Oesch et al., 1985; Basler 
et al., 1986). Several lines of research suggested that a normal host-encoded protein 
undergoes a post-translational modification to become an abnormal infectious form. There 
was no evidence to support the notion that the PrP encoding gene (PRNP) undergoes re-
arrangement during disease or a genetic basis for alternative splicing of the gene transcript 
(Basler et al., 1986).  Other studies demonstrated that the PrP mRNA does not increase 
during the course of prion disease (Oesch et al., 1985). Amino acid sequencing studies of 
the N-terminus of PrPC and PrPSc revealed similarities between the two, suggesting that the 
observed differences are due to post-translational modifications (Turk et al., 1988). 
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Figure 1.5 Prion protein isoforms.   
Bar diagram of the hamster Prnp gene and PrP isoforms.  The Prnp ORF encodes a protein 
of 254 residues, which is shortened to 209 residues during posttranslational processing. 
PrPsc is an alternate conformation of PrPC with  identical primary structure.  Limited PrPsc 
cleaves the amino terminus and produces PrP 27-30, composed of approximately 142 
residues4.  
The protein-only hypothesis was adapted, therefore, to suggest that infectivity arose 
from a single protein with an identical nucleic acid and amino acid sequence that could give 
rise to two conformations with exceedingly different properties. One is a normal cellular 
isoform (PrPC), expressed in normal brain which is readily soluble and protease-sensitive; 
the other an abnormal scrapie-associated isoform (PrPSc) that accumulates in infected 
brain, is poorly soluble and partially protease-resistant, and is associated with infectious 
activity. Prions are, therefore, encoded by alterations in protein conformation rather than 
in nucleic acid or amino acid sequence (Cashman, 1997). Further evidence for this comes 
                                                        
4 Adapted from Colby and Prusiner, 2011. Cold Spring Harb Perpect Biol. 
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from findings that inherited prion diseases are linked to mutations in the PRNP gene 
(Collinge, 2001), indicating that in these cases a genetic disease may be propagated in an 
infectious way. 
The dependence of PrPSc generation on PrPC has been demonstrated in vivo in PrP 
knockout mice, which are entirely resistant to scrapie (Sailer et al., 1994; Mallucci et al., 
2002). This finding is supported by a study in a cell-free system (Kocisko et al., 1994). These 
observations demonstrate that host-encoded PrPC is necessary for the disease (Pruisner et 
al., 1993). Studies in transgenic mice indicate that mutations in the PRNP gene or 
overexpression of PrP can lead to spontaneous spongiform changes (Prusiner, 1996). The 
protein-only hypothesis is now the most widely accepted model of prion propagation, and 
forms the basis of work to characterise the replication and transmission of the prion 
disease infectious agent (Prusiner, 1998; Abid and Soto, 2006; Tatzelt and Schatzl, 2007; 
Wadsworth and Collinge, 2007). 
Unequivocal proof of the protein-only hypothesis is frequently suggested to reside 
in demonstrating the in vitro generation of infectious prions solely from PrP. In vitro 
replication of PrPSc was first demonstrated using an amplification system that used radio-
labelled PrPC (Kocisko et al., 1994), but this method was not successful in transmission 
barrier studies (Bessen et al., 1995; Raymond et al., 1997). A more recent method of 
amplification, a protein misfolding cycling amplification (PMCA) assay, has proven more 
successful (Castilla et al., 2005).  Experiments using PMCA have been efficient in regards to 
amplification and infectivity, and have helped to demonstrate that infectious material can 
be produced in a cell-free system, leading to a scrapie–like disease when inoculated into 
mice (Supattapone, 2004; Castilla et al., 2005).  In addition, it has been reported that 
synthetic prions that polymerise into fibrils in vitro have been shown to be infectious in vivo 
(Legname et al., 2004).  
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1.7 The prion protein (PrP) 
1.7.1 PrPC structure and function 
 
The normal prion protein, PrPC, is a host-encoded 250 amino acid glycoprotein that 
is widely expressed throughout the body. This 30-35-kDa protein is found abundantly in the 
neurons and glia of the brain, as well as in several peripheral tissues and leukocytes 
(Dodelet and Cashman, 1998; Harris, 1999; Aguzzi and Polymenidou, 2004). There is slight 
variation in the exact size of the protein in different species due to the number of 
octapeptide repeat region in the N-terminus of the protein (Stahl et al., 1990; Stahl et al., 
1987). Most PrPC molecules are normally localized on the cell surface, where they are 
attached to the lipid bilayer via a C-terminal, glycosylphosphatidylinositol (GPI) anchor 
(Stahl et al., 1990; Stahl et al., 1987). 
Studies by Fourier Transform Infrared Spectroscopy (FTIR) and circular dichroism 
have demonstrated that PrPC is predominantly α-helical as compared to PrPSc, which is rich 
in β-sheet (Gasset et al., 1993; Pan et al., 1993). It contains a globular domain with three 
alpha-helices and a two-stranded antiparallel beta-sheet, an NH2 terminal tail, and a short 
COOH terminal tail (Riek et al, 1997). PrPC is divided into two distinct regions: one N-
terminal region that is flexible and contains an octapeptide repeat domain and a C-terminal 
region which comprise 3- alpha helical structures and two anti-parallel beta sheet 
structures. The C-terminal domain of PrPC is folded into alpha-helices that are stabilized by 
a single disulphide bond and nuclear magnetic resonance (NMR) revealed that it is 
monomeric (Riek et al, 1996).  Studies into the C-terminus of PrP revealed a crystal 
structure that has three alpha-helices and a short anti-parallel beta-sheet (Knaus et al., 
2001; Haire et al., 2004; Eghiaian et al., 2004). The octapeptide repeats have been shown 
to have tight binding sites for Cu2+ and Zn2+, suggesting possible regulatory and signalling 
properties (Riek et al., 1998; Hosszu et al., 1999; Jackson et al., 2001). The N-terminus of 
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PrPC contains an octapeptide repeat, which is thought to be involved in the cellular function 
of PrPC.   
Comparing the sequences of PrPC from various mammalian species demonstrates 
that it is highly conserved (Damberger et al., 1995).  However, its precise cellular function 
remains unknown. Possible suggestions have included copper binding, signal transduction, 
regulation of immune responses, synaptic functions and roles in apoptosis (Seidel and 
Engelhard, 2011; Haigh et al., 2010). As mentioned above, the N-terminal region of PrPC 
containing the octapeptide repeats represents a high-affinity binding site for copper ions 
properties (Riek et al., 1998; Hosszu et al., 1999; Jackson et al., 2001). In addition, recent 
evidence suggests that copper imbalance is an early change during infection, suggesting PrP 
may have a role in copper transport or metabolism.  PrPC has been described to be a 
positive regulator of neural precursor proliferation during developmental and adult 
mammalian neurogenesis. Several lines of evidence have also suggested that PrPC may 
exert a cytoprotective activity, particularly against internal or environmental stresses that 
initiate an apoptotic cascade (Roucou and LeBlanc, 2005; Roucou et al., 2004). Various 
studies suggest that PrPC can activate transmembrane signaling pathways involved in 
several different phenomena, including neuronal survival, neurite outgrowth, and 
neurotoxicity (Westergard et al., 2007).   
The biosynthetic pathway followed by PrPC is similar to that of other membrane and 
secreted proteins, involving synthesis on ER-attached ribosomes, transit to the Golgi, 
followed by delivery to the cell surface.  Since PrPC is a GPI-anchored protein, the entire 
polypeptide chain is located on the extracytoplasmic face of the lipid bilayer, which is 
known to serve as molecular scaffolds for signal transduction (Tsui-Pierchala et al., 2002; 
Taylor and Hooper, 2007). Some of the protein is transferred to clathrin-coated pits where 
it is subject to constitutive endocytosis and recycling (Sunyach et al., 2003; Naslavsky et al., 
1996; Shyng et al., 1994). PrPC can be produced in three topological conformations: the 
normal plasma membrane GPI-anchored PrPC; the transmembrane C-trans form (Ctm PrP), 
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for which the C-terminus part is in the ER lumen; and a N-trans membrane (NtmPrP) for 
which the NH2-terminus is in the lumen (Crozet et al., 2008).  
1.7.2  PrPSc structure 
 
Studies comparing PrPSc and PrPC reveal marked differences in their respective 
tertiary structure, with PrPSc containing a much higher percentage of β-pleated-sheet 
regions (~45%) as compared to PrPC (~3%) (Gasset et al., 1993; Pan et al., 1993; DeArmond 
and Prusiner, 1995).  This difference in tertiary structure causes PrPSc to have a high 
tendency to form aggregated, insoluble deposits (Prusiner, 1996; Riek et al., 1996). PrPSc is 
insoluble in non-ionic detergents and has a partial resistance to proteases. Only its N-
terminus is readily cleaved, leaving a protease resistant core that retains infectivity 
(Riesner, 2003).  The propensity of PrPSc to form aggregates correlates with its resistance to 
proteinase K digestion (Prusiner, 1996; Riek et al., 1996). 
Distinguishing PrPSc from PrPC relies on the differential mobility of the protein on 
SDS-PAGE and the partial resistance of PrPSc to proteinase K digestion (Parchi et al., 1996; 
Collinge et al., 1996b). Different prion strains, moreover, can exhibit different levels of 
proteinase K-resistance (Bessen and Marsh, 1994; Bessen and Marsh, 1992) and PrPSc 
glycosylation patterns (Khalili-Shirazi et al., 2005). For example, distinct ratios of the PrPSc  
domains glycoforms (di-, mono- and unglycosylated) have been reported when comparing 
several prion strains, and is clearly demonstrated by comparisons between the PrPSc 
associated with sCJD and vCJD prions in humans (Collinge et al., 1996a; Hill et al., 2003) 
(Figure 1.6). The C-terminus of PrPSc can be digested by cathepsin D, which liberates its GPI 
anchor, but leaves it retaining prion infectivity (Lewis et al., 2006). Indeed, it has been 
shown in transgenic mice expressing PrP lacking a GPI anchor can propagate prions 
(Chesebro et al., 2005), thereby suggesting that the GPI anchor is not a prerequisite 
component of the infectious prion. Unlike PrPC, which is readily cleaved from membranes 
by treatment with phosphatidylinositol-specific phospholipase C (PIPLC) (Stahl et al., 1987), 
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PrPSc is resistant to such treatment (Caughey et al., 1990; Borchelt et al., 1993). This 
suggests a conformational change preventing accessibility of PIPLC. 
    
Figure 1.6 Distinct prion strain of Creutzfeldt-Jakob disease.   
 (A) Immunoblot of  proteinase K digested brain homogenates using anti-PrP monoclonal 
antibody 3F4 showing PrPSc types 1-4 in human brain according to the London classification 
Types 1-3 PrPSc are seen in the brain of classical forms of CJD (either sporadic or iatrogenic 
CJD) and kuru, while type 4 PrPSc  is uniquely seen in vCJD brain.  (B) Relative proportion of 
di- and monoglycosylated PrPSc glycoforms following partial digestion with proteinase (K) in 
tonsil. The vCJD has a peripheral pathogenesis distinct from classical forms of CJD, with a 
prominent and uniform involvement of lymphoreticular tissues5. 
Further insights into the native conformation of PrPSc are hindered by its insolubility 
and aggregation state. Amyloid, defined as extracellular proteinaceous deposits with a 
cross β-sheet structure, is readily detected by reagents such as Congo Red (Pedersen et al., 
2010). Protease resistant PrPSc has been shown in vivo to re-arrange into amyloids rods, 
which stain with the dye Congo red and show green-gold birefringence, the typical 
presentation of amyloids (Prusiner et al., 1983). PrPSc deposits can vary in size and 
morphology, and amyloid plaques have been identified in the brain tissue of animals 
                                                        
5 Adapted from Wadsworth and Collinge, 2011 
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infected with scrapie (Merz et al., 1981). Studies using synthetic fibrils have provided clues 
on human prion diseases (Baskakov et al., 2002; Tattum et al., 2006).  Studies have 
demonstrated that small PrP oligomers of 14-28 molecules are maximally infective 
compared to monomeric or fibrillar PrP (Silveira et al., 2005). 
1.7.3  PrPSc conversion 
 
The precise mechanisms of the conversion of PrPC to PrPSc are not fully understood. 
PrPSc is suggested to act as a seed, providing a template for its own conversion from PrPC. 
As this conversion event proceeds, small soluble aggregates are formed, which then 
become large insoluble deposits as the disease progresses. These PrPSc deposits accumulate 
in neural cells leading to disruption of their function and cell death. Current models 
propose that PrP fluctuates between its native PrPC state and a series of conformations 
where the molecule self-associates to form a stable multimeric PrPSc molecule composed of 
misfolded monomers (Collinge, 2005).  Studies using recombinant protein have shown that 
ß-sheet-rich PrP aggregation occurs until it reaches a critical size at which it remains stable 
(Prusiner, 1998).  However, it is not clear whether such alternative conformational states of 
the protein are sufficient to adopt a PrPSc-like conformation that is infectious and causes 
disease. It has been reported that particular PrPSc molecules can only convert PrPC of the 
same, or at least similar, primary structure.  For example, yeast engineered to form two 
types of prions form two types of “pure” aggregates within the cell, suggesting that each 
type of prion finds and aggregates with others of its own type.  In PrP, this requirement for 
“like-with-like” resides in a short sequence at its N-terminal (Wickner, 1997; Serio and 
Lindquist, 2000; Wickner et al., 2007). 
The site of PrP conversion in the cell has been thought to either be the cell surface 
membrane or within the endocytic pathway. PrPSc is located at the membrane and is 
continuously recycled through endocytosis (DeArmond and Ironside, 1999). Recently, a 
unique cell system in which epitope-tagged PrPC is expressed in a PrP knock-down 
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neuroblastoma cell line demonstrated that the initial site of PrP conversion is at the cell 
surface membrane, after which PrPSc is trafficked into the cell (Goold et al., 2011). This 
conversion of PrPC to PrPSc at the cell membrane is extremely rapid following prion 
infection, with synthesis of PrPSc being observed within minutes of cells being exposed to 
infectious prions (Goold et al., 2011). 
 
1.8 Prion strains and transmission barriers  
 
Prion strains remain the most challenging phenomenon in prion biology. Different 
prion isolates often have different properties that remain consistent over repeated 
passages, and are referred to as strains.  Distinct prion strains can be distinguished in vivo 
by differences in clinical signs, histological markers and incubation time (Morales et al., 
2006). The possibility of distinct prion strains was first recognised in scrapie sick goats 
showing two different clinical syndromes, called “hyper” and “drowsy” (Pattison, 1965). 
Prion strains are defined as infectious isolates that when transmitted to identical host 
exhibit consistently distinct prion disease phenotypes (Aguzzi et al., 2007). The distinct 
pathologies and incubation periods in experimental animals associated with strains have 
been attributed to multiple forms of abnormal PrP folding (Telling, 1996).  The existence of 
prion strains could be the underlying cause of the different forms of prion disease, each 
with their own incubation time and clinical severity (Bruce et al., 1991). 
  
To comply with the criteria of the prion-only hypothesis of prion propagation, PrPSc 
needs to contain all the information necessary to encode strain formation (Hill and Collinge, 
2003; Bruce, 1993).  PrPSc encoded strain specificity was observed in the serial passage of 
two different strains of TME in hamsters, which demonstrated that they are associated 
with different physical and chemical properties of PrPSc (Bessen and Marsh, 1994; Bessen 
and Marsh, 1992). Prion strains can be propagated in lines of inbred mice with the same 
PRNP genotype (Scott et al., 1997), suggesting that strains are not encoded by differences 
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in the primary sequence of PrP. Strains most likely arise from alternative PrPSc 
conformations and glycosylation patterns (Bartz et al., 2000; Peretz et al., 2001; Morales et 
al., 2006). Indeed, distinct ratios of PrPSc glycoforms (di-, mono- and unglycosylated) are 
observed in different prion strains (Collinge et al, 2006; Hill et al, 2003) (Figure 1.6).  
  
Each prion strain is believed to have a precise set of biochemical characteristics in 
the infectious protein that is specifically linked to it. However, disease incubation times for 
a single prion isolate may vary when inoculated into different mouse strains (Collinge et al., 
1996; Hill et al., 2003). This variation depends on the PRNP gene, suggesting some forms of 
PrPC may be more easily converted to PrPSc than others.  For example, BSE can be 
transmitted to a wide range of hosts, while maintaining specific characteristics after 
passage through an intermediate species. A combination of PRNP genotype and properties 
of the infectious strain influence the pattern of PrPSc deposition, and strain specific 
incubation times can be explained by differences in the relative efficiency of allotypic 
interactions that lead to conversion of PrPC to PrPSc (Carlson et al., 1986).  
Prions isolated from one animal species often have reduced infectivity to other 
species, and if infectious at all, often have a longer incubation time (Wadsworth and 
Collinge, 2007). This phenomenon is known as a species barrier. Species barriers exist for all 
prion diseases, and these barriers are more impenetrable in some species than in others. 
This manifests itself in cases where prions from species A are used to infect species B, and 
not all animals from species B develop the disease, or those that do present a prolonged 
and variable incubation time of the disease (Moore et al., 2005).  Nonetheless, in some 
cases, on a secondary passage from species B to other members of the same species, all 
animals succumb to disease and display shorter and more consistent incubation times 
(Figure 1.7).  
The species barrier phenomenon is thought to depend on dissimilarities in PrP 
sequence and structure, thereby hindering the PrP conversion process (Palmer et al., 1991; 
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Chen and Gambetti, 2002; Vanik et al., 2004).  Minor differences in sequence between 
species in the gene for PrP may determine the risk of spontaneous misconformation, and 
other sequence differences may determine the likelihood of disease crossing species 
barriers and explain the lack of phylogenetic order in transmission.  For example, normal 
sequence differences could explain why scrapie can be transferred from sheep to mice but 
not pigs, or why bovine isoforms can cause degenerative disease in cats but not dogs, and 
why the disease may be spread to humans by beef products but not those from sheep. 
Species barriers have been studied extensively in mice, including transgenic mice 
expressing human rather than mouse PrP. In contrast to their wild-type counterparts, 
transgenic human PrP-expressing mice readily succumb to disease after infection with sCJD 
prions (Collinge et al., 1995a).  On the other hand, vCJD prions are able to infect both 
human PrP-expressing transgenic and wild-type mice (Hill et al., 1997; Bruce et al., 1997). 
Collectively, these studies highlight the fact that transmission barrier may be more suitable 
to describe transmissibility of prions strains instead of species barrier. Various models have 
been proposed to explain the transmission barrier (Hill and Collinge, 2003; Collinge and 
Clarke, 2007). Cross-species transmission remains a health concern founded on the 
emergence in the UK and later elsewhere of vCJD resulting from the consumption of BSE-
infected material (Hill et al., 1997; Bruce et al., 1997).   
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Figure 1.7 Schematic of prion transmission. 
Susceptibility of a host to prion infection is co-determined by the prion inocula and the PrP 
gene.  When prions are transmitted from one species to another disease develops only 
after a very long incubation period, if at all, but on serial passage in the new species the 
incubation time often decreases dramatically and then stabilizes.  This species barrier can 
be overcome by introducing a PrP transgene from the prion donor i.e. hamster PrPSc but 
not murine PrPC is a suitable substrate for conversion to hamster PrPSc by hamster prion. 
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1.9 Yeast prions 
 
Non-mammalian prion proteins were discovered in the yeast, Saccharomyces 
cerevisiae, by Reed Wickner in the 1990s, who proposed that unexplained instances of 
cytoplasmic inheritance in yeast and other fungi were due to the same phenomenon that 
had been proposed to underlie mammalian prion diseases (Wickner, 1997; Serio and 
Lindquist, 2000; Wickner et al., 2007).  Since then, the study of yeast prions has contributed 
significantly to a better understanding of mammalian prions. This is despite fungal prions 
not being associated with any known pathogenic state. These prions behave in a similar 
manner to the PrP protein, although they are generally not toxic to their hosts and may 
even confer an advantage through a form of a protein-based inheritance (Lindquist et al., 
2003). A few molecules of a PrPSc-like form of the Sup35 protein, when introduced into 
yeast cells, converts the yeast cell’s own Sup protein into prion aggregates. 
Two yeast proteins, Sup35 and Ure2, can exist as either normal PrPC-like forms or an 
abnormal PrPSc form.  Studies of fungal prions have given strong support to the protein-only 
hypothesis for mammalian prions and it has been demonstrated in vitro that purified 
protein extracted from yeast cells with a prion state can convert the normal form of the 
protein into the abnormal form.  In the case of the translation termination factor Sup35, 
the conformational conversion results in fibril formation and can be reproduced in a cell-
free system (Glover et al., 1997).  When introduced into normal yeast cells, the 
polymerised forms of Sup35 cause them to adopt the mutant, or {PSI+}, phenotype.  
Different forms of aggregates generated in vitro under specific conditions give rise to 
different phenotypes in the transformed yeast, demonstrating the link between protein 
conformation and phenotype (King and Diaz-Avalos, 2004). Collectively, these observations 
have shed considerable light on the mechanisms of conversion and propagation of 
mammalian PrP.  The degree to which yeast prions are pathogenic in these organisms, or 
have evolved for other specific functions, remains an area of considerable interest. 
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1.10 Prion-mediated neurodegeneration 
 
The mechanisms by which prions induce toxicity in neuronal cells are only partially 
understood.  However, some studies support a cytosolic localisation for a small proportion 
of PrPSc in prion infected neuronal cells (Figure 1.8).  In prion infected neuronal cells, 
toxicity is linked to a cytosolic localisation of a small proportion of PrPSc in aggresomes 
(Kristiansen et al., 2005). However, it is unclear how PrPSc oligomers traffic inside neurons 
and enter the cytosol resulting in UPS inhibition. Previous studies suggested that 
intracellular neuronal propagation of pathogenic PrPSc appears important in neurotoxicity 
(Brandner et al., 1996; Mallucci et al., 2003). Other studies have shown that various 
proteolytic stress condition can cause functional impairment of the UPS which result in 
cellular dysfunction and apoptosis (Lindsten et al., 2002). 
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Figure 1.8 Model for the mechanism of oligomeric PrP-induced 
neurodegeneration.   
 (1) PrP interacts with its ligand LPrP on the cell surface to generate a signal necessary for 
cell survival.  PrP binds to its natural ligand LPrP via its globular domain, while the 
interaction of the flexible N-terminus of PrP with LPrP triggers signal induction.  (2) In a PrP 
knockout cell, n can replace PrP for both binding and signal tranduction. (3) In experimental 
models where truncated forms of PrP (ΔPrP) or Doppel (Dpl, a member of the PrP 
supergene family harboring partial sequence and structure similarity with PrP) are 
expressed on a PrP0/0 background, binding of ΔPrP or Dpl to LPrP occurs, but not signal 
transduction in the absence of a complete N-terminus.  Suppression of PrP or π signalling 
triggers cell death. (4) PrP oligomers present an altered interaction with LPrP. They bind, 
but do not trigger signal transduction, and thus by competition prevent PrPC (PrP+/+ cells) or 
π (PrP0/0 cells) binding to LPrP, resulting in cell lethality.  (5) The hydrophobic domain of PrP 
at the surface of the oligomers enhances their insertion in the cellular membrane. This 
leads to membrane dysfunction, and hypothetically to the formation of pore-like structures 
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inducing toxic signals. (6) At high intracellular concentration, PrP oligomers accumulate in 
the aggresome and saturate the proteasomal or other degradation pathways of the cell, 
leading to the generation of apoptotic signals. (7) The hydrophobic domain of PrP 
oligomers interact abnormally with mitochondrial membranes, leading to the release of 
cytochrome C (Cyt C) triggering the apoptotic cascade6. 
1.10.1 PrPC loss of function vs. PrPSc gain of function  
 
It is well established that both normal and pathological isoform of prion protein, 
PrPC and PrPSc respectively, are involved in the development and progression of various 
forms of prion diseases. However, conflicting evidence is emerging with respect to the 
processing of abnormal PrPC. Thus, the identification of physiological functions of PrPC is 
crucial for understanding the pathology characteristics of prion diseases (Figure 1.8). 
Studies done by Bueler and colleagues revealed that PrPC –null mice do not succumb to 
disease when inoculated with prions, instead, they reported that prion-infected 
heterozygous mice showed longer incubation times compared to WT mice, suggesting that 
PrPSc incubation time and disease progression are inversely related to PrPC levels (Bueler et 
al., 1993). It is known that PrPC is essential for the development of prion disease (Bueler et 
al., 1993). However, a loss of function of PrPC is unlikely to be the cause of pathology since 
it was reported that neither embryonic mice nor adult knockout PrP mice results in 
neurodegeneration (Bueler et al., 1992; Manson et al., 1994; Mallucci et al., 2002). PrPC has 
been reported to confer cytoprotection against the deleterious effects of the pro-apoptotic 
protein Bax (Bounhar et al., 2001).  The truncated N-terminal of Bax has been shown to 
activate both Bax-dependent and independent neurotoxic pathways, suggesting a crucial 
region for putative cytoprotective activity of PrPC (Li et al., 2007).  In addition, primary 
neurons collected from PrPC -null mice were shown to be more sensitive to oxidative stress 
compare to WT neurons (Brown et al., 1997; White et al., 1999).  Moreover, cells exposed 
                                                        
6 Taken from Simoneau et al., 2007. 
56 | P a g e  
 
 
 
to synthetic peptide treatment have been shown to result in microglia activation and the 
production of reactive oxygen species (ROS) (Combs et al., 1999). Synthetic peptide 
treatment has been used as a model for PrPSc (Forloni et al., 1993). Furthermore, another 
study reports that expression of N-terminally truncated PrPC in PrP-null mice lead to a rapid 
degeneration of cerebellar neurons, which can be rescued by co-expression of WT PrPC 
(Shmerling et al., 1998). Despite compelling evidence for conformational conversion in the 
course of prion diseases, it is still not clear what leads to the accumulation and toxicity of 
the pathological conformer and the gain-of-toxic-function hypothesis is not well 
understood. 
1.10.2 Aberrant PrPC trafficking 
 
The physiological roles of the transmembrane forms of PrP are not clear.  However, 
transgenic mice expressing transmenbrane form of PrP termed (CtmPrP) develop 
neurological symptoms and neuronal death that resembles certain prion disease. PrPC is 
translocated to the ER due to the presence of the NH2-termianl peptide that is then 
cleaved into the ER lumen (Figure 1.9).  Studies have suggested that PrPC may be 
neuroprotective and atypical topology or aberrant PrP variants might be neurotoxic (Hegde 
et al., 1999; Hegde et al., 1998; Yedidia et al., 2001; Ma et al., 2002).  Remarkably, 
following translocation in the ER, PrPC can be synthesized with at least three topologies: a 
secreted form that reflects the main pathway for PrPC synthesis in vivo, plus COOH- and 
NH2- terminal transmembrane forms, CtmPrP and NtmPrP, respectively, due to 
transmembrane insertion of hydrophobic pocket (Hegde et al., 1999; Hegde et al., 1998).   
The CtmPrP was suggested to be toxic and cause neurodegeneration, and certain mutations 
appear to favour this conformer (Hegde et al., 1999; Hegde et al., 1998), although CtmPrP 
appears not to be infectious when inoculated in reporter mice (Stewart et al., 2005).  It was 
shown in vivo that the expression of PrP with the A117V mutation, which is linked to GSS, 
leads to neurodegeneration with a prion disease phenotype (Hegde et al., 1998).  It was 
shown increased levels of CtmPrP, but low levels of PrPSc accumulation, in the transgenic 
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mice carrying the AV117 mutation, as well as a patient (carrying the same mutation).  In 
addition, it was shown that neurodegeneration in CtmPrP transgenic mice depends on the 
co-expression of endogenous WT PrPC (Stewart et al., 2005).  It has been suggested that 
PrPC accumulation in the cytosol may be neurotoxic (Ma et al., 2002).  It is not clear why 
WT PrPC is occasionally retained in the cytosol, nor whether it serves any physiological 
function or may be associated with pathogenesis.  Indeed, in human primary neurons 
culture, cytosolic PrPC is not toxic and may, instead have anti-apoptotic functions (Roucou 
et al., 2003). Significant variable amounts of cytosolic PrPC usually detected after 
proteasome inhibition or overexpression of PRNP in neurons is still debatable. Under 
normal condition PrPC in the cytosol would be degraded by the proteasome.  However, 
following proteasome inhibition cytosolic PrPC has been shown to aggregate, acquire partial 
resistance to proteases and ability to self-replicate (Ma and Lindquist, 2001; Ma and 
Lindquist, 2002; Cohen and Taraboulos, 2003).  Furthermore, in the ER-associated 
degradation (ERAD) ER-resident proteins, in unassembled or misfolded forms, undergo 
retrograde transport to the cytosol, get ubiquitinated and are normally degraded by the 
proteasome (Meusser et al., 2005) (Figure 1.9).  Misfolded, mutant and WT forms of PrP 
have been shown to be degraded by ERAD when proteasome inhibitors are present 
(Zanusso et al., 1999; Jin et al., 2000; Ma and Lindquist, 2001; Yedidia et al., 2001; Ma et 
al., 2002; Cohen and Taraboulos, 2003).  Studies revealed evidence of ER stress and 
decreased translocation of nascent PrP during prion infection (Rane et al., 2008).  It is 
suggested that PrPSc accumulation could cause ER stress, leading nascent PrPC to retro-
translocate to the cytosol, where putative toxic PrP molecules accumulate (Rane et al., 
2008) (Figure 1.9). Although, cytosolic PrP has been attributed to ER re-translocation (Ma 
and Lindquist, 2002), others have found that cytosolic PrPC contains NH2-terminal signal 
peptide, indicating that this subcellular location may be exclusively related to abortive 
translocation into the ER (Drisaldi et al., 2003; Fioriti et al., 2005; Campana et al., 2005).    
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Figure 1.9 Toxicity mediated by abnormal topology or altered trafficking of PrPC.   
The normal isoform of prion protein, PrPC  is synthesized, folded and glycosylated in the ER 
where its GPI anchor is added, before further modification in the Golgi complex.  Mature 
PrPC translocates to the outer leaflet of the transmembrane form, generated in the ER, 
which have their COOH, NH2 terminus in the ER lumen, respectively.  Misfolded and 
aberrantly processed proteins which would normally be degraded by the proteasomes 
through the ER-associated degradation (ERAD) pathway, aggregate in the cytoplasm and 
cause cell death.  Putative proteasomal inhibition or malfunction during prion disease 
would contribute to this route of toxicity.  Induction of ER stress by PrPSc may lead to 
translocation of nascent PrPC molecules to the cytosol for proteasomal degradation as a 
way to alleviate the overload of the ER (pQC pathway). However, this mechanism of 
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defence turns negative under chronic ER stress conditions, overwhelming the proteasome 
and leading to the cytosolic accumulation of potentially toxic PrP molecule7.  
1.10.3 Intermediate PrP species 
 
There is evidence to suggest an implication of PrPC -mediated signalling.  However, 
the majority of signal transfers from PrPC to intracellular compartment still remain 
unknown.  The need for transmembrane signalling partners of PrPC has been long 
recognized, there is evidence that PrPC bind a variety of ligands, several of which may fulfill 
the requirement for a signalling intermediate and others may bridge PrPC with further 
transmembrane partners. Studies in cell suggest that, rather than playing a specific role in a 
straightforward signalling pathway, PrPC may serve as a scaffolding protein in multiple sets 
of poorly defined interactors at the cellular surface. It is likely that both the endogenous, as 
well as the ligand induced trafficking of PrPC may strongly affect its functions according to 
the intermediate membrane environment (Roucou and LeBlanc, 2005; Roucou et al., 2004).  
Several basic features of PrPC favour a dynamic scaffolding of multicomponent complexes.  
Distal to the lipid bilayer, specific PrPC domain binds various proteins, glycosaminoglycans 
and metal ions (Hosszu et al., 1999; Jackson et al., 2001). Since the binding of domains of 
PrPC are distinct for at least some of these ligands, and the affinity constants for confirmed 
ligand are variable, each cell likely interacts with a distinct set of partners through PrPC, 
depending on both level of expression of the latter and the characteristics of intermediate 
microenvironment. A link between prion propagation and neurotoxicity has been 
suggested; A possible explanation is that PrPSc is itself inert, but toxicity resides in a smaller, 
labile oligomeric PrP species named PrPL (for lethal), generated as an intermediate or side 
product during prion propagation (Hill et al., 2003; Hill and Collinge, 2003). It is suggested 
that neurotoxicity may require a critical PrPL concentration that is reached during 
                                                        
7 Adapted from Aguzzi et al., 2009. 
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conventional infections but the slower kinetic if increase in infective titre in the subclinically 
infected mice may not mean that toxic PrPL levels are reached (Collinge, and Clarke, 2007).  
 
 
1.10.4   Cellular aspects of prion toxicity 
 
The means by which neuronal cells die following prion infection remain poorly 
understood. Many studies done on cell and animal models have highlighted the potential 
role of neuronal apoptosis in prion disease pathogenesis.  Indeed, several studies done 
both in vitro and in vivo suggest the cause of cell death may be, in part, via apoptosis 
(Corsaro et al., 2012; Liberski et al., 2008; Liberski et al., 2005; Liberski et al., 2002; 
Thellung et al., 2000).  Prion infection can induce apoptosis in primary neurons (Cronier et 
al., 2004), and treatment of primary cultures of various brain regions infected with the PrP 
peptide (PrP106-126) has been shown to induce neuronal apoptosis (Forloni et al., 1993; 
Brown et al., 1994; Brown et al., 1996; Jobling et al., 1999; Thellung et al., 2000).  Studies 
conducted in vivo in mice using the same PrP106-126 peptide injected into the retina have 
also been shown to induce apoptosis (Ettaiche et al., 2000). However, the exact mechanism 
by which PrP106-126 leads to apoptosis is unclear.   
Alternative mechanisms of prion-induced toxicity include the production of reactive 
oxidative species (ROS) (Brown et al., 1996; Turnbull et al., 2003), or disruption of the 
mitochondrial membrane to cause release of cytochrome C and caspase activation 
(O’Donovan et al., 2001) (Figure 1.10).  Early production of ROS and activation of caspase 3 
may be caused by direct exposure of cells to PrP106-126, with other pathways such as that of 
the c-Jun N-terminal kinase (JNK) also being involved (Carimalo et al., 2005).  Activation of 
caspases such as caspase-12 has been detected in neuroblastoma cells treated with small 
amount of full-length PrPSc from scrapie infected mouse brain (Hetz et al., 2003). Prion 
infected neuronal cells have been shown to become apoptotic when exposed to mild 
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proteasome inhibition, with proteasome impairment resulting in the formation of cytosolic 
aggresomes that are associated with activation of caspases 3 and 8 (Kristiansen et al., 
2005). Such have been shown also to have a higher sensitivity to oxidative stress as 
compared to uninfected cells (Milhavet et al., 2000).  In addition, prion infection can alter 
the molecular mechanisms responsible for protection against oxidative stress, by 
decreasing superoxide dismutase (SOD) and glutathione levels (Milhavet et al., 2000) 
(Figure 1.10). 
 
 
Figure 1.10 Mechanisms for apoptosis in prion mediated-neurotoxicity. 
Misfolded PrPC can contribute to ER stress.  Excessive levels of misfolded proteins 
accumulate in the cytosol and might impair proteasome function either directly or 
indirectly by the incorporation of aggresomes.  Under conditions of proteasome inhibition, 
cytoplasmic forms of PrP aggregates are generated; for example the retranslocation of 
PrPres from the lumen of the endocytic and lysosomal vesicles into cytosolic aggresome.   
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The ER is the major organelle for protein synthesis and regulation of intracellular 
trafficking.  The activation of ER stress genes has been found to be significantly upregulated 
in prion pathogenesis.  In particular, the ER stress chaperone GRP78/Bip which belongs to 
the ER-stress resident Hsp70 family has been found to play a central role in the unfolded 
protein response (UPR) (Hetz and Soto, 2006).  Excess stress in the ER induces apoptosis, 
but the mechanism underlying this process in not yet clear. The release of ROS from 
chemokine-activated microglia cells could contribute to ER stress and/or the ERAD process 
by inactivation of ER chaperones such as GRP78 (Bip). 
Recently, it has been demonstrated that prion propagation in the brain proceeds via 
two distinct phases: a silent clinical phase in which infectivity increases and then a plateau 
phase before clinical endpoint. This finding indicates that production of neurotoxic species 
is triggered when propagation of infectivity has been saturated.  This subsequently leads to 
a switch in the auto-catalytic process producing two phases: firstly, an infectivity phase 1, 
and then secondly, a toxic pathway (phase 2) (Sandberg et al., 2011). 
 
1.11 Therapeutic approaches in prion diseases 
 
To date, there are no available cures, vaccines or treatments to halt or slow the 
course of prion diseases. The course of prion disease is alarmingly rapid compared with 
other neurodegenerative disorders. Overexpression of PrP increases the onset of disease in 
prion-infected transgenic mice (Mallucci et al., 2003; Mallucci et al., 2007).  It follows, 
therefore, that agents that reduce PrP expression may delay the onset of prion disease 
pathogenesis.  In particular, compounds that bind and stabilise the PrP conformation may 
be beneficial.  Similarly, agents destabilising the PrPSc conformation may be effective.  In 
this regard, several vaccines to amyloid plaques in Alzheimer’s disease are in clinical trials 
and agents that interfere with the putative PrPC-PrPSc interaction might be similarly 
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effective. Chemicals affecting the endocytosis, exocytosis, intracellular trafficking or 
degradation of PrP may also be effective.  
A range of potential therapeutic compounds have been studied. These include Congo 
red, polyanionic compounds, amphotericin B, porphyrins and quinacrine, which have each 
been shown to reduce accumulation of PrPSc in prion infected cell models (Trevitt and 
Collinge, 2005).  However, such models have not provided similarly stringent or reliable 
results in vivo (Aguzzi et al., 2001). Targeting endogenous PrPC in mice with early prion 
infection has been shown to reverse spongiform change and prevent clinical symptoms, 
neuronal loss, and cognitive as well as behavioural deficits (Mallucci et al., 2003; Mallucci et 
al., 2007).  The rise of RNA interference (RNAi) has been demonstrated to inhibit PrPC 
expression in neuroblastoma cells (Tilly et al., 2003) and prevent PrPSc accumulation in 
prion-infected cells (Daude et al., 2003).  Other studies have revealed prolonged survival in 
prion infected mice when a lentivirus-expressing shRNA that targets PrP is injected into the 
hippocampus (White et al., 2008). 
Targeting the conversion of PrPC to PrPSc has included the use of antibodies to bind to 
PrPC and stabilise it against conversion (Enari et al., 2001; Heppner and Aguzzi, 2004; white 
et al., 2003; Aguzzi et al., 2001; Perez et al., 2001).  Recently, anti-PrP antibodies capable of 
crossing the blood brain barrier and targeting cytosolic PrP have been described. However, 
administering large quantities anti-PrP antibodies into the CNS may be ineffective, as they 
have been shown to cause signs of neurodegeneration in mice (Solforosi et al., 2004).  A 
different approach has made use of a cationic ligand tetrapyrrole (Fe III-TMPyP), which 
displays potent anti-prion activity, can bind to the human PrPC via the C-terminus of PrP 
and potentially be used as therapeutic agent by preventing the conversion of PrPC to its 
disease-associated form (Nicoll et al., 2010; Nicoll and Collinge, 2009). 
Diagnosing the disease, or identifying potentially contaminated biofluids, is equally 
difficult. However, a standard steel binding assay (SSBA) has been developed, providing a 
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prototype blood test for detecting prion infection in the diagnosis of vCJD (Edgeworth et 
al., 2010).  The assay has been shown to quantify solid binding matrix in the infected blood 
by the capture and direct immunodetection of surface-bound material. Such developments 
may prove critical in identifying patients with the disease, and preventing exposure to 
potentially infectious biological fluids or tissue by donation or during surgery. 
 
1.12 The ubiquitin proteasome system (UPS) 
 
One of the factors that determine the biological activities of proteins are their 
concentration, which in turn is controlled by a balance between their synthesis and 
degradation rates. Enzymes that carry out such reactions are called proteases and are part 
of a major mechanism by which cells regulate the concentration of particular proteins and 
degrade misfolded proteins. Regulation and degradation of intracellular protein is a tightly 
regulated process and is called collectively proteostasis. There are two main cellular 
degradation pathways: the UPS and autophagy.  The UPS is a two-step mechanism that 
degrades intracellular proteins (Figure 1.11).  Proteins are first targeted for degradation by 
attachment of ubiquitin molecules, which are then recognized by a protease complex, the 
26S proteasome (Reinstein and Ciechanover, 2006). Autophagy involves the degradation of 
protein complexes and intracellular organelles as mediated by a cell’s lysosomes.  
Autophagy involves formation of double-membrane bound structures known as autophagic 
vesicles.  These vesicles then fuse with lysosomes and their contents are degraded by 
lysosomal hydrolases.  Autophagy-mediated degradation is generally considered to involve 
low specificity in substrate recognition (Rubinsztein, 2006).   
The UPS was discovered more than thirty years ago, but recently the field has rapidly 
expanded and gained the scientific interest that reflects its paramount role in cell biology 
and neuronal disorders.  The UPS regulates degradation of cytosolic and nuclear proteins 
that occurs in the process of cell survival.  In eukaryotes, the ubiquitination system often 
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serves as a triggering signal for degradation. It accounts for targeting selected proteins for 
degradation by tagging them with chains of a small heat stable protein, the adenosine 
triphosphate (ATP)-dependent proteolytic factor 1 (APF-1), which was later identified to be 
identical to the protein ubiquitin  (Wilkinson et al., 1980). Hersko and Ciechanover, in the 
period of 1970 to 1980, found that ubiquitin could be conjugated to lysine residues of 
proteins in an energy-dependent process that required ATP (Hershko and Ciechanover, 
1998. The ubiquitin modification of protein was followed by rapid degradation by an 
energy-requiring protease (Harper et al., 1997).  The groups of enzymes required for 
accomplishing ubiquitin conjugation include a ubiquitin activating enzyme (E1), the 
ubiquitin-conjugating enzymes (E2) and the ubiquitin ligases (E3) (Figure 1.11).  In a 
sequential manner, these enzymes collaborate to covalently conjugate ubiquitin first to the 
substrates and next to one of the lysine residues within the ubiquitin until a chain of 
conjugated ubiquitin is formed. This conjugated protein is recognised by the proteasome, 
resulting in degradation of the ubiquitinated protein (Hershko and Ciechanover, 1998; 
Hershko et al., 1983). 
Ubiquitin is encoded by a multi-gene family where monomeric ubiquitin genes are C-
terminally linked to a sequence encoding a ribosomal protein and multimeric ubiquitin 
genes that are encoded in a tandem repetitive manner.  The number of ubiquitin moieties 
in the precursors and the nucleotide sequence can vary substantially among different 
eukaryotic species.  However, the amino acid sequence shows variation only of three 
positions in the seventy six residue long protein, making ubiquitin one of the most 
conserved eukaryotic proteins (Jentsch et al., 1991; Glickman and Ciechanover, 2002).  
Yeast and human ubiquitin, for example, differ only at amino acid residue positions 19, 24 
and 28 (Graham et al., 1989).  Newly synthesized ubiquitin fusion proteins or multimeric 
ubiquitin precursor are post-translationally processed by ubiquitin C-terminal hydrolases 
(UCH) that recognize and cleave the last glycine residue of each ubiquitin moiety, releasing 
functional single ubiquitin units. The high expression levels and stability of ubiquitin, 
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combined with the fact that ubiquitin is recycled after being used to tag proteins for 
degradation, safeguards the nuclear and cytosolic expression levels that are required for a 
functional UPS.  In general, ubiquitin molecules are attached to an internal lysine in the 
protein and successive addition of other ubiquitin molecule is added to synthesize the 
polyubiquitin chain (Ciechanover, 2003; Glickman and Ciechanover, 2002). 
 
Figure 1.11 The ubiquitin proteasome pathway. 
 Ubiquitin is conjugated to proteins that are destined for degradation by an ATP-dependent 
process that involves three enzymes.  A chain of five ubiquitin molecules attached to the 
protein substrate is sufficient for the complex to be recognized by the 26S proteasome.  In 
addition to ATP-dependent reactions, ubiquitin is removed and the protein is linearized and 
injected into  the central core of the proteasome, where it is digested to peptides.  The 
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peptides are degraded to amino acids by peptidases in the cytoplasm or used in antigen 
presentation8.  
 
 
Two groups of proteins share sequence homology with ubiquitin: the ubiquitin-like 
proteins (UBL); and, proteins containing an ubiquitin–like domain (UDP) (Jentsch et al., 
2000).  UBLs like SUMO or Nedd8 can be conjugated to other proteins in a mode 
resembling ubiquitin modifications.  Yet they do not target for degradation but fulfil roles 
such as inhibition of ubiquitination, regulation of protein trafficking and activation (Jones et 
al., 2002; Muller et al., 2001).  The UDPs comprise a diverse family of proteins that have an 
uncleaveable ubiquitin-like domain most often located in their N-terminal part.  It has been 
shown that ubiquitin-like domain can interact with the proteasome, but it is not believed 
that this interaction results in degradation. 
1.12.1  Ubiquitination 
 
Ubiquitination of a substrate is performed in a series of enzymatic steps that start 
with the ATP-dependent activation of ubiquitin by the formation of a thiol-ester linkage 
between its C-terminal glycine and an active site cysteine residue present within the 
ubiquitin-activating enzyme (E1).  The ubiquitin is then transferred to a cysteine residue of 
a ubiquitin-conjugating enzyme (E2) enzyme, and then finally covalently linked by an 
isopeptide bond to the E-NH2 group of a lysine residue in the substrate, a process that is 
directed and catalysed by a substrate-specific ubiquitin ligase (E3) (Figure 1.12).  Once the 
first ubiquitin is linked to the substrate, the procedure is repeated and additional ubiquitins 
are covalently linked by their C-terminal glycine 76 residue to specific lysine residues within 
the previous ubiquitin to eventually form a polyubiquitin chain.  Long chains have higher 
affinity for binding to the proteasome, and a minimum of four ubiquitins are sufficient to 
serve as a recognition signal for degradation (Thrower et al., 2000). 
                                                        
8 Adapted from Lecker et al., 2006. 
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Only one E1 enzyme has been described, deletion of the gene for which in yeast is lethal 
(McGrath et al., 1991).  Mammalian cell lines expressing a temperature sensitive E1 tend to 
arrest in the G2 phase of the cell cycle and upregulate heat-shock proteins, indicating a 
strong stress response at non-permissive temperature (Finley et al., 1984; Ciechanover et 
al., 1984).  The precise number of different E2 enzymes is not known, but estimations 
based on sequence homology suggest that over twenty E2 enzymes are encoded in the 
mammalian genome (Joazeiro and Weissman, 2000).  The E2s are often small proteins 
identified by a characteristics core of around 15 kDa that contains the active site cysteine 
residues.  Each E2 can interact with a number of different E3s, which comprises an even 
larger family of enzymes (Figure 1.12).  The E3s, which can be single proteins or consists of 
multi-protein complexes, are responsible for the specificity of the UPS, since they recognize 
the proteasome substrate through the presence of degradation signals (section 1.12).  
There are multiple interactions between these enzymes: a single substrate can be 
ubiquitinated by different E2s and E3s and a single E3 can ubiquitinate different substrates 
and interact with different E2s. 
The E3s can be divided into three majors groups: the HECT (Homologues to E6-AP C-
Terminus) domain family, the RING (Really Interesting New Gene) finger domain family, and 
the recently identified U-box ligases (Hatakeyama et al., 2001; Pickart, 2001).  There are 
many fundamental differences in the enzymatic activities of these E3 families.  Recently 
characterised U-box domains of E3s contain a conserved 70 amino acid long stretch 
identified in at least six mammalian proteins (Pickart, 2001).  The domain is required for the 
E3 activity and also shares some structural similarities to the E3 RING finger domains 
(Aravind and Koonoin, 2000).  The prototype U-box protein is the yeast Ufd2 protein, which 
contributes to ubiquitination of the ubiquitin fusion degradation (UFD) substrates (Koegl et 
al., 1999).  CHIP (C-terminus of the Hsc70 interacting protein) is also a member of this 
group of E3s and together with the E3 parkin, promotes ubiquitination of the unfolded Pael 
receptor involved in Parkinson’s disease (Imai et al., 2002). It is noteworthy that both Ufd2 
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and CHIP ubiquitinate substrates in concert with classic E3s and mainly promote elongation 
instead of initiation of the ubiquitin chain. 
 
Figure 1.12 Overview of ubiquitination. 
Ubiquitination is an enzymatic cascade involving an ubiquitin (Ub) - activating enzyme (E1), 
an Ub- conjugating enzyme (E2), and an Ub-ligase (E3).  During ubiquitination, Ub is 
activated by the E1 Ub-activating enzyme and then transferred to an E2 Ub-conjugating 
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enzyme.  The E3 Ub-ligase enzyme recognises and binds both the target substrate and the 
Ub-E2 enzyme and transfers UB to the target substrate.  Ubiquitin is released as a single 
unit from its precursor forms through the cleavage by deubiquitination enzymes (DUBs).  
Ubiquitin is conjugated to proteins that are destined for degradation by an ATP-dependent 
process that involves three enzymes.  A chain of five ubiquitin molecules attached to the 
protein substrate is sufficient for the complex to be recognized by the 26S proteasome.  In 
addition to ATP-dependent reactions, ubiquitin is removed and the protein is linearized and 
injected into the central core of the proteasome, where it is digested to peptides.  The 
peptides are degraded to amino acids by peptidases in the cytoplasm or used in antigen 
presentation. Activation of ubiquitin is an ATP-dependent process that result a thioelester 
linkage between ubiquitin and the enzymes9.   
 
The primary function of ubiquitination is to serve as a reusable selecting tag to 
sorting proteins that are destined for proteasomal degradation. Yet this is not its only 
function.  Different modes of ubiquitination are involved in such diverse functions as DNA 
repair, protein activation and endocytosis.  The different ubiquitination signals are a 
consequence of the various possibilities to build a lysine-linked chain (Pickart, 2000).  
Ubiquitin carries seven lysine residues at positions 6, 11, 27, 29, 33, 48 and 63, of which 
lysine 29, 48 and 63 linked chains have been identified in vivo (Gregori et al., 1990; Chau et 
al., 1989; Arnason and Ellison, 1994; Spence et al., 1995).  The lysine 48-linked chain in 
which an isopeptide bond links the C-terminal glycine 76 residue of ubiquitin and the lysine 
48 of the previous ubiquitin, are the conical signal for proteolysis by the UPS. 
Overexpression of ubiquitin, in which the lysine 48 is substituted for an arginine residue, is 
lethal in yeast (Finley et al., 1984).  Though less common, lysine 29 linked ubiquitin chains 
can target a protein for degradation as well. 
                                                        
9 Adapted from Lindsten and Dantuma, 2003. 
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Poly-ubiquitin lysine 48 chains target proteins to 26S proteasome-mediated 
degradation, whereas polyubiquitin chains formed via lysine 63 target proteins for other 
diverse cellular activities (Hicke, 1999; Lauwers et al., 2009).  The level of membrane 
proteins are maintained by lysine 66 linked polyubiquitination, which functions as a signal 
for selective trafficking to the lysosomal lumen via multivescicular endosomal (MVE) or 
multivesicular body (MVB) degradation pathways (Raiborg and Stenmark, 2009).  This 
process of endosomal sorting is dependent on ubiquitination of membrane protein, or 
“cargo”. Ubiquitinated cargo is recognized by the endosomal sorting complex for 
transportation and recycling (Raiborg and Stenmark, 2009). 
Regulation of the ubiquitination status of activators is critical in the control of 
transcription factor promoter function.  The mechanism in which monoubiquitination 
balance is established with polyubiquitination and degradation has been the focus of 
intense investigation.  Studies in yeast on Gal4-dependent genes first indicated that the 19S 
proteasomal ATPases bind to the Gal4 activation domain independently of both the non-
ATPase 19S subunits and the 20S proteolytic core (Gonzalez et al., 2002).  In 2007, Ferdous 
and colleagues demonstrated a non-proteolytic “destabilizing” function of the APIS (19S 
ATPase proteins independent of 20S) complex involving an ATP-dependent, rapid, and 
reversible disassociation of the transactivator-promoter complex, which was inhibited in 
the presence of mono-ubiquitin (Archer et al., 2008; Ferdous et al., 2001).  Further studies 
have shown that mono-ubiquitination of transcription factors increase transactivation 
(Ferdous et al., 2007); however, the mechanisms involved in this process were unclear.  
Together, these studies shed light on the non-proteolytic and proteolytic role of 
ubiquitination. 
1.12.2   Deubiquitination 
 
Ubiquitination is a reversible protein modification process, as conjugated 
polyubiquitin can be removed and disassembled by the action of deubiquitination enzymes 
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(DUBs).  DUBs comprise a large family of enzymes within the ubiquitin proteasome system.  
All DUBs are cysteine proteases with the exception of one recently discovered DUB within 
the proteasome that is a metalloprotease (Verma et al., 2002; Yao and Cohen, 2002).  
There are two groups of DUBS: UCHs and ubiquitin-specific processing proteases (UBP).  
The two classes have some common residues in their active sites, but besides that there is 
a poor sequence homology between them and other proteases.  UCHs are typically small 
proteins that remove peptides fused to the C-terminus of ubiquitin while UBPs make up a 
more diverse family of proteins that are able to cleave isopeptide bonds between ubiquitin 
and lysine residues within a substrate or between ubiquitin in a polyubiquitin chain. DUBs 
play a vital role in maintaining a sufficient pool of free ubiquitin in the cell by processing the 
ubiquitin monomers from their precursors and by recycling polyubiquitin chains from 
substrates targeted for degradation (Chung and Baek, 1999; Wilkinson, 2004). 
1.12.3 Proteasomes 
 
Proteasomes are very abundant in the cellular cytosolic and nuclear compartment, 
accounting for up to 1% of total cellular protein (Baumeister et al., 1998). They can diffuse 
freely in the cytosol and the nucleus (Reits et al., 1997).  They enter the nucleus through 
the nuclear pore complex, or they get entrapped within the nuclear compartment when 
the envelope is restored after cell division.  In yeast, proteasomes are associated with the 
nuclear and ER membrane, and have an altered distribution during mitosis (Enenkel et al., 
1998).  Similar to lysosomes which degrade mostly extracellular proteins in a less selective 
manner, the proteasome controls its proteolytic activity through self-compartmentalisation 
of the responsive proteases. 
The proteasome was first observed in 1968 by electron microscopy, but it took 
almost twenty years before Goldberg and colleagues renamed the prosome, as it was 
originally known (Schmid et al., 1984) to the proteasome, highlighting its pivotal role in 
intracellular degradation (Arrigo et al., 1988). In eukaryotic cells, the proteasome forms a 
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barrel shaped complex consisting of a 20S core particle with the proteolytic active sites 
facing inward to the lumen of the proteasome (Figure 1.13). The 20S core particle is located 
between two 19S regulatory particles, also called PA700, that serve as proteasomal 
gatekeepers and control entry and exit of proteins and peptides.   Progressive degradation 
of proteins by the proteasome results in the production of peptides of various lengths.  
These peptides are further degraded by cytosolic peptidases, generating amino acids that 
can be reused in protein synthesis.  In vertebrates, these peptides can also be translocated 
into the ER and loaded in major histocompatibility complex (MHC) class I molecules that 
are subsequently transported and displayed at the cell surface, a process known as antigen 
presentation (Rock and Goldberg, 1999). Since the proteasome degrades the majority of 
intracellular proteins, the presented peptides are representative of the total pool of 
proteins present within the cell.  This pool also includes proteins that are derived from 
infectious agents and are consequently eliminated by cytotoxic T-cells.   Antigen 
presentation is one of the fundamentals phenomena of the immune system and is of major 
importance for the host response to viral infection (Dantuma et al., 2002; Lorenzo et al., 
2001).   
The mammalian proteasome is unique in that it has three exchangeable proteolytic 
βsubunits that are induced in the presence of the cytokine IFNγ, which is produced by 
activated CD4 and CD8 positive T-cells and natural killer cells, and plays a major role in 
mobilizing the host defence against infectious pathogens.  The β1, β2, and β5 subunits are 
exchanged into iβ1/LMP2, iβ2/MECL1 and iβ5/LMP7, respectively, resulting in the 
formation of the immunoproteasome complexes (Gaczynska et al., 1996).  These 
modifications cause an altered preference of cleavage sites favouring the generation of 
peptides with hydrophobic C-termini and reducing the output of peptides with acidic C-
termini.  A peptide with hydrophobic C-terminus is more likely to be suitable for antigen 
presentation by MHC class I.  The alteration of the cleavage specificity for the C-terminus is 
the most important for the proteasome (Serwold et al., 2002; Cascio et al., 2001). 
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1.12.4  The 20S core particle 
 The 20S proteasome consists of four heptameric rings, named α and β, forming the 
structure α-β-β-α.  The two inner rings consist of seven β-subunits and contain three 
proteolytic activities each.  The proteolytic active sites are located in the β1, β2 and β5 
subunits of the core particle, facing into the proteolytic chamber of the proteasome (Dick 
et al., 1998). The β1 subunit displays post-glutamyl peptide hydrolysing (PGPH) activity, 
cleaving preferably after acidic amino acids.  The β2 subunit has a trypsin-like activity, 
cleaving preferably after basic amino acids.  The β5 subunit is responsible for the 
chymotrypsin-like activity, which cleaves preferably after hydrophobic amino acids (Arendt 
and Hochstrasser, 1997).   
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Figure 1.13 The 26S Proteasome in Saccharomyces cerevisiae 
Schematic of the 26S proteasome in Saccharomyces cerevisiae, showing the 20S proteolytic 
core and one 19S regulatory particle. The ubiquitinated substrate binds to the 19S where 
the ubiquitin chain is removed. The 19S is composed of a “base” component and a “lid” 
component with nine non-ATPase subunits (Rpn3, Rpn5-9, Rpn11, Rpn12 andRpn15) in the 
lid and four non-ATPase (Rpn1, Rpn2, Rpn10 and Rpn13) and six ATPase subunits (Rpt1-6) 
in the base (shown in red). The C-termini of the ATPases dock into intersubunit pockets in 
the α-rings of the proteasome and open the gate for substrate hydrolysis by the 20S β 
subunits. Cross section of the β-ring reveals the positions of the caspase-like (β1), trypsin-
like (β2) and chymotrypsin-like (β5) subunits (all shown in yellow). Polyubiquitinated 
proteins are tagged for degradation, recognized and unfolded by the 19S ATPases, and are 
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translocated to the 20S core. The 20S cleaves the protein into peptides and free ubiquitin is 
released10.  
1.12.5 Ubiquitin 
 
All three catalytic sites are activated through cleavage of an N-terminal leader 
sequence that occurs during assembly of the proteasomal complex. The cleavage results in 
N-terminal threonine residues that exert the nucleophilic attacks on peptide bonds (Chen 
and Hoschtrasser, 1996). In addition, two less characterized proteolytic activities have been 
described, namely the “branched-chain amino acid preferring” (BrAAP) activity and the 
“small neutral amino acid preferring “(SNAAP) activity (Orlowski et al., 1993).  These 
additional activities are most likely accommodated by the already identified active β sites 
since the presence of additional proteases in the proteasome complex have been excluded 
by structural analysis (Groll et al., 1997), kinetic studies (Cardozo et al., 1999, McCormack 
et al., 1998) and site-directed mutagenesis (Dick et al., 1998).  In the end the cleavage 
repertoire makes sure that virtually any peptide bond in a protein can be potentially 
digested, thus the active sites of the proteasome show how much broader specificity than 
their names reveal. 
1.12.6 The 19S regulatory particle 
The 19S proteasome regulates the entry of substrates targeted for degradation.  It 
docks the 20S core protein and regulates the opening of a narrow hole of 10 Å (in diameter, 
a size that allows only unfolded protein to enter (Wenzel and Baumeister, 1995).  The α-
rings form the anterior chamber leading into the 20S, but without the association of the 
19S regulatory protein with the N-termini of the α-subunits to serve as a plug to hold 
together the α3 subunits and keep the 20S core protein closed (Groll et al., 2003; Groll et 
al., 2000; Ciechanover, 2006; Ciechanover and Brundin, 2003).  Electron microscopic 
                                                        
10 Adapted from Deriziotis and Tabrizi, 2008. 
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studies revealed that the 19S regulatory particle is flexibly linked to the core protein and 
exerts wagging movement in an uncorrelated manner (Walz et al., 1998).  
The 19S regulatory protein plays an important role in the recruitment of 
polyubiquitinated substrates, removal of polyubiquitin chains, as well as unfolding of 
protein substrates and their tethering into the 20S core chamber. The 19S regulatory 
protein can be subdivided into two sub-complexes, also known as the base and the lid.  
Using the nomenclature for mammalian proteasomes, the lid contains eight subunits: Rpn3, 
Rpn5, Rpn6, Rpn7, Rpn8, Rpn9, Rpn, and Rpn12 (Figure 1.13).  It has been suggested that 
the lid is required for proper protein degradation and substrate recognition.  However, the 
precise role of the lid in the protein degradation pathway is unclear. Studies have also 
revealed some deubiquitination activity in the Rp11 subunit, suggesting that it is important 
for the removal of the ubiquitin chain prior to degradation (Verma et al., 2002; Yao and 
Cohen, 2002). The base of the regulatory protein contains nine subunits: Rpt1, Rpt2, Rpt3, 
Rpt4, Rpt5, Rpt6, Rpn1, Rpn2 and Rpn1 (Figure 1.13).  Rpt1-6 are ATPases associated with a 
variety of cellular activities (AAA), and form the ring entrance.  AAA ATPases are known to 
be involved in protein remodelling and, in the context of the proteasome, it has been 
postulated that these subunits regulate unfolding and translocation of protein substrates 
into the proteolytically active chamber (Braun et al., 1999; Kohler et al., 2001). Rpt3 
contains a polyubiquitin binding site that may be responsible for positioning the 
ubiquitinated substrate directly adjacent to the entrance (Lam et al., 2002).  The two other 
base subunits, Rpn1 and Rpn2, are the largest subunits of the 19S regulatory particle and 
expose hydrophobic surfaces, possibly functioning as a scaffold for interacting proteins. 
Rpn1 has been shown in yeast to interact with UDP proteins such as Rad23 and Dsk2 
(Elsasser et al., 2002). 
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1.12.7 The 11S regulatory particle 
The formation of the immunoproteasome upon stimulation with IFNy stimulation 
involves the exchange of the 19S regulatory particle for another structure called termed the 
11S regulatory particle or PA28 (Li and Rechsteiner, 2001).  It has been shown that different 
complexes can be formed between the 20S core particle and either 19S or 11S regulatory 
particles (Tanahashi et al., 2000).  Unlike the 19S particle, the 11S regulator contains two 
different types of subunits that form a hetero-hexameric ring structure that upon binding 
to the 20S is believed to open the entrance hole to the inner proteolytic chamber (Whitby 
et al., 2000).  It has been shown that the Drosophila homologue of this regulator can 
modify the proteolytic activities of the proteasome (Masson et al., 2001). 
1.13 The UPS and neurodegenerative disease 
 
The UPS has been implicated in a range of neurodegenerative diseases, especially in 
conditions associated with the toxic accumulation of aberrant proteins that are prone to 
form potentially harmful aggregates.  The importance of the UPS is highlighted by the 
direct relationship between onset of neurodegenerative diseases and perturbations in the 
UPS (Ciechanover and Schwartz, 2004; Rubinstzein, 2006). Many neurodegenerative 
disorders are characterised by the accumulation of ubiquitinated protein, suggesting that 
UPS dysfunction may play a prominent role in disease pathogenesis (Jung et al., 2009; 
Bedford et al., 2008).  This accumulation of proteins may be caused by genetic or 
environmental factors, in combination with imbalances in anabolic and/or catabolic 
pathways in the cellular degradation system.  Genetic mutation or environmental factors 
can lead to the production of proteins with different rates of degradation, or proteins with 
tendencies to form persistent cellular aggregates (Figure 1.10).  Furthermore, disruption in 
gene expression also leads to accumulation of protein aggregates due to increased protein 
synthesis and reduced protein degradation by the 26S proteasome (Jung et al., 2009). 
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Intraneuronal aggregates contain ubiquitinated proteins and accumulation of these 
ubiquitinated aggregates is due to their impaired clearance by the proteasome.       
UPS impairment is reported to be involved in aging, brain ischemia, Alzheimer’s 
disease, Huntington’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS).  
Protein aggregation has recently been shown to directly impair the function of the UPS.  
Transient expression of two unrelated aggregation-prone proteins, a huntingtin fragment 
containing a pathogenic poly-glutamine repeat and a folding mutant of cystic fibrosis 
transmembrane conductance regulator, caused nearly complete inhibition of the UPS 
(Bennett et al., 2005; Bence et al., 2001).  These data confirm a potential mechanism 
linking protein aggregation to cellular dysfunction and cell death. The link between the UPS 
and neurodegenerative diseases is further strengthened by observations that several 
mutations linked to neurodegenerative disease onset are found in genes that code for 
proteins involved in the UPS.   
            It has become increasingly evident that altered activities of the UPS are crucially 
involved in the pathophysiology of Huntington’s disease, Parkinson’s disease and 
spinocerebellar ataxia (Bence et al., 2001; Lindsten et al., 2002) (Ciechanover and Brundin, 
2003). UPS impairment has also been studied in cell culture and animal models 
overexpressing mutant huntingtin protein (Lindsten et al., 2003) and consistent with data 
proposing a protective effect of aggregation due to sequestration of toxic species, 
treatment with a compound that increases inclusion formation prevents hungtingtin-
mediated proteasome inhibition (Bodner et al., 2006).  Global changes in the UPS were 
reported in HD, early in the disease course in both R6/2 transgenic model as well as in HD 
patient (Bennett et al., 2007), suggesting that impairment may be occurring at the level of 
ubiquitin turnover rather than impairment of proteolytic function.  However, the lack of a 
reporter indicating UPS dysfunction in a Huntington’s disease mouse model (R6/2) crossed 
to GFPu mice may be indicative of a more complicated relationship between 
overexpression of mutant polyglutamine proteins and UPS function (Bett et al., 2009). 
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Mutations in Parkin, encoding an ubiquitin-E3 ligase result in juvenile recessive PD 
(Dawson and Dawson, 2003). Decreased proteasome activity has been suggested as a cause 
of aggregation and Lewy body formation in Parkinson's disease.  This hypothesis is 
supported by the observation that yeast models of Parkinson’s disease are more 
susceptible to toxicity caused by α-synuclein, the major protein component of Lewy bodies, 
under conditions of low proteasome activity. Bedford et al reported data describing the link 
between the 26S proteasome dysfunction and the development of alpha-synuclein 
neuropathology (Bedford et al., 2008).  In the study, they genetically ablated a critical 
19S/PA700 subunit in the forebrain, and thus, prevented the formation of the 26S 
proteasome. A recent description of Usp14, a proteasome-associated deubiquitinating 
enzyme has been reported to inhibit the degradation of ubiquitin-protein conjugates in 
both in vitro and in vivo (Lee et al., 2011), suggesting that inhibition is mediated by the 
trimming of the ubiquitin chain on the substrate. 
1.14 The UPS and prion diseases 
 
               Prion infection is known to cause neuronal loss in the brain, but the molecular 
basis of prion neurotoxicity remains unknown. Significant evidence exists as to the 
involvement of UPS dysfunction in the pathogenesis of prion disease. Study by Bedford and 
colleague, shows evidence of a dysfunction of the 26S proteasome in the development of 
alpha-synuclein neuropathology in genetic mouse model using the Cre/Ioxp system 
(Bedford et al., 2008). Prion-infected cells are significantly more susceptible to apoptosis 
when treated with low levels of proteasome inhibition, accompanied by an accumulation of 
large cytosolic perinuclear PrPSc aggresomes (Kristiansen et al., 2005).  Proteasomal activity 
is significantly decreased in prion-infected cells and in brain regions exhibiting significant 
neuropathology in prion-infected mice (Kristiansen et al., 2007). This finding established a 
solid link between UPS impairment and neurodegeneration associated with prion infection. 
Both PrPSc and recombinant forms of PrP containing large amounts of β-sheet structure 
inhibit the 26S proteasome directly in vitro (Kristiansen et al., 2007).  Pre-incubation with 
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an anti-oligomer antibody or heat denaturation of PrPSc alleviates this inhibitory effect 
(Kristiansen et al., 2007).  It has been reported that increased levels of ubiquitin conjugate, 
which correlate with decrease proteasome function accumulate in the brain of mice 
infected with prion (Kang et al., 2004). Most recently, Deriziotis and colleagues reported an 
accumulation of UPS substrate in prion infected mouse brains, suggesting impairment of 
the 26S proteasome (Andre and Tabrizi, 2012; Deriziotis et al., 2011). However, other 
studies by Quiaglio and colleagues revealed that transgenic mice expressing a non-
infectious mutant form of PrP associated with certain inherited human prion diseases do 
not show UPS impairment (Quaglio et al., 2011). 
1.15  The UbG76V-GFP reporter mouse model 
 
In order to understand the precise role of the UPS under pathological conditions, the 
development of fluorescent-based reporters for monitoring the function of the pathway 
and quantifying proteolytic activities of substrate in mouse models is imperative.  The 
major work of this thesis is based on a particular green fluorescent protein (GFP) 
proteasome substrate that allows monitoring of the UPS (Dantuma et al., 2000).  GFP is a 
small soluble protein of 26 kDa that originates from the jellyfish Aequorea victoria.  Well 
established in the literature, it does not have any known interacting partners is relatively 
well tolerated at high concentrations in mammalian cells, and is very stable (Tsien, 1998).  
The generation of the fluorescent reporter system in both cell line and transgenic model 
has made it possible to monitor the functionality of the UPS (Tsien, 1998).  Furthermore, 
the development of fluorescent proteasome inhibitors has allowed specific labelling of 
proteasomes in vitro and in vivo (Dantuma et al., 2000).  GFP reporters were initially 
characterized and used for studies in cellular systems but more recently development of a 
transgenic mouse model constitutively expressing the GFP reporter was developed.  
Subsequently, the use of these models has allowed the investigation of the effect of 
proteotoxic stress condition in the degradation of different proteasomal substrates 
(Verdoes et al., 2006; Menendez-Benito et al., 2005) and to gain insight into the 
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mechanisms contributing to the long-term accumulation of deleterious proteins during 
proteotoxic stress (Menendez-Benito et al., 2005). 
The UbG76V-GFP proteasome substrates were generated by insertion of different N-
end rule of UFD degron that converted GFP into a substrate of the UPS. Ubiquitin is 
recognised as a degradation signal leading to ubiquitylation within the ubiquitin moiety and 
subsequently lead to the degeneration of the UFD containing protein (Dantuma et al., 
2000).  Degradation of the substrates results in low basal fluorescence intensities, with 
pharmacological inhibition of the proteasome leading to the accumulation of GFP-
fluorescent cells that can be monitored by fluorescence microscopy, flow cytometry and 
fluorimetry.  Although the ubiquitination of GFP by the N-end rule and UFD degrons rely on 
different enzymes, both pathways converge at the level of the proteasome.  This implies 
that these reporters cannot be used to test the individual catalytic activities of the 
proteasome, but rather monitor the general status of the UPS.  The UbG76V-GFP reporters 
have proven their general applicability in several species including mammals (Dantuma et 
al., 2000, Lindsten et al., 2002; Myung et al., 2001; Verhoef et al., 2002) Drosophiia 
(Lundgren et al., 2003) and yeast (Heessen et al., 2003; Heessen et al., 2002). 
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Figure 1.14 Generation of UbG76V-GFP transgenic mice. 
For generation of N-end rule of substrates ubiquitin was cloned in frame with GFP so that 
cleavage by UCH exposes the amino acid on the N- terminus.  Ubiquitin fused GFP is 
expressed in living cells.  Upstream of the promoter, the GFP substrate is fused to a mutant 
ubiquitin moiety. GFP reporter mice were designed to study proteasome inhibition. The 
transgene has a Cytomegalo virus (CMV) early enhancer upstream and chicken beta actin 
promoter. Upstream of the promoter the GFP substrate is fused to a mutant ubiquitin.  
 
The UbG76V-GFP reporter mouse model was generated from a chicken ß-actin 
promoter with a cytomegalovirus (CMV) immediate early enhancer, which is a promoter 
complex that is known to induce a constitutive expression (Figure 1.14) (Okabe et al., 
1997).  Indeed the transcript of the GFP reporter could be detected in all tissues examined 
(Lindsten et al., 2003).  However, inhibition of proteolysis is required in order to detect the 
UbG76V-GFP protein.  Studies in primary cultures of fibroblasts and other cells demonstrated 
a clear dose-dependent accumulation of the GFP reporter in response to inhibition 
treatment.  The functionality of the reporter was also confirmed in vivo by intraperitoneal 
injections with the different proteasome inhibitors MG-132, MG-262 and epoxomicin 
(Lindsten et al., 2003).  A dramatic accumulation of GFP occurred in the liver, which is in 
line with previous data showing that proteasome inhibitor treatment of drug-primed mice 
84 | P a g e  
 
 
 
induces hepatotoxicity in the form of accumulation of Mallory bodies (French et al., 2001). 
Other studies have been done on the generation of related reporter substrates.  Bence and 
colleagues described a GFP reporter that is targeted through a short hydrophobic sequence 
(Bence et al., 2001), which was originally identified in a screen for degrons in yeast (Gilon et 
al., 1998).   
The particular UbG76V-GFP construct was chosen based on its destabilizing and well 
tolerated effect in tissue culture.  The UbG76V-GFP reporter mouse was the first in vivo 
model developed to investigate proteasomal degradation.  It provides an excellent tool for 
studying the UPS in human disorders, especially neurodegenerative diseases characterized 
by pathologic accumulation of misfolded and aberrant proteins, which are potentially 
proteasome substrates. Previously, it has been shown that the functional analysis of the 
UPS can be accomplished by monitoring steady state levels of fluorescent reporter 
substrates (Salomons et al., 2005; Bence et al., 2001; Dantuma et al., 2000).   The 
availability of the GFP reporter UbG76V-GFP reporter mouse model has been instrumental 
for the studies presented in this thesis, since it allowed a direct monitoring of the UPS 
dysfunction in vivo and neuro-pathological conditions associated with prion disease.  The 
work described in this thesis shed light on understanding the role of UPS impairment in the 
pathogenesis of prion disease. 
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1.16 Aims 
 
• To generate both lines of the UbG76V-GFP reporter mouse and characterize the  
UbG76V-GFP reporter in primary neurons;  
• To investigate whether dysfunction of the ubiquitin- proteasome system (UPS) can be 
detected in RML prion infected UbG76V-GFP reporter mice; 
• To sequentially monitor UPS impairment in vivo over the time-course of prion infection 
and determine whether it is an early or late event; 
• To assess behavioural phenotype and motor skills deficits in the UbG76V-GFP reporter 
mice following RML prion infection. 
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2 MATERIALS AND METHODS 
2.1 UbG76V-GFP reporter mice 
Breeding pairs of UbG76V-GFP1 and UbG76V-GFP2 mice were provided by Professor Nico 
Dantuma at the Karolinska Center for Transgenic Technologies, Sweden (Lindsten et al., 
2003). They were provided as hemizygotes that had been back-crossed for approximately 
30 generations to a C57BL/6N background using both males and females.  The mice were 
subsequently bred in-house at the MRC Prion Unit Biological Safety Facility (BSF). 
2.1 Animal care 
 
All work with animals conformed to United Kingdom legislation and institutional 
guidelines for animal welfare. The mice were housed at an appropriate temperature (22°C) 
in a light-controlled room (12-hr light/dark cycle), and kept in groups of four to six per cage.  
All animals had free access to food and water. 
2.1.2 Genotyping 
 
Mice were genotyped by PCR of genomic DNA isolated from ear biopsies taken from 
each individual animal.  Ear biopsies were taken at three weeks of age. They were digested 
at 55°C overnight in a solution containing 49 µl Direct PCR lysis reagent (Viagen Biotech) 
and 1 µl proteinase K (PK) (21mg/ml) (Roche).  The lysates containing genomic DNA were 
then incubated at 85°C for 45 min and briefly centrifuged. 
PCR was performed on the genomic DNA using oligonucleotide primers specific to 
the UbG76V-GFP construct. A PCR stock solution was made containing 12.5 µl of 1x REDTaq 
ReadyMix PCR Reaction Mix with MgCl2 (Sigma), and 1 µM each of the forward and reverse 
primers.  The stock solution was added to individual reaction tubes, followed by the 
addition of 2 µL genomic DNA to a final volume of 25 µl of solution.  The samples were 
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subjected to cycling temperatures of 94C for 30 sec, 58C for 30 sec and 72C for 1 min, 
for 36 cycles. The PCR product was loaded onto a 1.25 % agarose gel or stored at 4 °C until 
ready for loading into gel. 
Primers were designed using Primer Express software (Applied Biosystems).  UbG76V-
GFP primer sequences were: forward primer 5’ CCT ACA GCT CCT GGG CAA CGT 3’; reverse 
primer 5’ TCG ACC AAG CTT CCC CAC CAC 3’). β-actin primer sequences were: forward 
primer 5’ ACC AGG GTG TGA TGG TGG GAA 3’; reverse primer 5’ AGC CAG GTC CAG ACG 
CAG GAT 3’).  
Agarose gel electrophoresis was conducted using 1.25 % agarose in 1x TAE buffer, pH 
8.0.  Ethidium bromide was added to the mixture to visualise the gel.  The mixture was 
poured into a mini-gel system with appropriate fitted combs (Thermo Fisher). Twenty five 
microlitres of PCR solution was loaded into each well.   To confirm the 300 base pair size of 
the product, 10 µl of TrackIt 1000 bp DNA ladder (Sigma) was added to a single well. The 
gel was run at 90 volts for 20-25 min.  The gel was examined on a BioRad Gel Doc 1000 
imaging system under UV light to evaluate sample integrity. Gels were photographed and 
analysed using Quantity One software (BioRad). 
2.2 Inoculation of mice with RML prions 
2.2.1 Preparation of inocula 
 
Inocula were made from homogenised brain tissue. Frozen brains were transferred 
to a Petri using clean a disposable forceps and 1 ml of sterile 1X PBS was added to the brain 
immediately. Homogenisation was done using a tissue RiboLyser (Eppendorf).  Screw cap 
tubes filled with small clean ribolysing beads were weighed and samples were ribolysed at 
a speed of 6.5 for 45 seconds; 10 %  (w/v) tissue homogenates were prepared. 
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2.2.2 Prion infection of mice 
 
Mice were inoculated intracerebrally (ic) between the midline of the two 
hemispheres with 30 µl 1% (w/v) RML (Rocky Mountain Laboratories) brain homogenate, or 
30 µl 1% (w/v) I7723 normal CD-1 brain homogenate as control. All mice were monitored 
on a daily basis and subsequently examined for clinical signs of scrapie-like disease.  
2.2.3 Timed-culls of mice 
 
            Following inoculation, a series of timed culls were carried out at days 45, 85, 105, 
125, 145 and 165 post-inoculation until end-stage disease. Early indicators for the onset of 
disease include erect ears, rigid tail, piloerection, ungroomed appearance and a hunched 
posture.  However, a definitive diagnosis was not made until a confirmatory sign was seen, 
such as ataxia, limb paralysis, ruffled fur and generalised tremor.  Animals were culled by 
an authorised Schedule 1 procedure (Animals Scientific Procedures Act 1986) using a 
sealed chamber with a rising concentration of CO2 for 5 min, followed by confirmation of 
death by cervical dislocation. 
2.2.4 Tissue handling and collection of samples 
 
            All procedures were carried out in a microbiological containment level III facility and 
strict safety protocols were followed. Tissue was harvested from animals immediately after 
they were culled.  The brains were separated into right and left hemisphere.  The left 
hemisphere was fixed into buffered formalin, whilst the right hemisphere was snapped-
frozen in iced cold isopentane and stored at -80 :C.   
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2.3 Primary cell culture 
 
Adult pregnant mice were culled at gestation day 16, as described above.  An incision 
was made along the length of the abdomen and the surrounding skin dissected away to 
expose the embryonic sac. Individual embryos were removed and kept on ice.  The head 
was removed from the embryo and pinned by the nose to a wax-filled Petri dish.  Dissected 
cortices were then placed in a dish containing ice-cold medium NeuroBasal medium 
supplemented with B27 supplement, 1% 200 mM L-glutamine, 1% penicillin (5000 U/ml)/ 
streptomycin (5000 g/ml) and 5% foetal bovine serum (FBS). Cortices were dissociated 
using a sterile surgical scalpel blade, then triturated through a series of three flamed glass 
pipettes with different diameters to produce a single-cell suspension.  The suspension was 
allowed to settle by gravity for 1 min to reduce un-dispersed clumps.  The supernatant was 
transferred into a fresh tube and centrifuged at 350 xg for 5 min. The resultant cell pellet 
was resuspended in pre-warmed culture medium, as above.  
Culture plates, or glass coverslips placed in 6-well tissue culture plates, were coated 
with 1 % poly-L-lysine (1mg/ml) at room temperature for 10 min.  Excess poly-lysine was 
then removed and the coverslips were washed three times in sterile water. The coverslips 
were left to dry in a sterile environment for at least 2 hr prior to use.  Single cell 
suspensions were counted using a haemocytometer. The cells were seeded at a density of 
1.125 x 105 cells cm-2 onto poly-L-lysine plated plates. Cultures were incubated at 37°C in a 
humidified, 5% CO2 incubator. After two days of culture, the cultures were given a full 
media change and a half media change every 4-5 days thereafter. 
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2.4 Immunocytochemistry 
 
          Primary cortical neurons were fixed onto coverslips with 4 % paraformaldehyde (PFA) 
for 20 min at room temperature. They were washed three times with D-PBS and 
permeabilised at -20 °C with pre-cooled 100 % methanol for 15 min.  They were then 
washed with 1x PBS and the cells were blocked with 10 % bovine serum albumin (BSA) 
(Sigma) for 1 hour at 37 °C. Coverslips were incubated for 1 h at 37 °C with primary 
antibodies diluted in 1x PBS (see Appendix I).  Alexa-fluor secondary antibodies diluted into 
1x  PBS was added onto each coverslip and incubated for 1 hour at 37 °C in the dark.  
Following incubation, a series of three washes were carried out with 1X PBS.  Coverslips 
were mounted onto Superfrost Plus slides (Thermo Fisher) using mounting medium (Dako) 
and left to dry in a cool dark place. 
Confocal microscopy was used to obtain fluorescence images. The confocal 
microscope (Zeiss microscope LSM510 META) was equipped with ‘plan-Apochromat’ 63 
x/1.40 Oil DIC objective and was controlled by Zeiss LSM software. Fluorescence was 
recorded at 488 nm using 30 mW Ar-laser for excitation or at 543 nm using 1 mW HeNE-
laser for excitation. Zeiss Imersol™ was used as the imaging medium.  
2.5  Immunohistochemistry 
 
For histological studies, half-brains were fixed in buffered formalin for at least 72 
hours and up to a maximum of seven days.  The sections were dehydrated and then 
embedded in a paraffin block by the MRC Prion Unit Histology staff.  Sagittal serial sections 
were obtained from each block, cut at a standard thickness of 3-5 µm.  Sections were 
mounted on Superfrost slides (Thermo Fisher), and allowed to dry at room temperature for 
2 hours and then overnight at 60 °C.  For a list of the antibodies used, see Appendix I. 
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2.5.1 Immunostaining for PrP 
 
For anti-PrP staining, sagittal sections were first de-waxed and re-hydrated through 
two washes with xylene and three washes with decreasing concentrations of ethanol.  
Sections were then washed in water and treated with 98 % formic acid for 5 min and boiled 
in EDTA-Tris-citrate buffer pH 7.8 for 25 min.  
The buffer solution was transferred to the pressure cooker, the temperature was 
set on high (setting 10) and the buffer brought to boil.  Sections were then placed in the 
boiling solution allowing full pressure to be reached in the cooker with the lid completely 
sealed.  The heating time began only when full pressure was reached.  After a constant jet 
of steam was emitted, the heat on the electric hotplate was reduced to setting 7 and the 
pressure in the cooker was released immediately; a timer was set for 3 min.  After the 
cooker was depressurised, the electric hot plate was turned off.  An additional 3 min was 
timed; the cooker was then transported to a nearby sink and put under cold running water. 
Immunohistochemical staining was performed using a Ventana Medical Systems, 
USA.  PrP deposition and distribution were visualised using an anti-PrP monoclonal 
antibody, ICSM35 (1:3000) (D-Gen), and a rabbit anti-mouse secondary antibody (Asante et 
al., 2002).  
2.5.2 Immunostaining for GFP and ubiquitin 
 
For GFP and ubiquitin stainings, the sections were not pre-treated; however, 
antigen retrieval was done through enzymatic digestion and standard citrate buffer. For 
primary antibody, either a rabbit polyclonal anti-GFP antibody (Invitrogen) was used, 
followed by a swine anti-rabbit secondary antibody (1:200).  Intracellular ubiquitin deposits 
were detected using a monoclonal anti-ubiquitin antibody (1:10:000) (Santa Cruz, 
Biotechnology) and a rabbit anti-mouse secondary antibody was used after a treatment of 
a citrate buffer (MCC2) pH 6.  
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All immunohistochemistry was carried out using Ventana Discovery or Benchmark 
automated systems, following manufacturer’s instructions (Ventana Medical Systems). 
Reagents supplied including a DAB Map kit designed for automated immunohistochemistry 
for detecting antigen localization in paraffin-embedded tissue section.  The DAB Map Kit 
contains a series of antigen detection reagents such as diaminobenzidine (DAB), horse 
radish peroxidise (HRP), copper sulphate and inhibitor D for reducing endogenous 
peroxidise activity.  An iView DAB Detection Kit was also used; it is an indirect biotin 
streptavidin system for detecting mouse IgG, mouse IgM and rabbit primary antibodies.  
The iView DAB Detection Kit contains; inhibitor (3 % hydrogen peroxide solution), SA-HRP 
(a conjugated streptavidin horseradish peroxidase, H2O2 (.04 %-.08% hydrogen peroxide in 
a phosphate buffer solution, DAB substrate; diaminobenzidine, copper sulphate. The iView 
DAB Detection Kit uses an indirect method to visualize specific antibodies bound to 
antigens by depositing a brown colour precipitate. Bluing reagent, a strong alkaline reagent 
help interpret the result as it blues the haematoxylin stained sections on the glass.  
Counterstains, haematoxylin and bluing reagent work through the combined effect of 
lithium ions for the staining of cellular nuclei. A signal amplification technique was used to 
enhance the sensitivity of GFP staining (Ventana Medical Systems). 
2.5.3 Immunostaining for GFAP 
 
Gliosis was detected with anti-glial fibrillary acidic protein (anti- GFAP) rabbit 
polyclonal antiserum (1:1000, Dako) at 42° C for 32 min using the Ventana automated 
immunohistochemical system   Sections for GFAP were not pre-treated, but antigen 
retrieval was done with protease 3 and mild citrate buffer. The enzymatic digestion method 
involved a process of dewaxing, rehydration and rinsing the sections under running water.  
The slides were then re-equilibrated in mild or standard citrate buffer and incubated for 2 
to 6 min protease level 1 or level (Ventana Medical Systems).  Antigen retrieval was either 
done with a strong protease (protease 1), an alkaline protease solution for strong 
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enzymatic treatment (0.55 ±.1 acidic units/ml), or protease 3, a mild alkaline protease 
treatment (0.02 ±.0075 units/ml).  Sections for GFAP staining were treated with protease 3. 
The sections were counterstained with haematoxylin for 5 min and a bluing reagent 
was used as post-counterstain.  A basic diaminobenzidine (DAB) detection kit was used 
according to the manufacturer’s instruction (Ventana Medical Systems).   
2.5.4 Immunostaining for NeuN and synaptophysin 
 
For the labelling of neurons and synapses, sections were placed in a stainless steel 
tray, de-waxed and, re-hydrated through three washes of xylene, two washes of 100 % 
ethanol through one wash of 90 % and one wash of 70 % ethanol.  The slides were then 
rinsed in cold running water. The slides were submerged in one litre of 1 M EDTA pH 7.8 
and microwaved for a period of 25 min in maximum power. After the microwave 
treatment, the sections were washed in cold dH20 before proceeding with immunostaining. 
Either a monoclonal neuronal nuclei (NeuN) antibody was used (1:2000) (Chemicon) for 32 
min or a monoclonal anti-synaptophysin (Zymed) was used and a rabbit anti-mouse 
secondary antibody (1:200) (Dako) using the Ventana automated system. To visualise 
neurons, basic diaminobenzidine detection system was used according to the 
manufacturer’s instruction (Ventana Medical Systems, USA). 
2.5.5 Light Microscopy 
 
Light micrographs of histological areas of interest were taken using a light microscope 
(Zeiss), attached to a digital camera on an ImageView digital microscope.  Images were 
analysed with the help of Professor Sebastian Brandner in the Department of 
Neuropathology at the UCL Institute of Neurology.   
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2.6 Immunoblotting 
2.6.1 Preparation of homogenates 
 
Tissue was homogenised in 100 mM Tris.HCl, pH 7.4, 300 mM NaCl, 4 mM EDTA, 1 % 
Triton-X-100, 1% deoxycholate using sequentially narrower syringe needles. Homogenates 
were treated with 50 U/ml benzonase for 20 min on ice. An aliquot was removed for 
protein assay to ensure equal loading. For PrPSc western blots, proteinase K was added to a 
final concentration of 50 g/ml for 30 min at 37 °C. Samples were then centrifuged at 
16,000 xg for 1 min to pellet cellular debris. Digestion was ended in samples by adding 8 
mM AEBSF. An equal volume of 2 X reducing sample buffer was added to each sample (125 
mM Tris, pH 6.8, 20 % glycerol, 0.05 % bromophenol blue, 4 % SDS), which were then 
boiled at 100 C for 10 min prior to use or storage.  
2.6.2 BCA protein assay 
 
A bicinchoninic acid (BCA) protein assay reagent kit (Pierce) was used to detect and 
quantify the total of protein in tissue homogenate.  The BCA assay is based on the ability of 
the protein to reduce Cu2+ to Cu+ in an alkaline environment.  Protein standards were 
prepared with bovine serum albumin (BSA) in the same diluent as the unknown sample.  A 
series of 0, 25, 50, 100, 150, 200 and 250 µg standards were used. Twenty five microliters 
of each standard or unknown sample was pipetted into a 96-well plate in triplicate.  Two 
hundred µl BCA working reagent was then added to each well and mixed gently for 30 
seconds follow by a 25 min incubation at 37: C. The plate was analysed using a plate reader 
(Tecan), with the absorbance filter set at 570 nm. 
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2.6.3 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Samples in 1x reducing sample buffer were centrifuged at 16,000 x g for 1 min, 
briefly vortexed, and finally spun again at 16,000 x g for 1 min. Samples were loaded on to 
pre-cast 16% Tris-Glycine mini gels (Novex, Invitrogen). They were electrophoresed 
vertically in tris/glycine SDS running buffer (National Diagnostics) in X-Cell Mini-Cell system 
(Invitrogen) apparatus at 200 V for 90 min. Pre-stained Seeblue (Invitrogen) or Precision 
(BioRad) protein standards were used as a molecular weight marker. 
2.6.4 Electroblotting 
 
SDS-PAGE protein samples were transferred onto PVDF membrane (Immobilon). 
Membrane was pre-cut at the same size as the gels and pre-soaked in 100% methanol for 2 
min to ensure even hydration prior to transfer. Proteins were transferred from the gel to 
the membrane in X-Cell II Blot modules (Invitrogen) and blotting buffer (National 
Diagnostics) at either 35 V for 90 min or 14 V overnight.  
2.6.5 Dot blotting 
 
Protein samples were prepared in 1x reducing samples buffer, as above. Fifteen 
micrograms of each sample was placed into a 96-well plate in triplicate and kept on ice. 
BioRad Bio-Dot microfiltration apparatus were assembled with a sheet of nitrocellulose 
membrane and 5-6 sheets of filter papers that had been pre-wetted in 1x TBS. A gasket was 
aligned above the support plate and placed over a vacuum reservoir, and the apparatus 
attached to a three-way flow valve. Samples were loaded into the 96-well frame of the Bio-
Dot apparatus and incubated at room temperature for 30 min. The flow valve was then 
adjusted to apply a vacuum to draw any remaining sample on to the membrane. The 
membranes were washed under vacuum suction twice with 1x TBS, following which the 
membrane was removed from the apparatus.   
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2.6.6 Immunodetection 
 
After electroblotting, membranes were transferred to an appropriately sized 
container and washed in either 1x PBS or 1x TBS.  Blots were then blocked for 1 h at RT 
with gentle agitation using either 5 % non-fat milk powder (Marvel) diluted in 1x PBS-T (1x 
PBS, 0.5% Tween-20), or Li-Cor blocking buffer (Li-cor Biosciences) diluted in an equal 
volume of 1x PBS. Incubation with the appropriate primary antibody (see Appendix I) 
diluted in either 1 % non-fat milk or Li-Cor blocking buffer diluted in an equal volume of 1x 
PBS-T was done with gentle agitation overnight at 4: C. The membranes were then washed 
in 1x PBS-T for a minimum of 45 min, changing the buffer five times. The membranes were 
incubated with an appropriate secondary antibody (see Appendix I), diluted in 1x PBS-T, for 
45 min at room temperature.  The membranes were then washed in 1x PBS-T for a 
minimum of 1 hr, changing the buffer ten times. 
Detection of alkaline phosphatase bound antibody was performed using Tropix CDP-
star (DAB) (Applied Biosystems), according to manufacturer’s instructions. Excess reagents 
were poured off and the membranes were placed between acetate films and transferred to 
a photographic cassette. Biomax MR films (Kodak from Anachem) were developed using 
Kodak developer and fixer by hand or by using a Xograph imaging machine (Xograph 
Imaging Systems). Developed films were scanned using an Epson scanner for electronic 
format and densitometry of digital images was achieved by using ToolLab 1D Gel analysis 
software. Detection of LI-COR antibodies was done by scanning the membrane using the 
Odyssey Infrared Imaging System and software (Li-cor Biosciences). For stripping and re-
probing of membranes, Re-Blot Plus Western Blot Strong Antibody Stripping Solution was 
used, following manufacturer’s instructions (Millipore). 
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2.7 Fluorogenic assays for proteasome activity 
 
A protocol was used as described previously (Berkers et al., 2005; Dantuma et al., 
2000; Kisselev and Goldberg, 2005). Homogenates were prepared, as described above, in 
50 mM Tris-HCl pH 7.4, 2 mM ATP, 5mM MgCl2, 250 mM sucrose. A small aliquot was taken 
for protein content determination by BCA assay and 1 mM DTT was added to the remaining 
sample. To control for non-specific peptide hydrolysis, an aliquot of sample homogenate 
was incubated with the specific proteasome inhibitor 50 µM epoxomicin for 30 min at 37°C. 
Proteasomal activity was measured in 10 µg of protein incubated with 100 µM fluorogenic 
substrates (Ac-nLPnLD-AMC for caspase-like activity (Bachem); Suc-LLVY-AMC for 
chymotrypsin-like activity (Enzo Life Sciences); Boc-LRR-AMC for trypsin-like activity (Enzo 
Life Sciences), and 50 mM Tris.HCl pH 7.4, 5 mM MgCl2, 2 mM ATP, 1 mM DTT, to a final 
volume of 100 μl. Samples were incubated for 1 hr at 37 °C and the release of 7-amino-4-
methylcoumarin (AMC) was monitored continuously every minute at 360 nm excitation and 
465 nm emission using a TECAN 96-well plate reader.   
2.8 Behavioural assessments 
 
          Behavioural testing was performed on groups of fifteen age-matched UbG76V-GFP 
mice.  Mice were grouped house prior to individual experiment and were monitor daily.  
Mice were inoculated soon after they were weaned; fifteen mice were inoculated with RML 
prions and fifteen mice were inoculated with control brain homogenate (CD1). Testing was 
initiated twenty days following inoculation.  Mice were tested within a conserved ~3 hour 
time period in the morning.  All protocols using these mice were first approved by the 
animal committee, and official approved procedures were followed for the care and use of 
these mice.  Experimental room environment was kept constant between test sessions with 
respect to temperature humidity and light intensity.  
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2.8.1 Nesting 
 
           Testing was followed as described previously (Deacon et al., 2001).  UbG76V-GFP mice 
were kept in groups of 4 or 5 mice per cage prior to testing.  Nesting assessments were 
carried out for period of fourteen weeks, starting at day 20 post-inoculation.  For an 
accurate assessment of nest building, the mice were single-housed for 24 hr and then 
regrouped after testing. Nesting material was placed in clean cages, positioned at the end 
of the cage opposite the mouth of the water bottle.  A square compact nest was put into 
the cage. The following morning, an assessment of the nest was made, and a grade was 
given to each mouse base on the amount of material shredded, the neatness of the nest 
and the height of the nest.  A grade of (1) = nestlet not touched (more than 90% intact); 
grade (2) = nestlet partially torn (50-90% remain intact); grade (3) = nestlet mostly 
shredded (less than 50 % remain intact); grade (4) = nestlet mostly torn and the material 
gathered into a flat nest; and grade (5) = nestlet nearly perfect, made into a crater with wall 
matching mouse body. Images were photographed of each scored nest.   
2.8.2 Burrowing 
 
          Testing was followed as described previously (Deacon et al., 2001; White et al., 2008).  
UbG76V-GFP mice were housed individually for the duration of the burrowing assessment.  A 
one-end closed opaque plastic tube (250 ml in length and 55 mm in diameter) was filled 
with 200 g of food pellets of normal food diet and placed into a clean cage.  The cylindrical-
shaped tube was left overnight for mice to burrow the pellet out.  The next morning, 
assessment was made by measuring the weight of the pellets displaced from the tube. 
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2.8.3 Grip Strength 
 
            Grip strength apparatus were calibrated for each trial.  Mice were lifted and held by 
the tail so that their forelimb could grasp a wire grip.  The mice were then pulled backward 
by the tail with their posture parallel to the surface of the table until they release the grid.  
The peak force applied by the forelimbs of the mouse was recorded in g.  Each mouse was 
tested three times, and the average value obtained.  The mouse body weight was 
measured. The mean of the three grip-strength measurements was used against the body 
weight to obtain the grip measurement. 
2.8.4 Rotarod 
 
           A rotarod apparatus (UGO Basile) with a rotating cylinder of 3 cm diameter was used, 
with assessments done for a period of ten weeks, starting at day 45 post-inoculation. Mice 
were placed on the stationary rod and allowed to become familiar with the environment 
for one minute before the rod motor was engaged.  On each day of testing, each mouse 
was tested for three trials with a 10 min inter-test resting period.  Mice were tested within 
a conserved 3 hr time period in the morning.  Mice were trained for 3 consecutive days 
prior to the first official testing date by repeatedly placing the mice on the rod until they 
were able to remain on the rod. Each mouse was held by the tail and placed on the rotating 
(4 r.p.m.) rod in such a way to walk forward on it.  After 5 s the rod was accelerated at a 
constant speed of 20 r.p.m./min and the speed and time at which the mouse fell off were 
noted.  Each mouse received three trials per session.  The mean speed for each mouse was 
taken and analysed.   
2.9 Statistical analysis 
Data were expressed as standard deviation (SD) and analysed by Student’ T-test or 
Two-way ANOVA with Bonferroni post-test. Significance was expressed as follows: P<0.05*; 
P<0.01**; P<0.001***, unless otherwise specified Appendix IV. 
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3 GENERATION AND PRION INOCULATION 
OF UbG76V-GFP REPORTER MICE 
 
3.1 BACKGROUND 
The functional state of the UPS can be monitored by steady state levels of a 
fluorescent reporter substrate (Dantuma et al., 2000). The UbG76V-GFP construct comprises 
a form of ubiquitin (G76V) fused to the N-terminus of GFP. When expressed in cells, UbG76V-
GFP is poly-ubiquitinated at both its lysine 29 and lysine 48 residues, under normal cellular 
conditions it is targeted for degradation by the 26S proteasome (Bence et al., 2001; Cheroni 
et al., 2009).  Fluorescent reporters have been expressed to study the function of the UPS 
in cells (Lindsten et al., 2003).  Such cell models can be maintained at a lower cost, are 
quick to work with and provide high volumes of data.  However, unlike transgenic animals, 
cell lines do not necessarily provide a full picture of complex diseases, thereby, cannot be 
used to study tissue specific responses involving changes of the UPS.  The UbG76V-GFP 
reporter transgene, consists of ubiquitin (G76V) protein substrates, has been applied to the 
generation of animal models for in-depth study of the UPS.  In this thesis, the first 
transgenic mouse model (UbG76V-GFP reporter), based on the ubiquitous expression of 
(G76V) protein substrates, developed for monitoring UPS degradation in vivo, has been 
used.   
This mouse model allows a direct monitoring of UPS dysfunction in mice inoculated 
with RML prions to determine its possible correlation with disease pathogenesis. The 
UbG76V-GFP reporter mouse is based on the constitutive expression of a UbG76V substrate, 
which was selected because of its half-life degradation rate and low toxicity in cell culture.  
The UbG76V-GFP reporter mouse model consists of a UbG76V-GFP transgene, expressed from 
a chicken β-actin promoter with a cytomegalovirus (CMV) immediate early enhancer from 
the pCCALL vector excised using ScaI and HindIII, and cloned blunt-ended in the NheI site 
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located upstream of the UbG76V-GFP open reading frame (Lindsten et al., 2003). High 
constitutive expression is normally detected in all tissues (Okabe et al., 1997). Other mouse 
models for monitoring the UPS function have been developed, one of them is based on 
xenografts of UFD-luciferase reporter-expressing human cell lines in nude mice (Berkers et 
al., 2005; Luker et al., 2003).  The UbG76V-GFP reporter mice are available as two lines: 
UbG76V-GFP1 and UbG76V-GFP2.  These lines were characterised for the presence of the 
transcript, which was seen in all examined tissues including lung, spleen, small intestine, 
muscle, heart, kidney, pancreas, liver, testis and brain (Lindsten et al., 2003).   Since its 
development, the usage of the UbG76V-GFP reporter mice has increased as UPS dysfunction 
has been increasingly reported to be linked with different neurodegenerative diseases 
(Cheroni et al., 2009; Rubinsztein, 2006).  Indeed, the UbG76V-GFP transgenic mouse model 
appears to be an excellent tool to monitor the functionality of the UPS in vivo.   
Work in this chapter presents the breeding and characterisation of the two lines of 
the UbG76V-GFP reporter mice, UbG76V-GFP1 and UbG76V-GFP2.  These mice were exposed to 
RML prions to check their susceptibility to prion infection in a manner, similar to that in 
their non-transgenic counterparts.  Brain tissue from RML-infected UbG76V-GFP1 and 
UbG76V-GFP2 mice at end-stage disease was analysed for the presence of typical 
pathological markers of prion disease, PrPSc and GFAP. The presence of the Ub-GFP 
reporter was also investigated, thereby confirming previous observations using a different 
prion strain (Kristiansen et al., 2007), and the suitability of the model for use in 
investigating the UPS throughout the course of prion disease pathogenesis. 
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3.2 AIMS 
• To breed UbG76V-GFP1 and UbG76V-GFP2 transgenic mice for subsequent study of the 
UPS.  
• To confirm expression of the Ub-GFP reporter in these mice in response to inhibition 
of the UPS. 
 
• To transmit RML prions to both UbG76V-GFP lines and confirm the onset of disease. 
 
• To characterize the UbG76V-GFP1 reporter mice in primary neurons. 
 
3.3 METHODS 
Breeding pairs of UbG76V-GFP1 and UbG76V-GFP2 mice were provided by Professor 
Nico Dantuma at the Karolinska Center for Transgenic Technologies, Sweden.  These mice 
had been backcrossed on to a C57Bl/6N background for at least thirty generations (Lindsten 
et al., 2003) and were maintained on this background in generating the animals for our 
experiments.  The mice were genotyped by PCR with GFP-specific oligonucleotide primers 
of genomic DNA isolated from ear biopsies taken from each individual animal (Section 
2.1.2). Confirmation of Ub-GFP reporter expression in these mice was obtained by 
establishing primary cortical neuronal cultures that were treated with proteasome 
inhibitors (Section 2.3). 
Transgenic and control mice were inoculated i.c. with 30 µl 1% RML brain 
homogenate (designated I6201), or 30 µl 1% I7723 normal CD-1 mouse brain homogenate 
(designated I7723) as a control (Section 2.2.2).  The mice were then culled at end-stage 
disease.  This work was done in collaboration with Dr Ralph Andre and the MRC Prion Unit’s 
Biological Services Facility (BSF) at Wakefield Street under project license number 70/6454. 
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3.4 RESULTS 
3.4.1 Establishing the UbG76V-GFP reporter mouse colony 
              To establish stable colonies of the UbG76V-GFP reporter mice, a single breeding 
pair for each of the UbG76V-GFP1 and UbG76V-GFP2 lines was obtained from Professor 
Nico Dantuma at the Karolinska Center for Transgenic Technologies, Sweden.  Using 
these breeding pairs, heterozygous UbG76V-GFP+/- mice and homozygous UbG76V-GFP-/- 
littermates were generated in an expected Mendelian fashion for further experimental 
use (Figure 3.1).   
 
 
Figure 3.1 Breeding of the UbG76V-GFP transgenic mice. 
Founders were backcrossed to C57BL/6N to produce UbG76V-GFP transgenic mice.  Offspring 
were generated in an expected Mendelian fashion when heterozygous UbG76V-GFP mice 
were mated together. (A) Breeding plan for the ST5/UbG76V-GFP1 line. (B) Breeding plan for 
the ST5/UbG76V-GFP2 line.  
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3.4.2 Genotyping of the UbG76V-GFP1 and UbG76V-GFP2 mice 
 
To identify UbG76V-GFP-positive mice, biopsies were taken from the ears of 5-6 
week-old UbG76V-GFP progeny.  Genomic DNA was analysed by PCR using primers to 
specifically detect the presence of the UbG76V-GFP transcript (Section 2.1.2).   PCR products 
were analysed by agarose gel electrophoresis and UbG76V-GFP-positive animals were 
identified by the presence of a specific band of 300 base pair (bp) (Figure 3.2).   
 
 
Figure 3.2 Genotyping of the UbG76V-GFP transgenic mice.   
Genotyping of genomic DNA isolated from the UbG76V-GFP mice.  The 300-bp PCR product 
identified Ub-GFP positive mice in the (A) UbG76V-GFP1 and (C) UbG76V-GFP2 lines. This 
method was not able to distinguish between heterozygous or homozygous Ub-GFP positive 
mice.  (B, D) Primers specific for β-actin were used as a control in all PCR reactions.  
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3.4.3 Ub-GFP reporter expression in response to inhibition of the UPS 
in UbG76V-GFP primary cortical neurons 
Accumulation of the Ub-GFP reporter was previously described in the UbG76V-GFP  
reporter mice (Lindsten et al., 2003).  To validate the UbG76V-GFP transgenic mouse model, 
primary cortical neurons from embryonic E16 UbG76V-GFP1 mice were harvested and 
analysed by immunohistochemistry to detect the presence of the Ub-GFP reporter. Primary 
cortical neurons were treated with lactacystin, a proteasome inhibitor, at concentrations of 
0.5 and 50 µM for 24 h. This treatment of lactacystin induced the accumulation of GFP in 
the neuronal cells, indicating the presence of the Ub-GFP reporter (Figure 3.3).  Indeed, the 
primary cortical neurons responded to treatment with the proteasome inhibitor in a dose 
dependent manner as previously described (Lidnsten et al., 2003). The most intense UbG76V-
GFP accumulation was observed in neurons treated with the highest concentration of 
lactacystin (Figure 3.3 C). This validated the functionality of the Ub-GFP reporter mouse 
model in detecting dysfunction of the cellular UPS machinery. 
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Figure 3.3 Functional characterisation of UbG76V-GFP expression in primary 
cortical neurons.   
Primary cortical neurons were harvested from neonatal E16 UbG76V-GFP1 mice. The 
proteasome inhibitor, lactacystin, was used to treat the cells in order to monitor Ub-GFP 
accumulation resulting from the inhibited UPS degradation pathway.  The cells were fixed 
and confocal immunofluorescence images were taken of primary cortical neurons treated 
with (B) 0.5 µM and (C) 50 µM lactacystin, as compared to (A) untreated controls. 
Increasing GFP fluorescence was observed with increasing concentrations of lactacystin. 
Fluorescent imaging were analysed with a confocal microscope (Zeiss). 
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3.4.4 Basal expression of the UbG76V-GFP reporter in primary cortical 
neurons from UbG76V-GFP1 mice. 
In analysing the induction of the UbG76V-GFP reporter in the UbG76V-GFP1, some 
basal level of the Ub-GFP reporter was detected in non-lactacystin treated cells.  This basal 
level of GFP was observed in UbG76V-GFP1 primary neurons that were co-immunostained 
for GFP and a neuronal marker, neurofilament (NF200) (Figure 3.4). 
 
 
Figure 3.4 Basal expression of the UbG76V-GFP reporter in expression primary 
cortical neurons from UbG76V-GFP1 mice.  
Primary cortical neurons were harvested from neonatal E16 UbG76V-GFP1 mice and fixed 
prior to immunocytochemistry. (A) Immunoreactivity using an anti-GFP antibody 
(Invitrogen) showed basal GFP expression in these cells. (B, C)  The GFP-positive cells were 
positively identified as neurons as shown by co-localisation with neurofilament (NF200).  
Fluorescent imaging were analysed with a confocal microscope (Zeiss). 
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3.4.5 Inoculation of UbG76V-GFP reporter mice with RML prions 
 
To monitor UPS impairment following prion infection, heterozygous UbG76V-GFP1+/- 
and UbG76V-GFP2+/- (henceforth termed UbG76V-GFP1 and UbG76V-GFP2, respectively) mice 
were inoculated with prions.  UbG76V-GFP1+/- and UbG76V-GFP2+/- mice, along with UbG76V-
GFP-/- littermate controls (termed Ub-GFPneg), were inoculated with RML brain 
homogenate, or normal CD-1 brain homogenate as a control (Section 2.2). The mice were 
then monitored on a daily basis for sign of illness.  Animals in the advanced stage of the 
disease showed the typical symptoms of inoculation with RML prions, including a ruffled 
coat due to poor grooming, erect ears, agitation, unusual gait and piloerection. As 
expected, the incubation period of the disease post-inoculation with RML prion was 
approximately 160 days (Figure 3.5). This incubation time period confirms previous 
incubation time observed in mice of the same C57Bl/6N strain (Llyod et al., 2001). 
Incubation period for the end-stage groups of the UbG76V-GFP1, UbG76V-GFP2 and UbG76V-
GFPneg mice were the same. This demonstrates that the Ub-GFP reporter itself does not 
influence the incubation period of RML prion infection in these mice. See Appendix IV for 
statistics report. 
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Figure 3.5 RML infected UbG76V-GFP mice succumb to disease at 160 days post-
inoculation. 
Groups of UbG76V-GFP1 (n=3) and UbG76V-GFP2 mice (n=5), alongside non-transgenic 
controls (n=8), were inoculated i.c with 30 µl of 1% RML-infected mouse brain homogenate. 
The x- axis shows the number of days post RML prion infection. The first observable signs of 
scrapie symptoms were seen at day 137 post-inoculation, with a mean incubation period to 
end-stage disease of 160.2 days. Non-transgenic (blue), UbG76V-GFP1 (red), UbG76V-GFP2 
(pink). No differences in incubation period were observed between the groups of UbG76V-
GFP1, UbG76V-GFP2 and non transgenic mice.  See Appendix IV. 
 
3.4.6 PrPSc accumulates in the brains of prion-infected UbG76V-GFP 
reporter mice. 
To confirm that the brains of RML prion-infected UbG76V-GFP1 showed 
neuropathological features of prion infection, brain tissue was assessed by 
immunohistochemistry for the presence of formic acid resistant disease-associated PrPSc.  
Abnormal PrPSc deposits were detected in the brains of RML prion infected UbG76V-GFP 
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mice, and were seen throughout key neuropathological regions of the brain, including the 
thalamus, cortex and hippocampus, in both RML-infected UbG76V-GFP1 and UbG76V- GFP-/- 
mice (Figure 3.6 A, B). No abnormal PrPSc was detected in non-infected littermate controls 
(Figure 3.6 C), and there were no differences in PrPSc accumulation or distribution between 
UbG76V-GFP1 and UbG76V- GFP-/- mice.  
Parallel analyses were done in UbG76V-GFP2 mice. As expected, abnormal PrPSc 
deposits were detected throughout key neuropathological regions of the brain in both 
RML-infected UbG76V-GFP2 and UbG76V- GFP-/- mice (Figure 3.7 A, B), and no abnormal PrPSc 
was observed in non-infected littermate controls (Figure 3.7 C). No differences in PrPSc 
accumulation or distribution were seen between UbG76V-GFP2 and UbG76V- GFP-/- mice, or 
the UbG76V-GFP1 mice.  
 
Figure 3.6 RML infected UbG76V-GFP1 mice accumulate PrPSc at end-stage disease.  
UbG76V-GFP1 mice (n=3) and non-transgenic controls (n=3) were inoculated i.c with 30 µl of 
1% RML-infected mouse brain homogenate. Immunohistochemistry analysis was carried 
out on paraffin-embedded end-stage disease mouse brain tissue using the ICSM35 anti-PrP 
antibody. Significant deposition of formic acid-resistant PrPSc was observed throughout the 
brain in (A) UbG76V-GFP1 mice and (B) non-transgenic controls. (C) No PrPSc was observed in 
non-infected mice inoculated with control CD1 mouse brain homogenate. Images are taken 
of the thalamus, scale bar = 20 µm.   
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Figure 3.7 RML infected UbG76V-GFP2 mice accumulate PrPSc at end-stage disease. 
UbG76V-GFP2 mice (n=5) and non-transgenic controls (n=5) were inoculated i.c with 30 µl of 
1% RML-infected mouse brain homogenate. Immunohistochemistry analysis was carried 
out on paraffin-embedded end-stage disease mouse brain tissue using the ICSM35 anti-PrP 
antibody. Significant deposition of formic acid-resistant PrPSc was observed throughout the 
brain in (A) UbG76V-GFP2 mice and (B) non-transgenic controls. (C) No PrPSc was observed in 
non-infected mice inoculated with control CD1 mouse brain homogenate. Images are taken 
of the thalamus, scale bar = 20 µm. 
3.4.7 Gliosis increases in the brains of prion-infected UbG76V-GFP 
reporter mice. 
To further investigate whether the UbG76V-GFP reporter mice demonstrate other 
typical hallmarks of prion disease pathology, brain tissue from both UbG76V-GFP1 and 
UbG76V-GFP2 mice were examined for the presence of astrocytic gliosis, a characteristic of 
neuropathological features in prion-infected brain tissue.  GFAP is a well-established 
marker for astrocytes and was analysed by immunohistochemistry. The occurrence of 
gliosis was detected in the brains of prion-infected UbG76V-GFP1 mice (Figure 3.8 A), 
coinciding with the accumulation of PrPSc in the hippocampus, cortex, thalamus, cerebellum 
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and hypothalamus. This gliosis was similarly observed in the brain of RML prion-infected 
UbG76V-GFP1neg mice (Figure 3.8 B), but not in uninfected controls brain (Figure 3.8 C).   
The same observations were made in RML-infected UbG76V-GFP2 mice. Gliosis was 
observed throughout key neuropathological regions of the brain in both RML-infected 
UbG76V-GFP2 and UbG76V-GFP2neg mice (Figure 3.9 A, B), whereas increased gliosis was not 
observed in non-infected littermate controls (Figure 3.9 C). No differences were observed 
in gliosis between UbG76V-GFP2 and UbG76V-GFPneg mice. 
 
 
 
Figure 3.8 RML infected UbG76V-GFP1 mice demonstrate gliosis at end-stage 
disease.  
UbG76V-GFP1 mice (n=3) and non-transgenic controls (n=3) were inoculated i.c with 30 µl of 
1% RML-infected mouse brain homogenate. Immunohistochemistry was carried out on 
paraffin-embedded end-stage disease mouse brain tissue using an anti-GFAP antibody 
(Dako). Increased gliosis, a secondary neuropathological marker of prion disease pathology, 
was observed throughout the brain in (A) UbG76V-GFP1 mice and (B) non-transgenic 
controls. (C) Similar gliosis was not observed in non-infected mice inoculated with control 
CD1 mouse brain homogenate.  Images are taken of the thalamus, scale bar = 20 µm.   
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Figure 3.9 RML infected UbG76V-GFP2 mice demonstrate gliosis at end-stage 
disease.  
UbG76V-GFP2 mice (n=5) and non-transgenic controls (n=5) were inoculated i.c with 30 µl of 
1% RML-infected mouse brain homogenate. Immunohistochemistry was carried out on 
paraffin-embedded end-stage disease mouse brain tissue using an anti-GFAP antibody 
(Dako).  Increased gliosis, a secondary neuropathological marker of prion disease 
pathology, was observed throughout the brain in (A) UbG76V-GFP2 mice and (B) non-
transgenic controls. (C) Similar gliosis was not observed in non-infected mice inoculated 
with control CD1 mouse brain homogenate. Images are taken of the thalamus, scale bar = 
20 µm.   
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3.4.8 Confirmation of GFP in 22 L prion infected UbG76V-GFP1 mice 
mouse brain 
 
Accumulation of the Ub-GFP reporter was previously described (Lindsten et al., 
2003) and recently, impairment of the Ub-GFP reporter was observed at end stage in 
UbG76V-GFP mice infected with 22L prion.  It was shown that prion infection with 22L prion 
causes UPS impairment in end stage mice (Kristiansen et al., 2007).  
 
To confirm and validate those previous findings, immunohistochemistry was done 
on brain sections of UbG76V-GFP1 mice infected with 22L prion, which were also used as 
positive control for the UbG76V-GFP mice infected with RML prion.  Brain sections of 22L 
prion were assessed as described by Kristiansen and colleagues.  GFP accumulation was 
observed in area of the thalamus as expected (Figure 3.10 A), no GFP was seen in mock-
infected animals (Figure 3.10 B) or non-transgenic (Figure 3.10 C).  Detection of the Ub-GFP 
reporter in the brains of these mice suggests that proteins accumulate as they are not 
degraded by the failing proteasome machinery, and that there is significant dysfunction in 
the activity of the UPS.  This observation was as reported by Kristiansen and colleagues 
previously (Kristiansen et al., 2007). 
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Figure 3.10 GFP accumulates in the brain of 22L prion infected UbG76V-GFP1 mice 
at end-stage disease.   
Both UbG76V-GFP 1+/- (A) and UbG76V-GFP1-/- (B) were inoculated with 30 µl of 1% RML-
infected 22 L prion, while UbG76V-GFP littermates (C), used as negative controls were 
inoculated with CD1 brain homogenate.  Immunohistochemistry was done on paraffin 
sections using an anti-GFP antibody (Invitrogen).  Scale bar = 20 µm. 22L prion infected 
brains embedded in paraffin were obtained from Prof. John Portis, Rocky Mountain 
Laboratories, USA.  
 
3.4.9 Ub-GFP reporter accumulates in the brains of prion-infected 
UbG76V-GFP reporter mice 
 
To analyse the UbG76V-GFP reporter in RML prion-infected UbG76V-GFP reporter mice, 
brains tissue was assessed by immunohistochemistry for the presence of the Ub-GFP 
reporter.  An anti-GFP antibody was used to confirm the presence of GFP in the brains of 
the UbG76V-GFP mice as they succumbed to disease.   
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 In both UbG76V-GFP1 (Figure 3.11) and UbG76V-GFP2 (Figure 3.12) mice, GFP 
immunoreactivity was observed in the brains of the prion infected mice. This accumulation 
appeared to be restricted to the region of the thalamus. Importantly, the Ub-GFP reporter 
was not detected in the brains of either RML-infected UbG76V-GFPneg mice, which lack 
expression of the reporter, or uninfected UbG76V-GFP mice (Figures 3.11 B, C, & Figures 
3.12 B, C). This result demonstrates the accumulation of the Ub-GFP reporter substrate, 
indicating UPS dysfunction. This impairment is in this case specific to mice inoculated with 
prions, and that the anti-GFP immunoreactivity was specific to the presence of the Ub-GFP 
reporter. This finding confirms previous observations (Kristiansen et al, 2007), and indicates 
the suitability of the UbG76V-GFP model as means of monitoring UPS dysfunction 
throughout the pathogenic time-course of disease.  
 
 
 
 Figure 3.11 The Ub-GFP reporter accumulates in RML infected UbG76V-GFP1 mice 
at end-stage disease.  
UbG76V-GFP1 mice (n=3) and non-transgenic controls (n=3) were inoculated i.c with 30 µl of 
1% RML-infected mouse brain homogenate. Immunohistochemistry was carried out on 
paraffin-embedded end-stage disease mouse brain tissue using an anti-GFP antibody 
(Invitrogen). Accumulation of the Ub-GFP reporter was observed in the thalamus of (A) 
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UbG76V-GFP1 mice, but not in (B) non-transgenic controls or (C) non-infected mice 
inoculated with control CD1 mouse brain homogenate. Scale bar = 20 µm.   
 
 
 
Figure 3.12 The Ub-GFP reporter accumulates in RML infected UbG76V-GFP2 mice 
at end-stage disease.  
UbG76V-GFP2 mice (n=5) and non-transgenic controls (n=5) were inoculated i.c with 30 µl of 
1% RML-infected mouse brain homogenate. Immunohistochemistry was carried out on 
paraffin-embedded end-stage disease mouse brain tissue using an anti-GFP antibody 
(Invitrogen). Accumulation of the Ub-GFP reporter was observed in the thalamus of (A) 
UbG76V-GFP2 mice, but not in (B) non-transgenic controls or (C) non-infected mice 
inoculated with control CD1 mouse brain homogenate. Scale bar = 20 µm.   
 
3.5 DISCUSSION  
Work presented here confirms the UbG76V-GFP reporter mice as a suitable model for 
monitoring UPS impairment following RML prion infection.  In addition, validation and 
characterization of the UbG76V-GFP mice were done in primary cortical neurons. Neurons 
are particularly vulnerable during the progression of prion diseases (Mallucci et al., 2007; 
Mallucci et al., 2002), therefore it was important to confirm the functionality of the UbG76V-
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GFP reporter in these cells.  Cortical neurons isolated from the UbG76V-GFP mice brain were 
shown to have an accumulation of the Ub-GFP reporter in response to the inhibition of the 
UPS, as previously reported (Lindsten et al., 2003).  This was achieved by treating the cells 
with lactacystin, a specific proteasome inhibitor.  However, these neurons appeared to 
show, at least while being cultured in vitro, some basal level of Ub-GFP expression. The 
degree to which the Ub-GFP reporter can accumulate in non-neuronal cells, such as 
astrocytes, was not investigated at this point. 
It was also important to demonstrate that the UbG76V-GFP mice are susceptible to 
infection with RML prions.  Previous studies have shown the UbG76V-GFP mice are 
susceptible to 22L prions (Kristiansen et al, 2007). Therefore, to ascertain whether RML 
prion exerts similar effect, the UbG76V-GFP reporter mice were inoculated with RML prion in 
the same manner as previously done with 22L prion. Detection of the UbG76V-GFP reporter 
was observed in 22L prion-infected transgenic mouse brains, whereas no UbG76V-GFP 
accumulation in mice inoculated with normal brain or in 22L prion-infected non-transgenic 
littermates was seen (Kristiansen et al, 2007).  Following inoculation of RML prion, the 
UbG76V-GFP mice succumbed to disease as would be expected. The incubation period until 
end stage disease of ~160 days was the same for the UbG76V-GFP1, UbG76V-GFP2 and UbG76V-
GFPneg mice. This demonstrates that expression of the Ub-GFP reporter itself does not 
influence the prion incubation period in these mice. Moreover, the incubation period 
observed was similar to previous observations of the C57Bl/6N background strain on which 
the UbG76V-GFP mice are based (Lloyd et al., 2001).  
 
To investigate whether the Ub-GFP reporter displayed the neuropathological 
markers associated with prion disease at end stage disease, histological analyses of brain 
tissue isolated from the UbG76V-GFP mice were carried out.  As expected, a widespread 
appearance of disease-associated PrPSc, accompanied by a marked astrocytosis and gliosis 
was observed throughout the brain, but more specifically in the region of the thalamus.  No 
noticeable differences in staining of PrPSc or GFAP were observed between the UbG76V-
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GFP1, UbG76V-GFP2 and UbG76V-GFPneg mice, indicating that expression of the Ub-GFP 
reporter itself does not influence the prion-mediated neuropathology induced in these 
mice.  
To confirm previous findings of GFP accumulation in 22L prion-infected UbG76V-GFP 
mice, similar detection methods were used.  Analysis of the Ub-GFP reporter by anti-GFP 
immunoreactivity demonstrated that the UPS is impaired by RML prion at end stage 
disease, as was observed with 22L prion previously (Kristiansen et al., 2007). Moreover, 
positive staining was observed only in the UbG76V-GFP1 and UbG76V-GFP2 mice, with no such 
staining being detected in prion-infected UbG76V-GFPneg mice.  Indeed, this result confirms 
the specificity of the immunohistochemistry procedure used to detect the Ub-GFP reporter.  
Interestingly, the anti-GFP immunoreactivity was stronger in the prion-infected UbG76V-
GFP1 mice than their UbG76V-GFP2 counterparts.  
The variation in GFP staining between the two lines of the UbG76V-GFP reporter mice 
could be explained by the high basal level expression of the Ub-GFP substrate reported in 
the UbG76V-GFP1 mice (Lindsten et al., 2003).  Similar variation was observed in the 
expression of the UbG76V-GFP transgene when double transgenic of ALS,  (SOD1G93A) and 
UbG76V-GFP reporter mice were examined (Cheroni et al., 2009).  Substantial differences 
were seen between the two transgenic lines of the reporter mice.  The basal level GFP in 
the UbG76V-GFP1 were clearly detectable by immunostaining in both dorsal and ventral 
lumbar spinal cord, but no immunostaining was observed in the UbG76V GFP2 (Cheroni et 
al., 2009), suggesting the study UbG76V-GFP2 must be done in conjunction with the UbG76V-
GFP1 transgenic mice.  Using the proteasome inhibitor lactacystin, a significant 
accumulation of the UbG76V-GFP substrate was observed in cortical neurons, indicating 
impairment in the UPS machinery.  This result was consistent with previous studies 
(Dantuma et al., 2000; Lindsten et al., 2003).  The level of proteasome inhibition observed 
is likely to have severe consequences on neuronal viability.   
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Although the molecular basis of prion neurotoxicity is not yet clear, it is suggested 
that intracellular accumulation of disease-associated PrPSc is required for cytotoxicity. 
Previous studies support a cytosolic localization for a small proportion of PrPSc in prion 
infected neuronal cells in line with our previous data demonstrating toxic cytosolic PrPSc 
aggresomes (Kristiansen et al., 2005; Kristiansen et al., 2007).  Granular deposits of disease-
related PrP have been reported in cell body of neurons and CJD brains, suggesting the 
occurrence of intraneuronal prion aggregates (Kovacs and Budka, 2008).  However, it is 
unclear how PrPSc oligomers traffic inside neurons and enter the cytosol to cause cell death.  
Other studies suggested that intracellular neuronal propagation of pathogenic PrPSc 
appears important in neurotoxicity (Brandner et al., 1996; Mallucci et al., 2003). However, 
it was shown that various proteolytic stress condition can cause functional impairment of 
the UPS which result in cellular dysfunction and apoptosis (Lindsten et al., 2002). 
 
PrPC is essential for prion propagation and neurotoxicity (Bueler et al., 1993).   
However, some studies reveal that PrPC knockout in adult mouse brain shows no overt 
phenotypic effect (Mallucci et al., 2002).  Moreover, embryonic PrPC knockout models 
demonstrate normal development and behaviour (Bueler et al., 1992; Manson et al.,1994).  
Therefore, PrPC knockout studies effectively exclude loss of function of PrPC in neurons as a 
significant mechanism in prion mediated neurodegeneration.  
Down-regulation of PrP expression has been proposed as a possible therapy for 
prion disease, assuming prion expression is required for infection (Bueler et al., 1993) and 
the down-regulation of PrP expression can prolong disease incubation time (Manson et al., 
1994; Prusiner et al., 1983).  Studies by Mallucci and colleagues have shown the down-
regulation of prion expression in mice can halt neuronal cell death and reverse the disease 
in the infected animal (Mallucci et al., 2007). 
The pathogenesis of prion disease is likely to be multifactorial, but inhibition of the 
proteasome by pathogenic PrP is likely to result in neuronal perturbation and contribute to 
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neuronal loss (Ma and Lindquist, 2002).  In vivo testing of the role of the UPS in 
neurodegeneration using the same Ub-GFP reporter mouse model as used here 
demonstrated that proteasome impairment does not contribute to pathogenesis in 
spinocerebellar ataxia 7 (SCA7) mice (Bowman et al., 2005).  The Ub-GFP reporter does not 
accumulate when there is neuronal apoptosis per se and is only seen when there is a 
significant UPS dysfunction.  Accumulation of the UbG76V-GFP reporter occurred only in 
prion infected mice brains and was associated with PrPSc deposition. 
PrPC accumulation in the cytoplasm by use of proteasome inhibitor is reported to be 
associated with neuronal cell death (Ma and Lindquist, 2002).  However, the data are 
controversial with evidence both for (Ma et al., 2002; Heller et al., 2003; Rambold et al., 
2006) and against (Drisaldi et al., 2003; Roucou et al., 2003; Fioriti et al., 2005).  A major 
drawback of many studies on cytosolic PrPC   is the high levels of proteasome inhibition 
used, which may limit any physiological relevance in experiments in vivo (Ding et al., 2003).  
Importantly, for a prion disease such as CJD, the abnormal prion conformer PrPSc inhibits 
the 26S proteasome in vitro, while either preincubation with an oligomer antibody or heat 
denaturation of PrPSc alleviated this inhibitor effect (Kristiansen et al., 2007), indicating a 
specific effect (Kristiansen et al., 2007).  Moreover, protesome activity also decreased in 
both cells exposed to prion-infected mouse brain homogenates and in brain region 
exhibiting significant prion neuropathology in mice infected with PrPSc (Kristiansen et al., 
2007.  This finding establishes a solid link between UPS impairment and neurodegeneration 
associated with prion infection.  
Other studies have suggested both the full-length PrPSc (Hertz et al., 2003) and the 
short PrP peptides are toxic to cell in vitro (Forloni et al., 1993), and their relevance in vivo 
pathogenesis should be carefully investigated.  However, strong evidence provided by 
several studies suggests PrP itself may not be the toxic component.  For instance, it has 
been shown that PrPC -null tissue can be in close proximity to PrPSc deposits without 
suffering deleterious effects (Brandner et al., 1996; Mallucci et al., 2003), and there is no 
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direct evidence to correlate between neuronal loss and PrPSc plaques in CJD brains (Parshi 
et al., 1996).  As already mentioned, some have reported studies done on prion diseases in 
which PrPSc is barely detectable (Collinge et al., 1995; Lasmezas et al., 1997), and subclinical 
infection where high levels of PrPSc accumulate in the absence of clinical symptoms are 
recognized (Hill et al., 2000; Race et al., 2001; 2002; Hill and Collinge , 2003).   
In vitro and in vivo experimental data presented in this chapter investigate UbG76V-
GFP reporter mice following RML prion infection and confirm the model as suitable for 
monitoring the UPS dysfunction through the progression of prion disease (presented in 
Chapter 4). 
3.6 SUMMARY 
 
In this chapter, I present data, which characterize and validate the UbG76V -GFP 
mouse model for the purpose of the direct monitoring of the UPS dysfunction in the 
pathogenesis of prion diseases.  Both UbG76V -GFP1 and UbG76V -GFP2 lines were generated 
and cross-bred in a C57BL6/N background to establish stable colonies.  The UbG76V -GFP 
reporter was characterized in primary cortical neurons, and offspring were inoculated with 
RML strain prion.  Both GFP reporter mice (UbG76V-GFP1 and UbG76V-GFP2) were generated 
to investigate the impairment of the UPS throughout the course of disease.  To date, it is 
the first time the UbG76V-GFP reporter mice have been inoculated with RML strain prion and 
a time-course was designed not only to monitor disease progression, but to investigate UPS 
impairment at early stages of prion infection.  
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4 PRION INFECTION IMPAIRS THE UPS IN 
UbG76V-GFP REPORTER MICE 
4.1 BACKGROUND 
Aberrations in the UPS machinery have been implicated in the pathogenesis of many 
diseases, including a variety of neurodegenerative diseases (Ciechanover and Brundin, 
2003), and significant evidence exists of UPS dysfunction contributing to those diseases 
(Section 1.13). Consequently, understanding the spatial and temporal activity of the UPS is 
important for understanding its exact role and function in a neurodegenerative disease 
such as prion disease.  Indeed, previous research has provided evidence for the implication 
of the UPS in prion disease (Section 1.14).  Studies in prion-infected mouse brain have 
shown a correlation between elevated levels of ubiquitin conjugates and reduced 
proteasome function (Kang et al., 2004), and functional impairment of the UPS in prion 
disease, leading to a potential role in disease pathogenesis has been described (Deriziotis & 
Tabrizi, 2008; Andre and Tabrizi, 2011).  
  
Direct interaction has been demonstrated between β-sheet-rich PrP species similar to 
disease-associated PrPSc and the 20S core particle of the 26S proteasome (Deriziotis et al., 
2011). These studies show that aggregated β-sheet-rich PrP oligomers inhibit the 
proteolytic activities of the 26S proteasome, in a manner that is specific to PrP in an 
aggregated non-native β-sheet form (Kristiansen et al., 2007).  The extent to which these in 
vitro observations are recapitulated in vivo in prion infected animals has not been 
previously fully investigated. Dysfunction of the UPS has been observed before in prion-
infected UbG76V-GFP mice, but the animals were analysed solely at end-stage disease 
(Kristiansen et al., 2007). As a result, little is known about whether such impairment occurs 
at an early stage in the time-course of the disease, or whether changes in UPS function 
after prion infection correlate with or even precede other aspects of cellular dysfunction as 
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the disease progresses. In this chapter, data is presented to address the in vivo time-course 
of UPS dysfunction in prion disease pathogenesis using both UbG76V-GFP UbG76V-GFP1 and 
UbG76V-GFP2 reporter mice (Chapter 3). Also investigated are other aspects of disease 
pathogenesis, including typical histopathological markers of prion disease such as disease-
associated PrPSc and a marker of gliosis, GFAP.  
4.2 AIMS 
 
• To evaluate the functional status of the UPS through a time-course during the prion 
disease pathogenesis; 
 
• To further clarify the relationship between UPS dysfunction and neuropathological 
markers of prion disease; 
 
• To potentially correlate UPS dysfunction and ER stress during the course of prion 
disease. 
 
 
 
4.3 METHODS 
Mice were generated and genotyped, as described in Chapter 3.  Heterozygous 
UbG76V-GFP1 and UbG76V-GFP2 mice, together with UbG76V-GFPneg controls were bred.  Mice 
were inoculated intracerebrally with either 30 µl 1% RML prion brain homogenate or 30µl 
1% normal CD1 mouse brain homogenate as a control (Section 2.2.2). This was followed by 
a series of timed culls at days 45, 85, 105, 125 and 145 post-inoculation, and at end-stage 
disease (~160 days) (Table 4.1).  At each time-point, one brain hemisphere was fixed for 
histological analysis and the other was frozen for biochemical studies. The presence of 
disease pathology was confirmed by immunohistochemical staining of PrPSc and GFAP, as 
shown in chapter 3. 
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Immunohistochemistry was performed using Ventana Medical Systems (Section 2.5). 
Western blots and/or dot blots were undertaken for PrPSc and ubiquitin. Fluorogenic assays 
were used to monitor the chymotrypsin-like activity of 26S proteasomes (Section 2.8). This 
work was done in collaboration with Dr Ralph Andre, MRC Prion Unit, UCL Institute of 
Neurology. 
Data were expressed as standard deviation (SD) and analysed by Student T t-test. 
Significance was expressed as follows: *** p <0.001; ** p <0.01, * p <0.05. See Appendix 
IV. 
 
 
 
 
 
 
 
 
 
 
 
 
 
126 | P a g e  
 
 
 
 
Table 4.1 UbG76V-GFP mice were in inoculated in groups and culled at various 
time points thereafter.   
  
Mouse type Inocula Day cull post 
inoculation 
 
UbG76V-GFP1 +/- 
 
I6201 RML i.c. 
 
45,85,105,125,145,165 
 
UbG76V -GFP1 +/- 
 
I7723 normal i.c. 
 
45,85,105,125,145,165 
 
UbG76V -GFP1 -/- 
 
I6201 RML i.c. 
 
45,85,105,125,145,165 
 
UbG76V -GFP1 -/- 
 
I7723 normal i.c. 
 
45,85,105,125,145,165 
 
UbG76V -GFP2 +/- 
 
I6201 RML i.c. 
 
45,85,105,125,145,165 
 
UbG76V -GFP2 +/- 
 
I7723 normal i.c. 
 
45,85,105,125,145,165 
 
UbG76V -GFP2 -/- 
 
I6201 RML i.c. 
 
45,85,105,125,145,165 
 
UbG76V -GFP2 -/- 
 
I7723 normal i.c. 
 
45,85,105,125,145,165 
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4.4 RESULTS 
 
4.4.1 Ub-GFP is expressed in the brains of RML prion-infected UbG76V-
GFP1 mice before the onset of clinical signs 
To investigate the earliest time-point in which UbG76V-GFP reporter accumulates in 
RML prion infected mice, brain sections from UbG76V-GFP1 mice were analysed by 
immunohistochemistry.   Accumulation of Ub-GFP was detected as early as day 85 in the 
thalamus of RML prion-infected UbG76V-GFP1 mice (Figure 4.1).  This accumulation 
increased as the disease progressed. Ub-GFP was not observed in the brains of RML prion-
infected UbG76V-GFPneg mice or control inoculated animals (Figure 4.1). In addition, some 
Ub-GFP was observed in the cortex towards end stage disease, but the appearance of the 
reporter was largely restricted to the thalamus. By cellular morphology, it seemed that the 
majority of the cells in which the Ub-GFP reporter was observed in the thalamus were 
astrocytes, although some Ub-GFP in neurons was observed. Taken together, this data 
shows that UPS dysfunction occurs in the brains of prion-infected mice relatively early in 
disease progression, and before the onset of clinical signs. 
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Figure 4.1 The Ub-GFP reporter accumulates in RML infected UbG76V-GFP1 mice at 
end-stage disease.  
UbG76V-GFP1 mice (n=3) and non-transgenic controls (n=3) were inoculated i.c with 30 µl of 
1% RML-infected mouse brain homogenates. Immunohistochemistry was carried out on 
paraffin-embedded mouse brain tissue using an anti-GFP antibody (Invitrogen). 
Accumulation of the Ub-GFP reporter was observed over time in the thalamus of UbG76V-
GFP1 mice (A, D, G, J, M, P), but not in non-transgenic controls (B, E, H, K, N, Q) or non-
infected mice inoculated with control CD1 mouse brain homogenate (C, F, I, L, O, R). Scale 
bar = 20 µm. Continued overleaf. 
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Figure 4.1(continued).  The Ub-GFP reporter accumulates in RML infected UbG76V-
GFP1 mice at end-stage disease. 
 
 
 
 
 
130 | P a g e  
 
 
 
4.4.2 Ub-GFP is expressed in the brains of prion-infected UbG76V-GFP2 
mice before the onset of clinical signs 
To verify whether similar accumulation of GFP could be observed in the UbG76V-GFP2  
mice, brain sections were analysed in the same manner as the UbG76V-GFP1 reporter mice.  
Accumulation of the Ub-GFP was also observed in the thalamus of RML prion-infected 
UbG76V-GFP2 mice, although convincing stainings of GFP appeared to be from day 125 post-
inoculation onwards (Figure 4.2). Ub-GFP was not observed in the brains of RML prion-
infected UbG76V-GFPneg mice or control inoculated animals. There were no differences in the 
histological or cellular patterns of the Ub-GFP accumulation between the UbG76V-GFP2 and 
the UbG76V-GFP1 mice. Collectively, this data shows that the two UbG76V-GFP lines behave 
similarly in response to prion infection.  However, due to its apparent increased sensitivity 
to UPS impairment, the UbG76V-GFP1 line was chosen for use in the majority of further 
studies. 
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Figure 4.2 The Ub-GFP reporter accumulates in RML infected UbG76V-GFP2 mice at 
end-stage disease.  
UbG76V-GFP2 mice (n=5) and non-transgenic controls (n=5) were inoculated i.c with 30 µl of 
1% RML-infected mouse brain homogenates. Immunohistochemistry was carried out on 
paraffin-embedded mouse brain tissue using an anti-GFP antibody (Invitrogen). 
Accumulation of the Ub-GFP reporter was observed over time in the thalamus of (A, D, G, J, 
M, P) UbG76V-GFP2 mice, but not in non-transgenic controls (B, E, H, K, N, Q) non-infected 
mice inoculated with control CD1 mouse brain homogenate or (C, F, I, L, O, R). Scale bar = 
20 µm. Continued overleaf. 
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Figure 4.2 (continued).  The Ub-GFP reporter accumulates in RML infected 
UbG76V-GFP2 mice at end-stage disease. 
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4.4.3 PrPSc deposition in the brains of RML prion-infected UbG76V-
GFP1 mice  
To determine whether PrPSc was present in RML prion-infected UbG76V-GFP1 mice, 
brain sections were analysed by immunohistochemistry. In the thalamus particularly where 
the Ub-GFP reporter could be detected from day 85 post-inoculation, significant amounts 
of disease-associated PrPSc deposition were observed (Figure 4.3).  Similar levels of PrPSc 
were observed in RML-prion infected UbG76V-GFPneg, indicating that the presence of the Ub-
GFP reporter had no influence on the deposition of PrPSc.  No PrPSc was detected in non-
infected control mice. The concurrent appearance of PrPSc with the Ub-GFP reporter 
indicates that there may be a relationship between the two. It should be noted, however, 
that the deposition of PrPSc was far more widespread than the appearance of the Ub-GFP 
reporter, with PrPSc being readily observed in cortical, striatal and hypothalamic regions 
that are typically associated with RML prion neuropathology (Figure 4.4).  
Furthermore, confirmation of the deposition of PrPSc was completed by Western 
blot analysis of protease K resistant material in 10% brain homogenates made from the 
RML prion-infected UbG76V-GFP1 mice. PrPSc was readily observed at later time-points, 
whereas a NaPTA precipitation of aggregated material was required to detect PrPSc at days 
85-125 post-inoculation (Figure 4.5). PrPSc was not observed at day 45 post-inoculation, in 
agreement with the immunohistochemistry analysis. Protease K-resistant PrPSc was not 
observed in the brains of non-infected control animals.   
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Figure 4.3 RML infected UbG76V-GFP1 mice accumulate PrPSc from day 85 post-
inoculation through to end stage disease.  
UbG76V-GFP1 mice (n=3) and non-transgenic controls (n=3) were inoculated i.c with 30 µl of 
1% RML-infected mouse brain homogenates. Immunohistochemistry analysis was carried 
out on paraffin-embedded end-stage disease mouse brain tissue using the ICSM35 anti-PrP 
antibody. Significant deposition of formic acid-resistant PrPSc was observed throughout the 
brain in (A, D, G, J, M, P) UbG76V-GFP1 mice and non-transgenic controls (B, E, H, K, N, Q). 
No PrPSc was observed in non-infected mice inoculated with control CD1 mouse brain 
homogenate(C, F, I, L, O, R). Images are taken of the thalamus, scale bar = 20 µm.   
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Figure 4.3 (continued).  RML infected UbG76V-GFP1 mice accumulate PrPSc from 
day 85 post-inoculation through to end stage disease. 
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Figure 4.4 PrPSc deposition is widespread throughout the brain in RML infected 
UbG76V-GFP1 mice.  
UbG76V-GFP1 mice (n=3) and non-transgenic controls (n=3) were inoculated i.c with 30 µl of 
1% RML-infected mouse brain homogenates. Immunohistochemistry analysis was carried 
out on paraffin-embedded end-stage disease mouse brain tissue using the ICSM35 anti-PrP 
antibody. Significant deposition of formic acid-resistant PrPSc was observed throughout the 
brain in (A, C, E, G) UbG76V-GFP1 mice. No PrPSc was observed in non-infected mice 
inoculated with control CD1 mouse brain homogenate (B, D, F, H).  Scale bar = 1 mm.   
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Figure 4.5 Immunoblot analysis of PrPSc expression in the brains of RML-prion-
infected UbG76V-GFP1 mice.  
 UbG76V-GFP1 mice were inoculated with RML prions and culled at various time-points (days 
45, 85, 105, 125, 145 and 165) post-inoculation. A 1% tissue homogenate was made for 
biochemical assay. (A) Samples obtained from the day 85, 105 and 125 groups required 
NaPTA precipitation prior to western blotting in order to observe a detectable PrPSc 
signal,(B) whereas as homogenates from days 145 and 165 produced a detectable signal 
without precipitation.  Immunoblots were probed with the ICSM35 anti-PrP antibody.  
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4.4.4 Gliosis in the brains of RML prion-infected UbG76V-GFP1 mice  
To directly assess neuropathological features of RML in the prion in UbG76V-GFP1 
mice, brain sections were analysed by immunohistochemistry using a typical marker for 
gliosis. Extensive astrocytosis is a secondary marker of the onset of prion disease 
pathology, which can be readily detected by immunoreactivity of the specific astrocyte 
marker, GFAP. An increase in GFAP immunoreactivity was observed from day 85 post-
inoculation onwards in the thalamus of RML prion-infected UbG76V-GFP1 mice (Figure 4.6), 
correlating to PrPSc deposits observed in the same time-point.  This astrocytosis was also 
seen in UbG76V-GFPneg mice, but not in non-infected controls. The increased GFAP 
expression was apparent throughout the brain (Figure 4.7).  The concurrent appearance of 
prion disease-associated pathology with the Ub-GFP reporter indicates that there may be a 
relationship between the two in the earliest stages of pathogenesis.  
Increasing evidence suggest that astrocyte pathology may contribute to a number of 
neurodegenerative disease mechanisms, including prion disease (Lepore et al., 2008; Wyss-
Coray et al., 2003; Raeber et al., 1997).  Astrogliosis is reported to be prominent, diffuse 
and intense throughout the affected CNS regions in CJD and other related prion disease, 
especially if clinical symptoms have been of long duration.  Although this astrogliosis exhibit 
some characteristics of severe diffuse reactive astrogliosis, it is not clear whether 
astrocytes play an active role in prion replication and disease pathogenesis or whether 
astrogliosis is largely reactive to the disease process in other cell types (Kovacs and Budka, 
2008).  
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Figure 4.6  RML infected UbG76V-GFP1 mice exhibit increased astrocytosis from 
day 85 post-inoculation through to end stage disease.  
UbG76V-GFP1 mice (n=3) and non-transgenic controls (n=3) were inoculated i.c with 30 µl of 
1% RML-infected mouse brain homogenates.  Immunohistochemistry was carried out on 
paraffin-embedded end-stage disease mouse brain tissue using an anti-GFAP antibody 
(Chemicon). Increased astrocytosis , a secondary neuropathological marker of prions 
disease pathology, was observed throughout the brain in (A, D, G, J, M, P) UbG76V-GFP1 
mice and non-transgenic controls (B, E, H, K, N, Q).   (C-I;O-P).  Similar gliosis was not 
observed in non-infected mice inoculated with control CD1 mouse brain homogenate (C, F, 
I, L, O, R). Images are taken of the thalamus, scale bar = 20 µm. 
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Figure 4.6 (continued). RML infected UbG76V-GFP1 mice exhibit increased 
astrocytosis from day 85 post-inoculation through to end stage disease. 
 
 
141 | P a g e  
 
 
 
 
 
Figure 4.7 Astrocytosis is widespread throughout the brain in RML infected 
UbG76V-GFP1 mice. 
 UbG76V-GFP1 mice (n=3) and non-transgenic controls (n=3) were inoculated i.c with 30 µl of 
1% RML-infected mouse brain homogenates. Immunohistochemistry was carried out on 
paraffin-embedded end-stage disease mouse brain tissue using an anti-GFAP antibody 
(Millipore). Increased astrocytosis, a secondary neuropathological marker of prions disease 
pathology, was observed throughout the brain in UbG76V-GFP1 mice (A, C, E, G). A lesser 
degree gliosis was observed in non-infected mice inoculated with control CD1 mouse brain 
homogenate (B, D, F, H). Scale bar = 1 mm. 
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4.4.4 Ubiquitin deposition in the brains of RML prion-infected UbG76V-
GFP1 mice  
To further clarify the relationship between prion infection and UPS dysfunction, 
immunohistochemistry was used to analyse ubiquitin deposition in the brains of RML prion-
infected UbG76V-GFP1 reporter mice.  Granular deposits of ubiquitin in the brain of end 
stage 22L prion-infected mice were previously reported (Kristiansen et al., 2007). Although 
discerning widespread changes in ubiquitin levels was proved difficult (Figure 4.8), similar 
granular ubiquitinated deposits as previously seen in the 22L prion infected mice were 
observed in the thalamus of the RML prion-infected UbG76V-GFP1 mice (Figure 4.9).  This 
result provides some further evidence that the UPS machinery is impaired in the brains of 
prion infected mice.  
Ubiquitin-protein conjugates within neurons have been previously reported in the 
brains of prion-infected mice, whereby intracellular ubiquitinated deposits were seen early 
and increased with disease progression (Lowe et al., 1992). Ubiquitin conjugates associated 
with pathological lesions have also been described in several neurodegenerative disorders.  
For example, In Parkinson’s disease the level of the 26S proteasome and proteasome 
activity are reduced (Rubinsztein, 2006). However, a direct role of ubiquitinated proteins in 
those neurodegenerative diseases has not been established. 
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Figure 4.8 Prion infection causes some increase in the deposition of 
ubiquitinated proteins in UbG76V-GFP mice.  
UbG76V-GFP1 mice (n=3) and non-transgenic controls (n=3) were inoculated i.c with 30 µl of 
1% RML-infected mouse brain homogenates. Immunohistochemistry analysis was carried 
out on paraffin-embedded day 45, 85, 125 and 165 mouse brain tissue using an anti-
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ubiquitin antibody (Appendix I). Ubiquitinated deposits were observed throughout the 
brain in UbG76V-GFP1 mice and non-transgenic controls. Images are taken of the thalamus, 
scale bar = 20 µm. 
 
 
Figure 4.9 Ubiquitinated inclusions are observed in the thalamus of the brain in 
prion infected UbG76V-GFP mice. 
 Intracellular cytosolic granular ubiquitinated deposits is shown to accumulate at day 125 
post RML prion infection in the brains of UbG76V-GFP1 reporter mice. These deposits could 
represent ubiquitinated-protein conjugates accumulate as they are not degraded by the 
failing proteasome.   Immunohistochemistry analysis was carried out on paraffin-
embedded day 125 on mouse brain tissue using an anti-ubiquitin antibody (Santa Cruz). 
Images are taken of the thalamus, scale bar = 20 µm. 
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In an attempt to quantify any differences in ubiquitin levels in the brains of RML 
prion-infected UbG76V-GFP1 mice, 10% homogenates were subjected to dot blot analysis. 
The data presented show that ubiquitin levels were significantly increased in the brains of 
RML prion infected mice from day 125 post-inoculation to end stage disease, as compared 
to their respective controls (Figure 4.10).  Such differences were not observed at earlier 
time-points post-inoculation. Ubiquitin levels corresponded to differences in the poly-
ubiquitin associated with accumulating UPS substrates, Western blots were carried out on 
the same samples (Figure 4.11). There was an increase in poly-ubiquitin level toward end 
stage disease in the RML prion infected mice brain. This result suggests that the differences 
on total ubiquitin levels could be ascribed to an accumulation of poly-ubiquitin associated 
with UPS dysfunction, rather than for example, differences in the expression level of non-
conjugated monomeric ubiquitin. Student t-test. ***p<0.001, **p<0.01. For statistics 
report, see Appendix IV.  
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Figure 4.10 Total ubiquitin levels are increased in the brains of prion-infected 
UbG76V-GFP1 mice.   
UbG76V-GFP1 mice were inoculated with RML prions and culled at various time-points (days 
45, 85, 125, and 165) post-inoculation. A 1% tissue homogenate was prepared for 
biochemical assay and analysed using 96-well dot blot apparatus. (A) Membranes were 
probed with an anti-ubiquitin antibody (Santa Cruz) and analysed using the Li-cor Odyssey 
system. (B) Quantification demonstrates an accumulation of total ubiquitin in the brains of 
prion infected mice from day 125 to end stage disease. Data were normalised to β-actin 
levels in the same samples measured by Western blot and Li-cor analysis in Figure 4.11. 
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Figure 4.11 Accumulating ubiquitin in the brains of prion-infected UbG76V-GFP1 
mice appears to consist of high molecular weight species.   
UbG76V-GFP1 mice were inoculated with RML prions and culled at various time-points (days 
45, 85, 125, and 165) post-inoculation. A 1% tissue homogenate was made for biochemical 
assay. Immunoblots were probed with anti-ubiquitin and anti β-actin antibodies. High 
molecular weight poly-ubiquitin species appear to accumulate in the brains of infected 
mice as disease progresses. 
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4.4.5 26S proteasome activity is impaired in the brains of prion-
infected UbG76V-GFP1 mice  
Given the observations made here that the UPS is impaired in the brains of RML-
infected UbG76V-GFP1 mice during prion disease pathogenesis, and that a direct inhibitory 
effect of β-sheet-rich PrP species on 26S proteasomes has been reported by (Deriziotis et 
al., 2011), the activity of 26S proteasomes in the brains of the RML-infected UbG76V-GFP1 
mice was assessed. The enzymatic function of the proteasomes in RML-infected UbG76V –
GFP mice was analysed using fluorogenic peptide activity assays, as used routinely in our 
laboratory (Kristiansen et al., 2007).  In particular, the chymotrypsin-like peptidase activity 
of the 26S proteasome was measured (Figure 4.12). The results demonstrate that 26S 
proteasomal activity was inhibited from day 145 post-inoculation onwards, correlating 
reasonably well with the deposition of poly-ubiquitinated substrates in the brain described 
above (Figure 4.10) at these time-points. Thus, the effect of prions to cause UPS 
dysfunction is associated with a functional loss of proteasome activity in the brains of these 
mice. Student t-test ***p<0.001, *p<0.05 (compared to uninfected control).  See Appendix 
IV for statistics report. 
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Figure 4.12 RML prion infection causes impairment of the proteolytic activity of 
the 26S proteasome in UbG76V-GFP1 mice.  
 26S proteasomes in the brains of RML prion-infected UbG76V-GFP1 mice showed a 
significant reduction in 20S proteasome chymotrypsin-like proteolytic activity as compared 
to control non-infected mice towards end stage disease. Data are means of three 
independent experiments. This experiment was done by Dr. Ralph Andre.  
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4.4.6 A marker of ER stress is observed at end stage disease in the 
brains of prion-infected UbG76V-GFP1 mice 
Alteration of ER homeostasis by several forms of stress, such as heat shock, 
overexpression of mutant proteins, or alteration of proteasome activity can cause the 
accumulation of misfolded proteins in the ER (Ferri and Kroemer, 2001; Liu et al., 1997).  
These alterations trigger specific activation of a protective cellular response, leading to 
upregulation of ER chaperones and a general decrease in protein synthesis (Rao et al., 
2002; Reddy et al., 1999).  Increased expression of ER chaperones glucose-regulated 
protein (grp) such as; Grp78/BiP (immunoglobulin chain binding protein) can exert a pro-
survival effect of the UPR (Reddy et al., 1999; Rao et al., 2002; Sitia and Braakman, 2003).   
 
To investigate whether a relationship exists between RML prion infection and ER 
stress, UbG76V-GFP1 reporter mice brains were evaluated for the ER stress marker, 
Grp78/BiP.  The Grp78/BiP protein was observed in a few dispersed cells at end stage 
disease in the thalamus of RML prion infected UbG76V-GFP mice brain, but not in non-
infected controls (Figure 4.13).  The small pool of cells expressing Grp78/BiP indicates that 
ER stress may be a late event in the course prion disease. This observation suggests that 
prion-induced UPS dysfunction may precede disease-associated ER stress, and that prions 
may trigger a non-classical ER stress response. 
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Figure 4.13 Prion infection increases the expression of Grp78/Bip, indicating ER 
stress, at end stage disease in the brains of UbG76V-GFP1 mice .  
UbG76V-GFP1 mice (n=3) and non-transgenic controls (n=3) were inoculated i.c with 30 µl of 
1% RML-infected mouse brain homogenates. Immunohistochemistry analysis was carried 
out on paraffin-embedded day 45, 85, 125 and 165 mouse brain tissue using an anti-
Grp78/Bip antibody (Cell Signaling). Deposits, shown with arrows, were observed in the 
thalamus of RML prion infected brain at end stage disease (J and K), but not in the non-
transgenic controls (L). Images are taken of the thalamus, scale bar = 20 µm.  
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4. 5 DISCUSSION  
 
The data presented in this chapter indicate an impairment of the UPS machinery in 
the brains of UbG76V-GFP reporter mice infected with RML prion infection, as shown by the 
accumulation of the model substrate, UbG76V-GFP (Dantuma et al., 2000; Lindsten et al., 
2003). Accumulation of the UbG76V-GFP reporter occurred only in the brains of prion-
infected mice, with no Ub-GFP being observed in animals injected with non-prion control 
homogenate. The observed accumulation of Ub-GFP coincided with markers of prion 
disease neuropathology such as PrPSc deposition and extensive GFAP immunoreactivity. 
The accumulation of the Ub-GFP reporter was observed early in the disease time-course, at 
least at 85 days post-inoculation following infection with RML prions in a ~160 day disease 
time-course (Figure 4.1). This was also the earliest time-point at which PrPSc and other 
neuropathological markers were observed. Moreover, these observations seemed to be 
restricted at these early time-points to certain regions of the brain such as the thalamus, 
suggesting some spatial as well as temporal correlation between UPS impairment and prion 
disease pathology. This supports the claim that impairment of the UPS may be an 
important contributor to prion disease pathogenesis (Kristiansen et al., 2007; Deriziotis and 
Tabrizi, 2008; Andre and Tabrizi, 2012). 
During the experimental time-course, clinical symptoms of prion disease were 
monitored in both UbG76V-GFP transgenic mice until end-stage disease. The onset of disease 
pathology was confirmed by the presence of PrPSc deposits, gliosis and spongiosis in 
affected areas of the brain in the RML prion-infected mice, but not in non-infected 
littermate control animals (Figure 4.3; Figure 4.6, Figure 4.7).  Further confirmation of PrPSc 
deposits was provided by western blot analysis of proteinase K resistant material in the 
brains of these animals. PrPSc was not observable at day 45 post-inoculation, in agreement 
with the immunohistochemistry analysis.  The onset of PrPSc was observed by Western 
blotting at day 85 post-inoculation, with a subsequent increase in PrPSc levels until end-
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stage disease, is also consistent with the immunohistochemistry observations. There were 
no obvious differences in the appearance or time-course of prion disease pathology 
between either of the two UbG76V-GFP lines and their non-transgenic UbG76V-GFPneg 
counterparts. This indicates that the expression of the Ub-GFP reporter itself does not 
influence the course of disease pathology in these animals.   
Due to its apparent increased sensitivity to UPS impairment, the UbG76V-GFP1 line was 
chosen for use in the majority of the experiments described in this Chapter. Detection of 
the Ub-GFP reporter was observed only in the brains of RML-prion infected mice. No Ub-
GFP reporter accumulation was seen in the brains of UbG76V-GFP inoculated with control 
normal brain homogenate, or in RML-prion infected UbG76V-GFPneg littermates (Figure 4.1). 
This indicates that the effects observed are specific to both infection of animals with RML 
prions and to the detection of the Ub-GFP reporter itself. Similar results were obtained 
with the two available reporter mouse strains, UbG76V-GFP1 and UbG76V-GFP2, established 
from different founders (Dantuma et al., 2002; Lindsten et al., 2003).  Taken together, 
these data show that UPS dysfunction occurs in the brains of prion-infected mice relatively 
early in disease progression, well before the onset of clinical signs.  
The majority of the cells in which the Ub-GFP reporter was observed in the thalamus 
appeared to be astrocytes, although some neurons were observed throughout the time-
course. Increasing evidence points towards reactive astrogliosis to play either a primary or 
a contributing role in neurodegeneration, either via a loss of normal astrocyte functions or 
a gain of abnormal effects (Eklund et al., 1967; Race et al., 1995; Raeber et al., 1997).  
Although diffuse reactive astrogliosis is one of the most prominent neuropathological 
features and most commonly observed in prion diseases (Scott and Fraser, 1984), it is not 
clear whether astrocytes play an active role in prion replication or disease pathogenesis, or 
whether astrogliosis is largely reactive to the disease process in other cell types (Kovacs and 
Budka, 2008).  In Parkinson’ s disease, astrocytes have been implicated as potentially 
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exerting both neurotoxic (Di Monte et al., 1996; Przedborski et al., 2000) and 
neuroprotective activities (Chen et al., 2009).   
There is evidence to suggest two different potential roles for astrocytes in 
neurodegenerative diseases, through the loss of a neuroprotective function and a gain of a 
neurotoxic effect (Lepore et al., 2008; Rothstein et al., 2005). In Huntington’s disease, 
astrocytes have been implicated in the disturbances of glutamate uptake that can alter 
synaptic function and lead to excitotoxicity, or in abnormal production of neurotoxic 
molecules (Lobsiger and Cleveland, 2007; Maragakis and Rothstein, 2006; Gil and Rego, 
2008). In Alzheimer’s disease, reactive astrogliosis tends to be focal such that they are 
intimately associated with amyloid plaques or diffuse deposits of amyloid and surround 
them with dense layers of processes (Nagele et al., 2004; Thal et al., 2000). It is also 
reported that reactive astrocytes can take up and degrade extracellular deposits of AB42 
(Wyss-Coray et al., 2003), and this function is attenuated in ApoE-/- astrocytes (Koistinaho 
et al., 2004), suggesting that both the function and dysfunction of astrocytes could play a 
role in the progression and severity of Alzheimer’s disease.  
The occurrence of astrogliosis and impaired proteasome activity in 
neurodegenerative diseases has led to the speculation that the UPS might contribute to the 
regulation of astrogliosis (Midderldorp et al., 2009; Sabbatini et al., 1999; Yoshida et al., 
1996). GFAP protein levels are generally up-regulated in reactive astrocytes in diseases, in 
which impaired proteasome activity is confirmed, (Tang et al., 2006; Maragakis et al., 
2006). By contrast, it was shown that proteasome inhibition does not induce an 
accumulation of GFAP protein but rather induces a sharp decrease in the transcript levels 
of all expressed GFAP isoforms in vitro (Midderldorp et al., 2009). Furthermore, 
proteasome inhibition prevents GFAP accumulation in reactive astrocytes in vivo, thereby 
suppressing reactive astrocytes (Midderldorp et al., 2009). The decrease in proteasome 
activity described by others, however, was measured in whole brain homogenates without 
discriminating between different cell types (Keller et al., 2000; Lopez et al., 2000; Glenn et 
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al., 2004).   Moreover, ubiquitin immunoreactivity was found mostly in inclusion bodies 
within neurons  (Layfield et al., 2005; Lowe et al., 1988), but not astrocytes.  Taken 
together, it could be argued that the proteasome is not inhibited in astrocytes but might 
rather be activated. 
 
Intracellular cytosolic granular ubiquitinated deposits have been shown to 
accumulate in the brains of 22L prion-infected mice, accompanying with the appearance of 
the Ub-GFP reporter (Kristiansen et al., 2007). These deposits may represent ubiquitinated-
protein conjugates that accumulate as they are not degraded by the failing proteasome.  
Although, similar intracellular cytosolic granular ubiquitinated deposits were observed by 
immunohistochemistry in the present study in the brains of RML prion-infected UbG76V-
GFP1 mice, they were not observed at early time-points to coincide with the accumulation 
of the Ub-GFP reporter.  Nevertheless, a slight increase of ubiquitinated-protein was 
observed towards end-stage disease in the thalamus of the RML prion-infected UbG76V-
GFP1 mice (Figure 4.8). Interestingly, ubiquitin-protein conjugates within neurons have 
been reported in the brains of prion-infected mice, whereby intracellular ubiquitinated 
deposits were seen early and increased with disease progression (Lowe et al., 1992). In 
addition, the pathological accumulation of the intracellular ubiquitin-protein structures 
corresponded temporally with the earliest detection of PrPSc (Lowe et al., 1992). 
  To further assess differences in ubiquitin levels in the brains of RML prion-infected 
UbG76V-GFP1 mice, brain homogenates from these mice were analysed by immunoblotting. 
Using a quantitative dot-blotting assay, ubiquitin levels were significantly increased in the 
brains of RML-prion infected mice from day 125 post-inoculation to end stage disease, as 
compared to their non-infected controls (Figure 4.10).  Such differences were not observed 
at earlier time-points post-RML infection. Furthermore, Western blots were carried out on 
the same samples to determine whether changes in total ubiquitin levels corresponded to 
differences in poly-ubiquitin associated with UPS substrates that may have failed to 
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degrade by the proteasome, (Figure 4.11). The results demonstrate that increase in total 
ubiquitin levels correlates with the appearance of high-molecular weight poly-ubiquitin 
conjugates. Collectively, these data suggest that the differences in total ubiquitin levels can 
be ascribed to an accumulation of poly-ubiquitin associated with UPS dysfunction, rather 
than differences in the expression level of non-conjugated monomeric ubiquitin. 
Recent work done by our group described a novel mechanism of inhibition by PrP 
isoforms containing a β-sheet-rich structure similar to that of PrPSc (Deriziotis et al., 2011; 
Andre and Tabrizi, 2012). This occurs by a direct interaction between the 20S proteasome 
core particle and β-sheet-rich PrP isoforms, as demonstrated by immunoprecipitation both 
in vitro and in vivo (Deriziotis et al., 2011).  The interaction causes an impairment of the 
opening of the gate of the 20S core particle through which substrates are able to pass into 
the catalytic core of the proteasome.  Such impairment results in reduction in the rate of 
proteolytic cleavage by each of the peptidase sites; (chymotrypsin-like, trypsin-like and 
caspase-like) in the 20S proteasome (Deriziotis et al., 2011).  Similar findings have been 
shown in Alzheimer’s disease, where in vitro studies demonstrated a direct binding of Aβ 
protein to bovine 20S proteasomes, resulting in a reduction in chymotrypsin-like activity 
(Gregory et al., 1995, Gregory et al., 1997).  Moreover, transgenic Alzheimer’s disease mice 
have been shown to have impaired proteasome activity that correlates with an 
accumulation of intraneuronal Aβ oligomers (Tseng et al., 2008).  
Direct interaction of PrPSc with the 20S core particle to mediate impairment of the 
26S proteasome may be the cause of the accumulation of the Ub-GFP reporter in RML-
prion infected UbG76V-GFP mice. If so, a reduction in the proteolytic activity of the 26S 
proteasome in brains extract from these mice would be expected. Therefore, to ascertain 
this inhibitory effect in the brains of RML-prion infected UbG76V-GFP mice, fluorogenic 
peptide activity assays were performed to assess proteasomal function (Figure 4.12).  
Indeed, the chymotrypsin-like activity measured in brain tissue lysates was significantly 
reduced from day 145 post-inoculation onwards. The data presented here correlate 
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reasonably well with the deposition of poly-ubiquitinated substrates described above 
(Figure 4.11).  However, the proteasome inhibition described here is observed much later 
than the initial appearance of the Ub-GFP reporter in the brains of the RML-prion infected 
mice. Presumably, this discrepancy can be explained by the limited spatial distribution of 
UPS impairment at these earlier time-points, to an extent that fluorogenic peptide activity 
assays of whole brain tissue lysate would not be sensitive enough to detect such an 
impairment.  
Accumulation of ubiquitin may be related to the activity of protein degradation 
machinery attempting to degrade aggregates of misfolded proteins, or misfolded proteins 
themselves have an inhibitory effect on the UPS (Bence et al., 2001; Glickman and 
Ciechanover, 2002).  A large number of in vitro studies support the potential importance of 
UPS impairment in neurodegenerative diseases (Ciechanover and Brundin, 2003), but the 
precise role of the UPS and its mechanisms of action in disease remains unclear despite the 
huge increase of in vivo studies.  Mass spectrometry-based method revealed that lysine 48-
linked polyubiquitin chains, which is typically associated with proteasomal targeting, 
accumulate early in the pathogenesis of both transgenic Huntington’s disease mice and in 
Huntington’s disease patients (Bennett et al., 2007).  In addition, Psmc1(Rpt2) knock-out 
mouse model with a neurodegenerative phenotype and ubiquitin-positive inclusions 
displayed 26S proteasomal dysfunction in neurons (Bedford et al., 2008), providing in vivo 
evidence for a direct role of the UPS in the pathogenesis of these neurodegenerative 
diseases. Taken together, the results presented here suggest that UPS dysfunction is 
associated with neurodegenerative diseases. However, the mechanism(s) of UPS 
impairment remain unclear. 
ER stress is not only caused by disturbances in the ER structure and function, but 
also by accumulation of misfolded proteins, as well as alterations in calcium homeostasis 
(Ciechanover and Brundin, 2003; Imai et al., 2001; Korhonen and Lindholm, 2004). In case 
of prolonged or aggravated ER stress, cellular signals leading to cell death are activated. 
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Indeed, cell expressing mutant presenilin involved in familiar early-onset AD are more 
sensitive to ER stress compared to normal cells (Guo et al., 1999). ER resident chaperones 
involved in quality control play a major role in neurodegenerative disorders. High capacity 
and low affinity of calcium of Grp78/Bip and Grp94 has led to the suggestion that 
chaperones may act as a calcium buffer and are thus protective against alteration in 
calcium homeostasis (Michalak et al., 2002).  Heat shock protein, Hsp90 and Hsp70 can 
inhibit Aß aggregation (Evans et al., 2006).   One of the chaperones of the UPR, BiP/GRP78 
has been found to be upregulated in AD brain (Hoozemans et al., 2005). In addition, 
increased levels of Bip/Grp78 and the protein kinase, perk have been shown in AD brain, 
suggesting neurotoxicity leading to cell death (Hoozemans et al., 2005).  BiP (GrP78) binds 
regulating protein APP in AD and reduces the production of Aß aggregates (Kudo et al., 
2006; Yang et al., 1998).  
 
A frequently discussed hypothesis to explain the pathogenesis of 
neurodegenerative disorders involves chronic oxidative stress. Dysfunction of any of 
several interconnected cellular pathways is sufficient to cause oxidative stress in the brain, 
including defects in the ubiquitin-proteasome system and the presence of aggregated 
proteins (Halliwell, 2006; Menendez-Benito et al., 2005).   Several lines of evidence suggest 
that PrPC may play a role in protecting cells from oxidative stress (Milhavet and Lehmann, 
2002; Brown et al., 1997; Brown et al., 2002).  Perhaps the most compelling observation is 
that neurons cultured from cerebellar granular layer and neocortex from Prn-p0/0 mice are 
more susceptible than neurons from wild-type mice to treatment with agents that induce 
oxidative stress, including hydrogen peroxide and copper ions (Brown et al., 1997; Brown et 
al., 2002).  
There is evidence to suggest that activation of ER stress genes are significantly 
upregulated in prion pathogenesis, suggesting that ER stress is linked to the disease. ER 
specific caspases, such as the caspase-12, are thought to directly induce cell death. The 
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correlation between caspase-12 activation and neuronal loss was confirmed in model of 
prion-infected mice as well as in CJD patients (Castilla and Soto, 2005). Previously, it was 
shown that prion replication is accompanied by increased expression of Grp58 in the brain 
regions showing extensive neuronal loss at terminal stage of the disease in both human 
affected with CJD and mouse models (Yoo et al., 2002; Hetz et al., 2003).  In addition, 
downregulation of Grp58 at the terminal stage of the disease correlated with the 
occurrence of neuronal loss (Hetz et al., 2005; Hetz et al., 2003), suggesting a general 
mechanism of neuronal toxicity initiated by the accumulation of misfolded proteins in 
neurodegenerative diseases (Soto, 2003).  Bip/Grp78 and Grp94 have been reported to 
have protective activity against ER stress-mediated apoptosis and control protein folding 
and components of the UPR (Liu et al., 1997; Reddy et al., 1999; Rao et al., 2002). 
Therefore, to investigate whether ER stress is implicated in the RML prion infection, UbG76V-
GFP reporter mice brain, were assessed for Bip/Grp78 expression.   
 
A small increase in Bip/Grp78 protein level was observed in the UbG76V-GFP mice 
brain infected with RML prion but not in non-infected controls (Figure 4.13).  It is important 
to note that this effect was seen only at the late stage of prion disease, indicating that ER 
stress may be a late event in the course of prion disease, occurring after the onset of UPS 
impairment.  The question that remains, however, is whether cell death is caused by ER 
stress and not the result of other pathway malfunction.   Indeed, very little is known about 
the importance of interaction in the control of cell death, and the proteins taken part in ER-
cross pathways communication.   
 
Collectively, data presented in this chapter support the hypothesis that relates prion 
infection with the impairment of the UPS machinery.  Evidence for a direct relationship 
between neuropathology and the UPS impairment in the UbG76V-GFP reporter mice is 
presented.  Together, results in this chapter support a potential role of the UPS in prion 
disease mediated neurodegeneration. 
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4.6 SUMMARY 
The work in this chapter describes an early UPS impairment in the UbG76V-GFP 
reporter mice during the course of prion disease, following RML infection. The Ub-GFP 
reporter accumulates only in the brains of RML-prion infected mice and not in the brains of 
UbG76V-GFP inoculated with control normal brain homogenate, or in RML-prion infected 
UbG76V-GFPneg littermates, indicative of a functional impairment in the UPS machinery. The 
observed accumulation of Ub-GFP coincides with markers of prion disease neuropathology 
such as PrPSc deposition and extensive GFAP immunoreactivity. The majority of the cells in 
which the Ub-GFP reporter was observed in the thalamus appeared to be astrocytes, 
suggesting that astrocyte pathology may contribute to disease pathophysiology.  
Additionally, ubiquitin levels were significantly increased in the brains of RML prion 
infected mice from day 125 post-inoculation to end stage disease, correlating with 
fluorogenic peptide assays data, which show prion infection inhibits the chymoptrypsin-like 
and 26S proteasomal activities in brain lysates of the UbG76V-GFP mice.  An assessment of 
ER stress indicates that ER stress may be a late event in the course of prion disease.  
Together, these results provide evidence for a direct relationship between prion 
neuropathology and UPS impairment in UbG76V-GFP -reporter transgenic mice. Collectively, 
this chapter described UPS impairment as an early phenomenon in prion disease 
pathogenesis.  
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5 MOTOR SKILLS DEFICITS AND SYNAPTIC 
DYSFUNCTION IN UbG76V-GFP REPORTER 
MICE 
 
 
5.1 BACKGROUND 
The neuropathology of prion diseases is associated with a dysfunction and/or loss of 
neurons that contributes to the onset and progression of disease symptoms (Malucci et al., 
2007). A combination of behavioural and neurophysiological analysis provides direct 
evidence for early neuronal dysfunction, which leads to cognitive impairment in prion 
infected mice (White et al., 2008; Mallucci et al., 2003). Furthermore, typical 
neuropathological features of prion infection and behavioural deficiencies are accompanied 
with a progressive cognitive dysfunction in prion diseases (Nazor et al., 2005; Nazor et al., 
2007). Prion infected mice show changes in species-typical motivational behaviours long 
before emergence of motor signs (Guenther et al., 2001; Deacon et al., 2001), which 
correlate with early loss of presynaptic terminals in the dorsal hippocampus (Cunningham 
et al., 2003). Until recently, the majority of studies on prion disease have been focused on 
the terminal stages of the disease, and criteria for the onset of clinical prion disease in mice 
have relied on detecting changes in locomotor activities that appear within a few weeks of 
death (Hunter et al., 1986).  However, the complexity of the spectrum of clinical symptoms 
and of the neuropathology at terminal disease has made it difficult to draw conclusions 
about these relationships and the underlying mechanisms of prion disease pathogenesis. 
Based on the relationship between prion disease neuropathology and the UPS 
presented in Chapters 3 and 4, this present chapter attempts to determine whether the 
UPS dysfunction observed in the UbG76V-GFP reporter mice correlates with behavioural and 
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motor measures throughout the time-course of disease, and with markers of neuronal loss 
or dysfunction that may underlie them. 
5.2 AIMS 
• To monitor specific neuronal and synaptic markers in RML prion-infected UbG76V-GFP 
mice; 
• To assess motor function and behavioural phenotypes in RML prion-infected UbG76V-
GFP mice. 
 
5.3 METHODS 
All protocols using these mice were first approved by the MRC Prion Unit animal 
committee, and official approved procedures were followed for the care and use of these 
mice.  The environment of the experimental room was kept consistent between test 
sessions with respect to temperature, humidity and light intensity (Section 2.9). 
Mice were grouped together prior to individual experiments and were monitored 
daily.  Behavioural testing was performed on groups of at least ten age-matched UbG76V-
GFP1 mice, which had been inoculated i.c. with 30 µl of 1% RML-prion infected mouse brain 
or control homogenates (Section 2.2.2). Each mouse was given a unique identification 
number and all subsequent behavioural assessments were performed blinded as to which 
experimental group the animal belonged to. Testing was initiated from twenty days post-
inoculation with RML prions. The animals were tested within a conserved ~3 hour time 
period in the morning.   
For histological analysis, brains were dissected rapidly after sacrifice and immersed 
into a fixing formalin buffer solution.  Half brain tissues were embedded in paraffin and 4 
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µm saggital sections were obtained and mounted onto positively charged glass slides for 
immunohistochemistry analysis (Section 2.5).  
Data were expressed as standard deviation (SD) and analysed by two-way ANOVA 
with Bonferroni post-test. Significance was expressed as follows: *** p <0.001; ** p <0.01, 
* p <0.05. See Appendix IV. 
 
5.4 RESULTS 
5.4.1 Neuronal loss in the brains of RML prion infected UbG76V-GFP 
reporter mice  
Previous work showed that neurons are lost during prion disease progression. For 
example, significant loss of cells from the CA1 region of the hippocampus has been 
reported in ME7 prion infected mice (Cunningham et al., 2003). Therefore, to determine 
whether the UPS dysfunction observed in prion-infected mice correlates either temporally 
and/or spatially with neuronal loss, RML prion-infected UbG76V-GFP1 mice were examined 
by immunohistochemistry for the neuronal marker, NeuN.  In the thalamus of the prion-
infected mice, little difference was seen in the pattern of NeuN staining at any stage of the 
disease course until end-stage disease at ~160 days post-inoculation (Figure 5.1). This 
contrasted with the evidence of UPS dysfunction observed early in this part of the brain 
described in Chapter 4.  This may indicate that UPS dysfunction seen in certain areas of the 
brain in prion-infected mice does not necessarily lead to neuronal cell death. Nevertheless, 
these data demonstrate that UPS dysfunction in the brains of prion-infected mice precedes 
the onset of neuronal loss as the disease progresses. 
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Figure 5.1 NeuN expression in the thalamus in the brain of RML prion-infected 
UbG76V-GFP mice.  
UbG76V-GFP1 mice were inoculated i.c with 30 µl of 1% RML-prion infected mouse brain or 
control homogenates, and culled at days 45, 85 and 125 post-inoculation, and at end-stage 
disease. Immunohistochemistry analysis was carried out on paraffin-embedded brain tissue 
using an anti-NeuN antibody. Images are taken of the thalamus and, in this region, show 
similar levels of staining between the RML-prion infected mice and non-infected controls. 
Scale bar = 20 µm.  
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5.4.2 Neuronal loss in the CA1/CA3 region of the brains of UbG76V-GFP 
mice following RML prion infection 
To assess whether neuronal loss could be detected in other neuropathological 
region of the brain, the hippocampus of the prion-infected mice was evaluated by 
immnohistochemistry.  A noticeable loss of neurons was observed in the CA1/CA3 region at 
the later stages of the disease time-course, from day 125 post-inoculation with RML prions 
onwards (Figure 5.2). However, despite a widespread accumulation of PrPSc, these areas 
did not show consistent evidence of UPS dysfunction (see Chapter 4). Other prion strains 
have been shown to induce hippocampal pathology which gives rise to distinct phases of 
behavioural and anatomical abnormalities (Guenther et al., 2001; Jeffrey et al., 2000; 
Betmouni et al., 1999), and it has been demonstrated that early behavioural deficits 
correlate with a selective disorganization of the CA1 synapses that initially occurs in the 
absence of cell death (Cunningham et al., 2003).   
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Figure 5.2 NeuN expression in the hippocampus in the brain of RML prion-
infected UbG76V-GFP mice. 
 UbG76V-GFP1 mice were inoculated i.c with 30 µl of 1% RML-prion infected mouse brain or 
control homogenates, and culled at days 45, 85 and 125 post-inoculation, and at end-stage 
disease. Immunohistochemistry analysis was carried out on paraffin-embedded brain tissue 
using an anti-NeuN antibody. Images are taken of the hippocampus (CA1/CA3) and, in this 
region, show a loss of neurons in the RML-prion infected mice as compared to the non-
infected controls. Scale bar = 20 µm.  
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5.4.3 Synaptic loss in the brains of UbG76V-GFP mice following RML 
prion infection 
Dysfunction in synaptic function is thought to underlie the earliest symptoms in 
several neurodegenerative diseases, and loss of synapses is thought to precede the loss of 
neuronal cell bodies (Mallucci, 2009; Wishart et al., 2006). To assess any synaptic 
dysfunction UbG76V-GFP1 mice brain were analysed by immunohistochemistry. 
In the thalamus of the prion-infected mice, small deposits of synaptophysin staining 
indicating dysfunction of synapses were observed towards end-stage disease at ~160 days 
post-inoculation (Figure 5.3). This subtle staining was not observed in other parts of the 
brain. The localisation of synaptic dysfunction in the thalamus is similar to where UPS 
dysfunction was most strongly observed in prion-infected UbG76V-GFP1 mice (see Chapter 
4). This indicates that UPS dysfunction may precede some synaptic dysfunction during the 
time-course of prion disease progression.  
In an attempt to quantify any loss of synapses during prion disease pathogenesis, brain 
homogenates of UbG76V-GFP1 mice were examined by Western blots using an anti-
synaptophysin antibody. No differences were observed in comparing prion-infected UbG76V-
GFP1 mice and their non-infected control counterparts (Figure 5.4). This observation may 
reflect a lack of sensitivity using this particular method to detect small or focal differences 
in certain parts of the brain.  
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Figure 5.3  Synaptophysin expression in the thalamus of RML  prion-infected 
UbG76V-GFP mice.  
UbG76V-GFP1 mice were inoculated i.c with 30 µl of 1% RML-prion infected mouse brain or 
control homogenates, and culled at days 45, 85 and 125 post-inoculation, and at end-stage 
disease. Immunohistochemistry analysis was carried out on paraffin-embedded brain tissue 
using an anti-synaptophysin antibody. Deposits of synaptophysin are seen in the thalamus 
of RML-prion infected mice, as compared to the non-infected controls. Scale bar = 20 µm.  
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Figure 5.4 Immunoblot analysis of synaptophysin expression in the brains  of 
RML prion-infected UbG76V-GFP mice.  
UbG76V-GFP1 mice were inoculated i.c with 30 µl of 1% RML-prion infected mouse brain or 
control homogenates, and culled at days 45, 85 and 125 post-inoculation and at end-stage 
disease. A 1% tissue homogenate was made and immunoblotted with anti-synaptophysin 
or anti β-actin antibodies. Detection of Li-Cor secondary antibodies was done by scanning 
the membrane using the Odyssey Infrared Imaging System (Li-Cor Biosciences). No 
significant differences in synaptophysin in whole brain lysates was detected between RML-
prion infected and control UbG76V-GFP1 mice.  
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5.4.4 Balance and coordination impairment in RML prion-infected 
UbG76V-GFP reporter mice 
Previous work indicates that sensorimotor deficits precede the spontaneous onset of prion 
disease in Tg (GSS) mice, and behavioural abnormalities appear in prion-infected mice long 
before the manifestation of clinical signs (Nazor et al., 2007; Bertmouni et al., 1999). To 
evaluate whether prion infection causes a loss of balance and coordination in prion-
infected UbG76V-GFP1 reporter mice, correlating with the onset of UPS dysfunction, 
assessments were made using rotarod apparatus. This comprises a well-characterised 
behavioural task designed to monitor motor function by requiring mice to ambulate on an 
accelerating rotating rod (Dunham and Miya, 1957; Jones and Roberts, 1968). Mice were 
tested at various time-points from day 45 until day 105 post-inoculation with RML-prions. A 
significant difference was observed in the performance of the UbG76V-GFP1 reporter mice, 
as compared to non-infected control animals, from the earliest post-inoculation time-point 
onwards (Figure 5.5). This indicates that deficits in this motor test are apparent early in the 
disease-course, well before the onset of disease pathology. Two-way ANOVA with 
Bonferroni post-test*** p <0.001. See Appendix IV for F values and DF or relevance. 
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Figure 5.5 Early motor deficits in UbG76V-GFP mice following RML prion infection. 
 Rotarod testing was performed on groups of ten RML prion-infected and ten non-infected 
UbG76V-GFP1 reporter mice. They were inoculated i.c with 30 µl of 1% RML-infected mouse 
brain or control homogenates. The mean latency to fall over two trials for each individual 
mouse was analysed.  A significant difference was observed between the groups of RML 
prion-infected and control UbG76V-GFP1 mice at every time-point tested, including the 
earliest time-point at day 45 post-inoculation with RML prions.  
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5.4.5 Burrowing impairment in RML prion-infected UbG76V-GFP 
reporter mice.  
Spontaneous burrowing behaviour by rodents has a robust association with early prion 
pathology (Mallucci et al., 2007; Deacon et al., 2001). Burrowing has been proposed as a 
powerful tool for elucidating brain function requiring a high degree of reorganisation and 
executive function that are thought to reflect motivational aspects of spontaneous 
behaviour in rodents (Deacon et al., 2001; Guenther et al., 2001). To investigate the ability 
of RML-prion infected UbG76V-GFP1 mice to burrow, a container filled with objects food 
pellets was placed into a clean cage and left overnight (Appendix III). Typically, non-
infected mice actively burrowed to displace 70-80% of the pellets (Figure 5.6). This was also 
observed at the earliest time-point post-inoculation, at day 25, in the RML-prion infected 
UbG76V-GFP1 animals. Thereafter however, a progressive decrease in burrowing was 
recorded from day 45 post-inoculation onwards in the RML prion-infected mice. Two-way 
ANOVA with Bonferroni post-test*** p <0.001. See Appendix IV for F values and DF or 
relevance. 
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Figure 5.6 Burrowing behaviour is progressively lost in RML prion-infected 
UbG76V-GFP mice.   
Burrowing was investigated in groups of fourteen prion-infected and fifteen non-infected 
UbG76V-GFP1 mice. They were inoculated i.c with 30 µl of 1% RML prion-infected mouse 
brain or control homogenate. The displacement of food pellets from a filled tube placed in 
the animal’s cage was analysed. Whilst burrowing was similar at the earliest time-point 
tested, day 25 post-inoculation with RML prions, a significant difference was observed 
between the groups of RML prion-infected and control UbG76V-GFP1 mice at every time-
point tested thereafter. This deficit progressively worsened as the disease progressed. See 
Appendix IV. 
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5.4.6 Nest building impairment in RML prion-infected UbG76V-GFP 
reporter mice. 
Nest building in rodents is a natural behaviour that is important for heat conservation, as 
well as for reproduction and shelter. It is a task that requires an intact dorsal hippocampus 
(Deacon et al., 2002). To evaluate nest building, RML-prion infected UbG76V-GFP1 reporter 
mice were at various time-points post-inoculation left overnight with a nestlet placed into 
the home cage.   The animals routinely shredded the tightly-packed material and arranged 
it into a nest. Qualitative assessments were made based on the neatness of the nest and 
the amount of un-shredded material left (see Appendix III).  Mice were tested at various 
time-points from day 25 until day 105 post-inoculation with RML prions. A significant 
difference was observed in the performance of the prion-infected UbG76V-GFP1 reporter 
mice, as compared to non-infected control animals, from the earliest post-inoculation time-
point onwards (Figure 5.7). This data indicates that deficits in this behavioural test are 
apparent early in the disease-course, well before the onset of disease pathology.  
Moreover, the deficit became progressively worse as the disease progressed. Two-way 
ANOVA with Bonferroni post-test*** p <0.001. See Appendix IV for F values and DF or 
relevance. 
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Figure 5.7 Nesting scores decline during disease progression in prion-infected 
UbG76V-GFP mice.  
Nesting was investigated in groups of ten prion-infected and ten non-infected UbG76V-GFP1 
mice. They were inoculated i.c with 30 µl of 1% RML-prion infected mouse brain or control 
homogenates. Scores of shredding of nesting material placed in the cage were analysed. 
Mice in all groups constructed nestlets. However, shredding was significantly lower in the 
RML prion-infected mice when compared to the non-infected groups. A moderate 
difference was observed at day 25 post-inoculation, which got progressively larger as the 
disease progressed thereafter. See Appendix IV. 
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5.4.7 RML Prion infection does not affect grip strength in UbG76V-GFP 
reporter mice   
To investigate whether neuromuscular strength was impaired in prion-infected UbG76V-GFP 
reporter mice, a grip strength test was used to evaluate limb strength in both healthy and 
prion-infected mice.  This method is used to measure disease progression and 
neurobehaviour, as well as to test specific therapeutic interventions in mouse models 
(Spurney et al., 2009; Rayavarapu et al., 2010).  This test is based on the natural tendency 
of the mouse to grip a bar or grip when suspended by the tail. Mice were tested at various 
time-points from day 25 until day 105 post-inoculation with RML prions. There were no 
consistently significant differences in the performance of the RML prion infected UbG76V-
GFP1 reporter mice, as compared to non-infected control animals (Figure 5.8).  Two-way 
ANOVA with Bonferroni post-test. *** p <0.001; ** p <0.01, * p <0.05.  See Appendix IV for 
F values and DF or relevance. 
 
 
 
 
 
177 | P a g e  
 
 
 
 
 
Figure 5.8 Grip strength in RML prion-infected UbG76V-GFP mice.   
Grip strength was investigated in groups of fourteen prion-infected and fifteen control 
UbG76V-GFP1 mice. They were inoculated i.c with 30 µl of 1% RML-prion infected mouse 
brain or control homogenates. The mean peak force applied by the forelimbs of the mouse 
was analysed. Although grip strength appeared to be slightly reduced in the RML prion-
infected mice at some time-points, a progressive deficit was not observed. See Appendix 
IV. 
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5. 5 DISCUSSION  
Premature neuronal cell death is typical in prion disease (Collinge et al., 1995; Medori 
et al., 1992; Forloni et al., 1993).  However, the underlying mechanisms that contribute to 
neuronal loss are far from being elucidated. As reported in Chapters 3 and 4, substantial 
PrPSc deposits accumulate in the brain of RML prion-infected mice during the disease time-
course following prion infection.  Whether PrPSc is the toxic component involved in the 
molecular mechanisms leading to neurodegeneration remains unclear. There are 
indications that neuronal cell death might be related to the altered function of several 
cellular processes, including cell signalling, intracellular trafficking and cellular proteostasis. 
Indeed, experimental evidence suggests that neuronal death is associated with UPS 
impairment (Goldberg, 2003; Tydlacka et al., 2008).  However, it is not known if UPS 
dysfunction is the cause or the consequence of cellular damage.  Impairment of the UPS 
has been shown to be important in prion disease (Ma et al., 2002; Ma and Lindquist, 2002; 
Kang et al., 2004; Deriziotis et al., 2011), as further evidenced by data presented in Chapter 
4 of the present thesis. 
The data presented in this chapter attempts to determine whether aspects of prion 
neuropathology such as neuronal and synaptic integrity, and behaviour and motor function, 
are altered in prion-infected mice in a manner that relates to the UPS dysfunction reported 
in Chapter 4. The UPS was impaired in the thalamus of RML prion-infected UbG76V-GFP mice 
at day 85 post-inoculation of a ~160 day disease time-course, but in this region, overt loss 
of neurons was not observed (Figure 5.1). Notably, however, obvious neuronal loss was 
observed in the CA1 and CA3 regions of the hippocampus of the prion-infected mice (Figure 
5.2), as well as to a lesser extent in some other areas. This neuronal loss in the 
hippocampus was observed from day 125 post-inoculation onwards. This coincided with 
widespread increases in markers of prion disease pathology such as extensive PrPSc 
deposition and GFAP immunoreactivity, and with the broadly increased ubiquitin levels and 
deficits in 26S proteasome peptidase activity first observed at this time-point (Chapter 4). 
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Nevertheless, whilst the temporal correlation of neuronal loss with some indicators of UPS 
dysfunction was clear, the overt impairment of the UPS in the thalamus was not particularly 
reflected by a loss of neurons in this area.  
To further assess whether UPS dysfunction corresponded with any synaptic loss or 
dysfunction, the brains of prion-infected UbG76V-GFP1 mice brain were examined for the 
specific marker, synaptophysin. Some synaptic loss, in the form of small synaptophysin 
deposits indicating a retraction of functional synapses, was detected towards end-stage 
disease in the thalamus of prion-infected mice (Figure 5.3). Such differences were not 
observed at earlier time-points post-prion infection. These changes were particularly 
marked in the thalamus, the area of the brain in which UPS impairment was most obvious. 
The focal nature of the altered synaptophysin staining was reflected by Western blots of 
whole brain homogenates that did not show any differences in total synaptophysin levels 
as compared to non-infected controls (Figure 5.4).  Clearly, the discrepancy in the data with 
the synaptophysin marker may be explained due to the sensitivity of the different 
detection methods.  Nevertheless, that UPS dysfunction in the thalamus precedes a loss of 
synapse integrity seems to be clear. 
During the experimental time-course, infected UbG76V-GFP transgenic mice showed 
the expected clinical symptoms of prion disease. This led to a closer assessment of 
behavioural and motor abnormalities, which might associate temporally with the onset of 
UPS dysfunction and other aspects of prion neuropathology.  Therefore, a small 
behavioural study was designed such that clear behavioural phenotypes correlating to 
pathological features would be measurable. Behavioural testing can reveal effect in prion-
infected mice long before the manifestation of clinical signs appears (Bertmouni et al., 
1999). Indeed, it has been shown that sensorimotor deficits precede the spontaneous 
onset of prion disease in Tg(GSS) mice (Nazor et al., 2007). 
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Several well characterised behavioural tasks designed to assess performance in 
motor function and coordination were employed. One of them, burrowing, was used to 
measure motor coordination in prion-infected mice. Burrowing, as measured by the 
displacement of food pellets from a tube in the home cage, decreases in ME7 prion-
infected mice early in disease at twelve weeks post-inoculation (Guenther et al., 2001). In 
the present study, the RML infected groups showed a progressive decrease in burrowing 
ability from day 45 post-inoculation onwards (Figure 5.5). This is notable in that it precedes 
markers of prion neuropathology, including UPS impairment, by up to forty days.   
Nest construction, a species-typical behaviour test was also measured, starting at 
day 20 post-RML prion infection. Nesting ability was significantly impaired in the RML 
prion-infected group, as compared with non-infected animals. Taken together, these data 
support the claim that burrowing and nesting tests are sensitive, early indicators of 
behavioural impairment in prion infected mice (Deacon et al., 2001).  Nesting and 
burrowing strengthens the preclinical changes seen in an earlier study (Bermouni et al., 
1999). However, it is unclear whether the effects observed were due to motor rather than 
motivational impairments and further studies would be needed to resolve this question.  
The rotarod task has been described as a sensitive indicator of motor skills 
impairment and cerebellar abnormalities (Hilber and Caston, 2001). It not only assesses 
motor coordination and balance, but also characterises the motor phenotype of transgenic 
and knockout mice. The latency to fall at a set speed was measured in both RML prion-
infected and non-infected groups of mice. A significant difference was observed in the 
performance of the prion-infected UbG76V-GFP1 mice, as compared to non-infected control 
animals, from the earliest time-point at day 45 post-inoculation (Figure 5.6). This indicates 
that deficits in this motor test were apparent early in the disease-course, well before the 
onset of disease pathology. In contrast, a grip strength test was used to assess forelimb 
strength, which can also be influenced by co-ordination deficits. However, no difference 
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was detected in grip strength ability between RML prion-infected and the non-infected 
animal groups (Figure 5.8). 
The main findings of the data presented here were that characteristic behavioural 
changes can be reliably detected in this model of prion disease. However, many pathways 
that underlie diverse clinical signs are complex and thus it is difficult to relate a particular 
clinical symptom to a specific neuropathological feature. It is not clear whether the 
behavioural phenotype and motor skills deficits observed in these mice can be correlated 
with particular aspects of loss of neurons or synapses in particular brain areas. Prion 
infected mice show changes in species-typical motivational behaviours before emergence 
of motor signs (Guenther et al., 2001; Deacon et al., 2001), which correlate with early loss 
of pre-synaptic terminals in the dorsal hippocampus (Cunningham et al., 2003).  It should 
be recognised that several limitations to this study may have affected the data presented 
here. Validity of the results obtained from behavioural phenotyping is largely dependent on 
methods of animal husbandry, so physiological parameters were kept constant throughout 
the time of testing.  The majority of mouse behavioural studies are dependent on age, sex 
and strain, and it was important to keep these parameters comparable throughout a single 
experiment. Environment factors contribute to the levels of anxiety within the mouse, so 
temperature, humidity, ventilation, noise and lighting intensity were kept at a constant 
level that is appropriate to the mice.  Mice were also kept at a uniform environment before 
and after testing to avoid anomalous results.  
The work presented here indicates that deficits in the behavioural tests are early in 
the disease-course, well before the onset of disease pathology.  However, It is not clear 
that neuronal loss and alteration of synapses alone are sufficient to account for the 
behavioural deficiency observed.  Previous studies give strong evidence that UPS 
impairment is linked to prion disease, and altered activities of the UPS are crucially involved 
in the pathophysiology of several other neurodegnerative diseases. This study clearly 
indicates an early effect of prion infection to behavioural function in the UbG76V-GFP1 mice.  
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However, a more in depth behavioural study is needed with a baseline set at pre-
inoculation with RML prion to better understand the relationship between prion infection 
and behavioural abnormalities in these mice. 
 
5.6 SUMMARY 
 
The work in this chapter presents data which support previous report that neuronal 
and synaptic loss contribute to the pathological features that underlying early behavioural 
dysfunction in prion diseases.  Significant impairment in motor functions was observed in 
UbG76V-GFP reporter mice infected with RML prion and a marked neuronal loss was 
observed in key neuropathological region of the hippocampus. In addition, some sign of 
synaptic loss was observed toward end stage of prion disease.  Neuromotor deficits and 
prion disease-related neuropathology in the RML infected UbG76V-GFP reporter mice 
observed in this study suggest that prion disease mediates important pathological and 
behavioural changes during the course of disease. Taken together, the data in the present 
chapter demonstrate evidence of neuronal loss and synaptic dysfunction in the brains of 
prion-infected mice that may, especially the latter in the thalamus, correlate with UPS 
dysfunction. Collectively, these changes may underlie behavioural changes that are seen 
early disease in prion-infected mice, although some of these changes precede discernible 
alterations in neuropathology. The causative nature, however, of these different 
observations remains to be determined.  Collectively, data presented in this chapter 
suggest a relationship, which correlates UPS dysfunction observed in the UbG76V-GFP 
reporter mice with behavioural and motor skills deficits and neuropathological features of 
prion disease. Although, the mechanisms/pathways contributing to this relationship are not 
well understood.  
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6 CONCLUSIONS AND FUTURE WORK 
 
  The work described in this thesis aimed to investigate impairment of the UPS in 
vivo in the pathogenesis of prion disease.  Specifically, this thesis aimed to monitor the 
functional status of the UPS following RML prion infection using UbG76V-GFP reporter mice.  
Previous studies have suggested a role for the UPS in prion disease (Ma et al., 2002; Kang et 
al., 2004; Kristiansen et al., 2007; Deriziotis et al., 2011), but it is not known how early in 
disease progression that this phenomenon occurs and how it correlates with other aspects 
of disease pathogenesis. Determining those pathogenic events that are causative to disease 
progression and those that are secondary to other disease-associated events remains a 
difficult task.  However, it may be expected that underlying causative events in disease 
pathogenesis should be observed relatively early in disease progression and in those areas 
of the brain that are considered most pathologically important.  In the present studies, a 
temporal relationship with the onset of typical prion neuropathology and of impairment of 
the UPS was observed in prion-infected UbG76V-GFP mice. This onset was first detected at 
day 85 post-inoculation with RML prions, which was about halfway through a disease time-
course of about 160 days.  
The UPS dysfunction observed by accumulation of the UbG76V-GFP reporter was 
followed, as might be expected, by a measurable increase in total ubiquitin in the brains of 
prion-infected mice, which seemed to correspond to an increase in high-molecular weight 
poly-ubiquitin species. The UPS is associated with the degradation of substrates that are 
tagged by the addition of polyubiquitin that is lysine-48 linked. Most poly-ubiquitinated 
substrates targeted for proteasomal degradation are lysine-48 linked (Pickart and Fusman, 
2004) and their steady-state cellular levels are expected to reflect proteasome function. If 
the UPS is impaired in prion-infected animals, it might be expected that lysine-48 linked 
poly-ubiquitin accumulates as disease progresses. Lysine 48-linked poly-ubiquitin is often 
used as an endogenous marker of UPS function, and its levels have been measured by UBA 
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pull-down and mass spectrometry analysis to assess UPS function in neurodegenerative 
disease (Bennett et al., 2007), and quantify poly-ubiquitin chains (Kirkpatrick et al., 2006). 
Moreover, if the substrate proteins to which accumulating lysine-48 linked polyubiquitin 
were linked could be identified, this would allow the identification of subsets of 
accumulating aberrant proteins accumulating as cells die during disease pathology. The 
underlying molecular mechanisms of the UPS impairment observed in prion-infected mice 
remain only partially understood. The underlying cause of this UPS dysfunction could lie in 
a recently described mechanism of proteasome inhibition by β-sheet-rich PrP species 
(Deriziotis et al., 2011). In that in vivo study, proteasome proteolytic activity as was 
measured by fluorogenic substrate assays shown to be impaired prior to end-stage disease. 
This impairment was observed much later than the Ub-GFP reporter UPS dysfunction.  An 
explanation for this discrepancy could be due to a lack of sensitivity of these assays in a 
whole brain homogenates. 
Given the potential limitations of the UbG76V-GFP mouse model, the data presented 
here could be validated further by use of alternative UPS reporter substrates.  Since 
substrates carrying different degradation signals are likely to be handled differentially by 
the UPS, a different type of substrate to that used in UbG76V -GFP mice could be used 
(Menendez-Benito et al., 2005), which could potentially reflect how another class of 
substrate is handled by the UPS. Kumarapeli and colleagues generated a ubiquitously 
expressing GFPdgn transgene, modified GFP targeted for proteasome degradation 
(Kumarapeli et al., 2005). This model is comparable to the UbG76V-GFP model and has been 
shown to delineate dysfunction of the UPS in several disease models (Kumarapeli et al., 
2005; Chen et al., 2005; Liu et al., 2006). Alternatively, specific aberrant ubiquitin 
substrates can be measured in relation to the UPS. For example, UBB+1 is a mutant form of 
ubiquitin that accumulates in cells in neurodegenerative diseases, and appears to be both a 
substrate and an inhibitor of the UPS (Lindsten et al., 2002; Verhoef et al., 2007).  UBB+1 
causes a general blockage of proteasomal degradation in neuronal cells, and that inhibitory 
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effect is dependent on ubiquitination of UBB+1. UBB+1 has been found to play a role in 
Alzheimer’s disease (Van Leeuwen et al., 2000), where it mediates Aβ toxicity via inhibition 
of the 26S proteasome (Song et al., 2003). It would be of interest to investigate whether 
UBB+1 accumulates during prion disease pathogenesis and, if so, is associated with 
inhibition of the 26S proteasome.   
Beyond the use of monitoring UPS dysfunction, GFP reporter substrate models can 
be used as research tools in cell biology for the purpose of through screenings for small 
compound inhibitors of the UPS as well as the bioviability of compound in combination 
with therapeutic potential of proteasome inhibitors (Verdoes et al., 2006; Dantuma et al., 
2000; Tsien, 1998).  This is of great importance since it is well documented that proteasome 
inhibitors have many therapeutics purpose. However, limitations still exist within the model 
in detecting UPS impairment.  Nevertheless, the UbG76V-GFP reporter mouse model 
provides a useful tool for monitoring the functional status of the UPS in the pathogenesis of 
prion disease and several other neurodegenerative diseases.  This mouse model based on 
the ubiquitin-proteasomal reporter substrate opens new opportunities to gain insight into 
the global effect of pathological conditions on the UPS (Menendez-Benito et al., 2005; 
Bowman et al., 2005; Luker et al., 2003).  
Experiments to examine the links between UPS dysfunction and prion disease 
pathogenesis could be undertaken using agents that activate or decrease UPS function. For 
example, it may be expected that compounds that increase activity of the UPS might be 
beneficial to the onset of pathology in prion-infected animals. Recently, a small molecular 
inhibitor of a proteasome-associated deubiquitinating enzyme called USP14 was shown to 
up-regulate activity of the UPS (Lee et al., 2010).  USP14 dissembles the ubiquitin chain, 
thereby slowing down proteasome degradation (Lee et al., 2004), but its loss in mice leads 
to an ataxic neurological phenotype (Wilson et al., 2002; Anderson et al., 2005).  However, 
IU1-mediated inhibition of USP14 indirectly accelerates proteasomal degradation of 
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proteins, including tau and ataxin-3, both of which are involved in neurodegenerative 
disease (Lee et al., 2010). Therefore, a similar approach could be explored in prion-infected 
cells and mice, in which USP14-inhibition might be expected to reduce levels of misfolded 
protein, possibly including disease-associated PrP. 
Conversely, experiments could be done that monitor UPS dysfunction in animals in 
which the production of disease-associated PrPSc is altered. For example, lentivirus-
mediated delivery of RNAi targeting PrP that would be expected to show a reduction in 
PrPSc production, may show a concurrent reversal in the UPS dysfunction observed in prion-
infected mice. An RNAi-based approach such as this has been used previously, in which 
White and colleagues demonstrated the development of phenotypic deficits in parallel with 
the development of early spongiform changes, and the recovery of these deficits in mice in 
which PrP was depleted (White et al., 2008). It has been shown that transgenic mice 
generated by lentiviral transduction of embryos stably express anti-PrP shRNAs have 
increased resistance to prion infection because of RNAi –mediated reduced expression of 
endogenous PrP (Pfeifer et al., 2006). Injection of virus into the hippocampus after prion 
infection could prevent behavioural deficits associated with early pathology (Cunningham 
et al., 2003). 
Astrocytes in the thalamus seemed to be particularly affected by prion-infection in 
terms of UPS dysfunction, as shown by accumulation of the Ub-GFP reporter in this thesis 
work. In many studies in which the UPS has been studied in brain tissue, proteasome 
activity has been measured in whole brain homogenates without discriminating between 
the different cell types present (Wang et al., 2008; Keller et al., 2000; Glenn et al., 2004; 
Lopez et al., 2000). This may to some degree reflect differences in the detection of the 
sensitivity of the Ub-GFP reporter in different cell types. For example, it may be that 
expression of sequence encoding the UbG76V-GFP reporter may be inherently higher in 
astrocytes rather than other neural cells. This could be tested in primary cultures of 
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different neural cells isolated from UbG76V-GFP mice, in which mRNA sequences encoded by 
the UbG76V-GFP transgene are quantified by real-time PCR. Alternatively, in situ 
hybridisation could be used to monitor UbG76V-GFP transgene expression in different cells in 
the brains of the mice. If expression of the transgene does differ between different cell 
types, it may be possible detect Ub-GFP in, for example, increased numbers of neurons 
using more sensitive detection techniques.  Alternative methods of tissue processing, such 
as cryosections from frozen tissue, might be a better method of detecting the Ub-GFP 
reporter in neurons and other cells type.  The use of fluorescent detection methods may 
increase detection sensitivity and would allow the co-localisation of Ub-GFP with specific 
cellular markers such as GFAP for astrocytes and NeuN for neurons. Fluorescence-based 
methods would facilitate visualisation using laser confocal microscopy, where more in-
depth images could be obtained of various sub-cellular groups.   
Nevertheless, astrocyte function is becoming increasingly recognised as important 
in the maintenance of the neuronal environment in neurodegenerative disease, and 
alterations in astrocyte function may be important in disease pathogenesis. If the UPS is 
particularly impaired in astrocytes in prion disease, then the reasons for this could be 
investigated further. A more detailed time-course experiment to monitor the functional 
relevance of astrocytes could be important. Specific aspects of UPS dysfunction in 
astrocytes could be investigated in vitro, but might be hampered by a lack of suitable 
astrocyte cell lines that are susceptible to prions.     
Altered behavioural and motor phenotypes were observed in prion-infected UbG76V-
GFP mice, but these preceded the onset of neuropathology, including measures of UPS 
dysfunction. This suggests that the very earliest underlying events of prion disease 
progression remain to be determined. Nevertheless, the UPS dysfunction observed in the 
thalamus of prion-infected mice corresponded with some later loss of synaptic integrity 
seen in this area, as shown using synaptophysin as a marker. Previous reports have shown 
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that prion disease pathogenesis is accompanied by neuronal and synaptic loss associated 
with early behavioural impairments. Mallucci and colleagues showed evidence for recovery 
of behavioural and synaptic impairments, as well as spongiosis when neuronal PrPC was 
depleted in prion infected mice (White et al., 2008; Mallucci et al., 2007).  Moreover, 
experiments in ME7 prion-infected mice show loss of synapses early, with a significant 
reduction in synaptophysin in the CA1 region of the hippocampus, thirteen weeks after the 
ME7 prions were injected in the hippocampus (Belinchenko et al., 2000; Cunningham et al., 
2003). Synaptic loss was observed in my study in the same thalamic regions, albeit 
substantially later in the disease time-course, in which UPS dysfunction was most 
pronounced in the RML prion-infected UbG76V-GFP mice. Synaptic loss and dysfunction are 
well documented in several other neurodegenerative diseases (Wang et al., 2008; Klyubin 
et al., 2005; Ross and Pickart, 2004). Importantly, a study done by Wang and colleagues in 
Huntington’s disease mice showed that mutant huntingtin causes a loss of proteasome 
activity in neurons that is specifically localised at the synapses (Wang et al., 2008). Such an 
observation has not yet been described in prion diseases, but it is possible that similar 
events take place. Localised UPS dysfunction in synapses could be investigated in purified 
synaptosome in which fluorogenic peptidase assays could be carried out to measure 
proteasome activity in the synapses of neurons from prion-infected mice.  
Given the impairment of the UPS observed following prion-infection, it would be 
interesting to investigate whether other aspects of cellular proteostasis are altered as well. 
The other major intracellular degradation system is autophagy.  Unlike the UPS, autophagy 
is mainly responsible for the degradation of long-lived proteins and large intracellular 
bodies, including organelles (Levine and Klionsky, 2004; Lum et al., 2005).  At least twenty 
seven ATG genes have been defined to participate in autophagy or autophagy-related 
process (Klionsky et al., 2003).  However, the functional connection of autophagy to the 
UPS is not well understood.  Ding and colleagues demonstrated that the two cellular 
degradation systems are functionally coupled and suppression of the UPS can activate 
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autophagy (Ding et al., 2007, Ding et al., 2006).  Simultaneous inhibition of autophagy 
promotes accumulation of ubiquitinated protein aggregates, ER stress and cell death. 
Whereas the evidence by Ding and colleagues that UPS and autophagy are functionally 
linked is derived from inhibiting proteasome function, evidence indicating such a 
connection has also emerged in other studies where autophagy machinery is disrupted.  
Mice deficient in key autophagy genes, atg5 or atg7, accumulate ubiquitinated protein 
aggregates in neurons at an early stage and develop symptoms of neurodegenerative 
diseases (Kotmatsu et al., 2006; Hara et al., 2006). Therefore, it is worth investigating 
whether the inhibition of the proteasome induces autophagy.  The use of a proteasome 
inhibitor could reveal whether the two proteins degradation pathways are functionally 
coupled as inhibition of proteasome activates autophagy.  Proteasome inhibition of MG132 
for example, could elicit a time-dependent and dose-dependent accumulation of LC3II, a 
lipid form of LC3, which is localized on the autophagic vacuoles (Kabeya et al., 2000). It has 
become evident that the function of autophagy and UPS are coordinated in several 
neurodegenerative diseases, and the impairment of the UPS can result in the upregulation 
of autophagy. 
During neurodegeneration ER stress may have a protective effect initially as 
expression levels of ER chaperones are increased, thus helping cell handle misfolded 
proteins.  On the other hand, prolonged activation of the UPR pathways may lead to cell 
death and eventually neurodegeneration.  Therefore, molecular mechanisms mediate the 
change in the UPR from being a beneficial to cell death-inducing response is worth 
investigating. It would be of a particular interest to study the vulnerability of the UPS 
towards proteotoxic stress conditions in the UbG76V –GFP reporter model and different cell 
types.  Impairment of the UPS may also be linked to ER stress, which has been shown as 
PrPSc accumulates in cells (Budka, 2003; Menendez-Benito et al., 2005; Hetz and Soto, 
2006).  
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Several studies indicate that ER resident chaperones involved in quality control play 
a major role in neurodegenerative disorders and there is evidence to suggest the activation 
of ER stress genes have been found to be significantly upregulated in prion pathogenesis, 
suggesting that ER stress is linked to the disease.  Previous studies have shown that the 
expressions of Grp78 and Grp94 have protective effects against ER stress-mediated 
apoptosis (Liu et al., 1997; Reddy et al., 1999; Rao et al., 2002), and ER specific caspases, 
such as caspase-12 is thought to directly induce cell death. The correlation between 
caspase 12 activation and neuronal loss was confirmed in models of prion infected mice as 
well as in CJD patients (Castilla and Soto, 2005).  Previously, it was shown in both human 
affected with CJD and mouse models that prion replication in brain is accompanied by 
increased expression of Grp58 in the terminal stage of the disease and in the brain regions 
showing extensive neuronal loss (Yoo et al., 2002; Hetz et al., 2003).  However, it is not 
clear whether this alteration is early or late during disease progression. Although a small 
increase in Bip/Grp78 protein level was observed in the UbG76V-GFP mice brain, it is not 
clear whether upregulation of Bip/Grp78 and other binding partners influence the UPS.  
Therefore, a more detailed time-course experiment to monitor the expression levels of 
Grp58, Grp78 and Grp94 in different brain areas could be done by quantitative Western 
blotting. 
         In summary, work presented in this thesis indicates early UPS dysfunction in the brains 
of prion-infected UbG76V-GFP mice.  In addition, neuropathological features of prion disease 
correlate with the accumulation of the Ub-GFP substrate. Taken together, this work 
supports the hypothesis that UPS dysfunction occurs relatively early and may play an 
important role in disease pathogenesis. Further studies to elucidate the mechanisms of UPS 
impairment in prion disease may be important in understanding the underlying processes 
of disease pathogenesis.  
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7 APPENDICES 
Appendix I 
 
Table 7.1 List of antibodies for immunocytochemistry 
Antibody Species Company Dilution 
GFP Rabbit polyclonal Invitrogen 1 g/ml 
NF200 Mouse monoclonal Insight genomics 1 g/ml 
AF 488 Goat anti-mouse Life Technologies 1 g/ml 
AF 568 Goat anti-rabbit Life Technologies 1 g/ml 
 
 
Table 7.2 List of primary antibodies used for immunohistochemistry 
 
Antibody Species   Company Dilution 
ICSM35 Mouse monoclonal D-GEN 2 g/ml 
GFAP Mouse monoclonal Dako 1 g/ml 
GFP Rabbit polyclonal Invitrogen 1 g/ml 
Ubiquitin Mouse monoclonal Santa Cruz 1 g/ml 
Synaptophysin Mouse monoclonal Santa Cruz or 
Zymed 
1 g/ml 
NeuN Mouse monoclonal Chemicon 1 g/ml 
GRP78 (Bip) Mouse monoclonal Cell Signalling 1 g/ml 
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Table 7.3 List of primary antibodies used for immunoblotting 
Antibody Species   Company Dilution 
ICSM35 Mouse monoclonal D-GEN 5 g/ml 
Ubiquitin Mouse monoclonal Santa Cruz 10 g/ml 
Synaptophysin Mouse monoclonal Santa Cruz or 
Zymed 
5 g/ml 
β-actin Mouse monoclonal Sigma .1 g/ml 
 
Appendix II 
 
Primary cortical neuron culture medium 
 
NeuroBasal medium 
B27 supplement 
L-glutamine (200 mM) 
Penicillin (5000 U/ml)/ streptomycin (5000g/ml)  
Foetal bovine serum (FBS) 
 
Homogenisation buffer solution 
 
50mM Tris pH 7.5  
5mM MgCl2  
250mM sucrose  
1mM DTT 
2mM ATP 
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Antigen retrieval buffer 
 
Mild citrate (MCC1) Tris/citrate EDTA buffer pH 7.8 
1.3 mM EDTA 
2.1 mM Tris 
1.1 mM citrate, pH 7.8 
 
Ventana reagents 
 
DAB Map Kit  
Diaminobenzidine (DAB) 
Horse radish peroxidise (HRP) 
Copper sulphate 
Inhibitor D 
 
iView DAB Detection Kit  
Inhibitor (3 % hydrogen peroxide solution) 
SA-HRP (Conjugated streptavidin horseradish peroxidase) 
 H2O2 (.04 %-.08% hydrogen peroxide in an phosphate buffer solution 
Diaminobenzidine DAB substrate 
Copper sulphate. 
 
Lysis Buffer 
 
100 mM Tris-HCl, pH 7.4 
300 mM NaCl 
4 mM EDTA 
 1 % Triton-X-100 
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1 % deoxycholate 
8 mM AEBSF  
 
 
2x reducing sample buffer  
 
125 mM Tris, pH 6.8 
20 % glycerol 
0.05 % bromophenol blue 
4 % SDS 
 
Fluorogenic assay reagents 
 
Homogenization buffer  
 
50 mM Tris.HCl, pH 7.4,  
2 mM ATP 
5mM MgCl2 
250 mM sucrose 
1 mM DTT 
 
Assay buffer 
 
50 mM Tris.HCl, pH 7.4 
5 mM MgCl2 
2 mM ATP 
1 mM DTT 
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Appendix III 
 
Behavioural assessment 
 
 
Nesting assessment 
 
 
 
A. Grade (1) = nestlet not touched (more than 90% intact) 
B. Grade (2) = nestlet partially torn (50-90% remain intact), 
C. Grade (3) = nestlet mostly shredded (less than 50 % remain intact) 
D. Grade (4) = nestlet mostly torn and the material gathered into a flat nest 
E. Grade (5) = nestlet nearly perfect 
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Burrowing assessment 
 
 
 
 
A one-end closed opaque plastic tube (250 x 55 mm, length x diameter) was filled with 200 
g of normal food diet pellets were placed into a clean cage and left overnight for mice to 
burrow the pellet out. 
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Appendix IV 
 
 
Statistical report 
 
Survival curve 
Log-rank (Mantel-Cox) Test 
  Chi square 0.1572 
 df 2 
 P value 0.9244 
 P value summary ns 
 Are the survival curves sig different? No 
 
   Logrank test for trend 
  Chi square 0.09846 
 df 1 
 P value 0.7537 
 P value summary ns 
 Sig. trend? No 
 
   
 
Non-
transgenic GFP1 GFP2 
159.1 161 160.8 
9.478 3.464 1.643 
3.351 2 0.7348 
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Ubiquitin dot blot 
Table Analyzed Data 1     
      
Two-way ANOVA      
      
Source of Variation % of total variation P value    
Interaction 7.16 0.0543    
Column Factor 30.46 < 0.0001    
Row Factor 42.8 < 0.0001    
      
Source of Variation P value summary Significant?   
Interaction ns No    
Column Factor *** Yes    
Row Factor *** Yes    
      
Source of Variation Df Sum-of-
squares 
Mean 
square 
F  
Interaction 3 65.46 21.82 2.927  
Column Factor 1 278.4 278.4 37.35  
Row Factor 3 391.2 130.4 17.49  
Residual 24 178.9 7.454   
      
Number of missing 
values 
0     
      
      
Bonferroni posttests      
      
Control vs RML      
Row Factor Control RML Difference 95% CI of diff. 
  45 7.105 10.97 3.863 -1.350 to 9.075 
  85 9.88 12.39 2.507 -2.705 to 7.720 
  125 12.35 19.88 7.533 2.320 to 12.75 
  165 12.72 22.42 9.695 4.482 to 14.91 
      
Row Factor Difference t P value Summary  
  45 3.863 2.001 P > 0.05 ns  
  85 2.507 1.299 P > 0.05 ns  
  125 7.533 3.902 P<0.01 **  
  165 9.695 5.022 P<0.001 ***  
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Fluorogenic assay 
 
 
Chymotrpysin D45 
 
 
Table Analyzed Data 1 
  Column A control 
  vs vs 
  Column B RML 
  
    Unpaired t test 
   P value 0.2879 
  P value summary ns 
  Are means signif. different? (P < 0.05) No 
  One- or two-tailed P value? Two-tailed 
 t, df t=1.225 df=4 
 
    How big is the difference? 
   Mean ± SEM of column A 100.0 ± 2.887 N=3 
 
Mean ± SEM of column B 
105.00 ± 2.887 
N=3 
 Difference between means 5.000 ± 4.082 
 95% confidence interval -6.333 to 16.33 
 R square 0.2727 
  
    F test to compare variances 
   F,DFn, Dfd 1.000, 2, 2 
 P value 1 
  P value summary ns 
  Are variances significantly different? No 
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Chymotrpysin D85 
 
 
Table Analyzed Data 1 
 Column A control 
 vs vs 
 Column B RML 
 
   Unpaired t test 
  P value 0.2379 
 P value summary ns 
 Are means signif. different? (P < 0.05) No 
 One- or two-tailed P value? Two-tailed 
t, df t=1.470 df=3 
   How big is the difference? 
  Mean ± SEM of column A 100.0 ± 7.782 N=3 
Mean ± SEM of column B 125.2 ± 18.65 N=2 
Difference between means -25.22 ± 17.15 
95% confidence interval -79.80 to 29.36 
R square 0.4188 
 
   F test to compare variances 
  F,DFn, Dfd 3.830, 1, 2 
P value 0.3789 
 P value summary ns 
 Are variances significantly different? No 
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Chymotrpysin D105 
 
 
Table Analyzed Data 1 
 Column A control 
 vs vs 
 Column B RML 
 
   Unpaired t test 
  P value 0.416 
 P value summary ns 
 Are means signif. different? (P < 0.05) No 
 One- or two-tailed P value? Two-tailed 
 
t, df 
t=0.9064 
df=4 
 
   How big is the difference? 
  Mean ± SEM of column A 99.98 ± 2.994 N=3 
Mean ± SEM of column B 112.5 ± 13.49 N=3 
Difference between means 
-12.52 ± 
13.81 
 95% confidence interval -50.87 to 25.83 
R square 0.1704 
 
   F test to compare variances 
  F,DFn, Dfd 20.29, 2, 2 
 P value 0.0939 
 P value summary ns 
 Are variances significantly different? No 
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Chymotrpysin D125 
 
 
Table Analyzed Data 1 
 Column A control 
 vs vs 
 Column B RML 
 
   Unpaired t test 
  P value 0.0755 
 P value summary ns 
 Are means signif. different? (P < 0.05) No 
 One- or two-tailed P value? Two-tailed 
 
t, df 
t=2.386 
df=4 
 
   How big is the difference? 
  Mean ± SEM of column A 100.0 ± 7.741 N=3 
Mean ± SEM of column B 81.18 ± 1.523 N=3 
Difference between means 18.82 ± 7.890 
95% confidence interval -3.080 to 40.72 
R square 0.5873 
 
   F test to compare variances 
  F,DFn, Dfd 25.85, 2, 2 
 P value 0.0745 
 P value summary ns 
 Are variances significantly different? No 
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Chymotrpysin D145 
 
 
 
 
Table Analyzed Data 1 
 Column A control 
 vs vs 
 Column B RML 
 
   Unpaired t test 
  P value 0.019 
 P value summary * 
 Are means signif. different? (P < 0.05) Yes 
 One- or two-tailed P value? Two-tailed 
t, df t=3.806 df=4 
   How big is the difference? 
  
Mean ± SEM of column A 
100.0 ± 8.069 
N=3 
Mean ± SEM of column B 
65.96 ± 3.858 
N=3 
Difference between means 34.04 ± 8.944 
95% confidence interval 9.212 to 58.87 
R square 0.7836 
 
   F test to compare variances 
  F,DFn, Dfd 4.374, 2, 2 
P value 0.3722 
 P value summary ns 
 Are variances significantly different? No 
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Chymotrpysin End stage 
 
 
Table Analyzed 
Data 1  
Column A control  
vs vs  
Column B RML  
   
Unpaired t test   
P value 0.0002  
P value summary ***  
Are means signif. different? (P < 0.05) Yes  
One- or two-tailed P value? Two-tailed 
t, df t=13.78 df=4 
   
How big is the difference?   
Mean ± SEM of column A 99.99 ± 0.1898 
N=3 
Mean ± SEM of column B 52.37 ± 3.450 
N=3 
Difference between means 47.62 ± 3.455 
95% confidence interval 38.03 to 57.21 
R square 0.9794  
   
F test to compare variances   
F,DFn, Dfd 330.4, 2, 2 
P value 0.006  
P value summary **  
Are variances significantly different? Yes  
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Behavioural assessment statistics report 
Rotarod 
     
 
    
Table Analyzed 
Total data bar 
chart 
    
      
Two-way RM ANOVA Matching by cols     
      
Source of Variation % of total variation P value    
Interaction 2.75 0.006    
Time 4.55 0.0001    
Column Factor 69.2 < 0.0001    
Subjects (matching) 4.846 0.4263    
      
Source of Variation P value summary Significant?   
Interaction ** Yes    
Time *** Yes    
Column Factor *** Yes    
Subjects (matching) ns No    
      
Source of Variation Df Sum-of-
squares 
Mean 
square 
F  
Interaction 4 15614 3903 3.833  
Time 4 25835 6459 6.342  
Column Factor 1 392871 392871 371.3  
Subjects (matching) 26 27513 1058 1.039  
Residual 104 105912 1018   
      
Number of missing 
values 
0     
      
Bonferroni posttests      
      
Control vs RML      
Column Factor Control RML Difference 95% CI of diff. 
  45 111.2 33.07 -78.1 -109.7 to -46.44 
  60 154.3 56.55 -97.79 -129.4 to -66.13 
  70 169.6 49.52 -120 -151.7 to -88.39 
  85 144.2 49.07 -95.12 -126.8 to -63.46 
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  105 175.2 36.55 -138.7 -170.3 to -107.0 
      
Column Factor Difference t P value Summary  
  45 -78.1 6.45 P<0.001 ***  
  60 -97.79 8.076 P<0.001 ***  
  70 -120 9.914 P<0.001 ***  
  85 -95.12 7.855 P<0.001 ***  
  105 -138.7 11.45 P<0.001 ***  
      
 
Burrowing 
Table Analyzed Total data     
      
Two-way RM ANOVA Matching by cols     
      
Source of Variation % of total 
variation 
P value    
Interaction 10.41 < 0.0001    
Time 4.82 0.0002    
Column Factor 46.14 < 0.0001    
Subjects (matching) 14.2731 < 0.0001    
      
Source of Variation P value 
summary 
Significant?   
Interaction *** Yes    
Time *** Yes    
Column Factor *** Yes    
Subjects (matching) *** Yes    
      
Source of Variation Df Sum-of-
squares 
Mean 
square 
F  
Interaction 5 18148 3630 11.11  
Time 5 8409 1682 5.149  
Column Factor 1 80441 80441 84.05  
Subjects (matching) 26 24884 957.1 2.93  
Residual 130 42458 326.6   
      
Number of missing values 0     
207 | P a g e  
 
 
 
      
Bonferroni posttests      
      
Control vs RML      
Column Factor Control RML Difference 95% CI of diff. 
  20. 70.51 57.79 -12.72 -33.71 to 8.264 
  45. 95.8 61.06 -34.74 -55.72 to -13.75 
  60. 89.02 48.97 -40.05 -61.03 to -19.06 
  70. 85.98 50.48 -35.5 -56.49 to -14.51 
  85. 90.07 27.73 -62.34 -83.32 to -41.35 
  105. 95.79 18.55 -77.24 -98.22 to -56.25 
      
Column Factor Difference t P value Summary  
  20. -12.72 1.62 P > 0.05 ns  
  45. -34.74 4.424 P<0.001 ***  
  60. -40.05 5.1 P<0.001 ***  
  70. -35.5 4.521 P<0.001 ***  
  85. -62.34 7.938 P<0.001 ***  
  105. -77.24 9.835 P<0.001 ***  
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Nesting  
Table Analyzed Total data 
    
      Two-way RM ANOVA Matching by cols 
    
      Source of Variation % of total variation P value 
   Interaction 7.43 < 0.0001 
   Time 6.57 < 0.0001 
   Column Factor 71.71 < 0.0001 
   Subjects (matching) 6.4608 < 0.0001 
   
      Source of Variation P value summary Significant? 
  Interaction *** Yes 
   Time *** Yes 
   Column Factor *** Yes 
   Subjects (matching) *** Yes 
   
      
Source of Variation Df 
Sum-of-
squares 
Mean 
square F 
 Interaction 6 23.23 3.871 24.16 
 Time 6 20.55 3.425 21.37 
 Column Factor 1 224.3 224.3 299.7 
 Subjects (matching) 27 20.21 0.7484 4.671 
 Residual 162 25.96 0.1602 
  
      Number of missing 
values 0 
    
      Bonferroni posttests 
     
      Control vs RML 
     Column Factor Control RML Difference 95% CI of diff. 
  20. 4.867 3.571 -1.295 -1.795 to -0.7958 
  30. 5 3.786 -1.214 -1.714 to -0.7148 
  45. 5 3.071 -1.929 -2.428 to -1.429 
  60. 5 3 -2 -2.499 to -1.501 
  70. 5 2.571 -2.429 -2.928 to -1.929 
  85. 5 2.429 -2.571 -3.071 to -2.072 
  105. 5 1.714 -3.286 -3.785 to -2.786 
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Column Factor Difference t P value 
Summar
y 
   20. -1.295 7.053 P<0.001 *** 
   30. -1.214 6.612 P<0.001 *** 
   45. -1.929 10.5 P<0.001 *** 
   60. -2 10.89 P<0.001 *** 
   70. -2.429 13.22 P<0.001 *** 
   85. -2.571 14 P<0.001 *** 
   105. -3.286 17.89 P<0.001 *** 
 
      
 
 
 
Grip strength 
     
 
    
Table Analyzed 
Total data edited     
      
Two-way RM ANOVA Matching by cols     
      
Source of Variation % of total 
variation 
P value    
Interaction 1.86 0.2647    
Time 2.67 0.1016    
Column Factor 28.08 < 0.0001    
Subjects (matching) 28.9401 < 0.0001    
      
Source of Variation P value summary Significant?   
Interaction ns No    
Time ns No    
Column Factor *** Yes    
Subjects (matching) *** Yes    
      
Source of Variation Df Sum-of-
squares 
Mean 
square 
F  
Interaction 5 1.562 0.3123 1.307  
Time 5 2.248 0.4495 1.881  
Column Factor 1 23.62 23.62 26.2  
Subjects (matching) 27 24.34 0.9015 3.772  
Residual 135 32.26 0.239   
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Number of missing 
values 
0     
      
Bonferroni posttests      
      
Control vs RML      
Column Factor Control RML Difference 95% CI of diff. 
  30. 5.573 4.577 -0.9964 -1.583 to -0.4097 
  45. 5.333 4.364 -0.9697 -1.556 to -0.3830 
  60. 5.173 4.6 -0.5733 -1.160 to 0.01337 
  70. 5.273 4.533 -0.7399 -1.327 to -0.1532 
  85. 5.077 4.586 -0.4912 -1.078 to 0.09549 
  105. 5.017 4.364 -0.6533 -1.240 to -0.06662 
      
Column Factor Difference t P value Summary  
  30. -0.9964 4.536 P<0.001 ***  
  45. -0.9697 4.415 P<0.001 ***  
  60. -0.5733 2.61 P > 0.05 ns  
  70. -0.7399 3.369 P<0.01 **  
  85. -0.4912 2.236 P > 0.05 ns  
  105. -0.6533 2.974 P < 0.05 *  
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